129567	Y	schizophrenia; body fat; weight gain	PSYCH	PSY	Weight Gain	7	7q31.3	LEP	127668566	127684917		Zhang, Z. J.  et al. 2003	14720418	(-2548 G/A)		promoter	Leptin (obesity homolog, mouse)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000230.1	Chinese		CDC GDPinfo	3952	Hs.194236			Zhonghua yi xue za zhi. 2003 Dec;83(24):2119-23	[Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain]		164160	12145	2	2003	 The finding identify that the -2548G/A polymorphism in promoter region of leptin gene associated with APS-induced weight gain and abdominal fat deposition and distribution. -2548AA may be a genetic risk factor for the development of weight gain and body fat deposition in Chinese Han schizophrenic patients during APS acute treatment.	Case:128 Chinese Han untreated patients with schizophrenia;Control:38 age and gender matched healthy controls	chlorpromazine risperidone									
146166	Y	QT intervals	PHARMACOGENOMIC	PHARM		15	15q24	CYP1A2	72828236	72835994		Tay, J. K.  et al. 2007	17611010	C allele of the CYP1A2()1F			Cytochrome P450, family 1, subfamily A, polypeptide 2	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000761.3			CDC GDP info	1544	Hs.1361			Prog Neuropsychopharmacol Biol Psychiatry    2007	Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia		124060		CDC	2007	there was a trend of those with the C allele of the CYP1A2()1F polymorphism having longer QTc intervals.		antipsychotic drug chlorpromazine									
153637		attention deficit hyperactivity disorder schizotypal personality traits	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Ettinger, U.  et al. 2006	17109713				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Caucasian		CDC GDP info	6531	Hs.406			Psychiatry Clin Neurosci    2006    60(6)    764-7	Schizotypy, attention deficit hyperactivity disorder, and dopamine genes		126455		CDC	2006												
153638		delinquent behavior violent behavior	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Guo, G.  et al. 2006	17120049				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Hum Genet    2006	Contributions of the DAT1 and DRD2 genes to serious and violent delinquency among adolescents and young adults		126455		CDC	2006												
153639	N	intelligence	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Genro, J. P.  et al. 2006	17130883				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Mol Psychiatry    2006    11(12)    1066-7	No association between dopaminergic polymorphisms and intelligence variability in attention-deficit/hyperactivity disorder		126455		CDC	2006												
153640	N	weight gain	PHARMACOGENOMIC	PHARM	Obesity; Weight Gain	5	5p15.3	SLC6A3	1445908	1498543		Hu, J.  et al. 2006	17135598				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Obesity (Silver Spring)    2006    14(11)    1863-7	No evidence for a major role of polymorphisms during bupropion treatment		126455		CDC	2006	our results do not support a major role for these five candidate genes in weight gain after smoking cessation.		bupropion									
153641	N	extrapyramidal side effects	NEUROLOGICAL	NEUR	Basal Ganglia Diseases	5	5p15.3	SLC6A3	1445908	1498543		Lafuente, A.  et al. 2006	17150335				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	European		CDC GDP info	6531	Hs.406			Schizophr Res    2006	Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics		126455		CDC	2006	Our results suggest that the VNTR polymorphism did not influence AP-induced EPS and did not affect DAT gene expression or protein function.											
153643		Tourette syndrome	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Yoon, D. Y.  et al. 2006	17171650				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2006	Dopaminergic polymorphisms in Tourette syndrome		126455		CDC	2006												
153645	N	personality traits	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Kim, S. J.  et al. 2006	17191306				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Korean		CDC GDP info	6531	Hs.406			Yonsei Med J    2006    47(6)    787-92	Lack of Association between Polymorphisms of the Dopamine Receptor D4 and Dopamine Transporter Genes and Personality Traits in a Korean Population		126455		CDC	2006												
153646	Y	disruptive behavior	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Lee, S. S.  et al. 2006	17192955				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2006	Association of dopamine transporter genotype with disruptive behavior disorders in an eight-year longitudinal study of children and adolescents		126455		CDC	2006												
153647		dystonia, acute parkinsonism tardive dyskinesia	PHARMACOGENOMIC	PHARM	Basal Ganglia Diseases	5	5p15.3	SLC6A3	1445908	1498543		Guzey, C.  et al. 2007	17225991				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Eur J Clin Pharmacol    2007	Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia		126455		CDC	2007	Presence of the Taq1A A1 allele of the DRD2 and the 9 repeat allele of the DAT1 VNTR polymorphisms might be risk factors for EPS caused by antipsychotic drugs.		antipsychotic drug									
153649	Y	smoking behavior	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		O'gara, C.  et al. 2007	17264803				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Pharmacogenet Genomics    2007    17(1)    61-67	Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment		126455		CDC	2007	We find evidence, although modest, of a medium-sized effect of DAT1 genotype on the ability to stop smoking early in a smoking cessation attempt. If the effect is real, and is strongest in the very early stages of smoking cessation, this suggests that the primary utility of DAT1 screening in this field will be in the identification of those most at risk of early relapse after quitting.											
153650		appetite suppression	PHARMACOGENOMIC	PHARM		5	5p15.3	SLC6A3	1445908	1498543		Davis, C.  et al. 2007	17314918				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Neuropsychopharmacology    2007	Dopamine Transporter Gene (DAT1) Associated with Appetite Suppression to Methylphenidate in a Case-Control Study of Binge Eating Disorder		126455		CDC	2007			methylphenidate									
153651		bipolar disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Ohadi, M.  et al. 2007	17316573				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Iranian		CDC GDP info	6531	Hs.406			Brain Res    2007	Gender dimorphism in the DAT1 -67 T-allele homozygosity and predisposition to bipolar disorder		126455		CDC	2007												
153653		personality traits	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Hunnerkopf, R.  et al. 2007	17392738				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Neuropsychopharmacology    2007	Interaction between BDNF Val66Met and Dopamine Transporter Gene Variation Influences Anxiety-Related Traits		126455		CDC	2007												
153654	Y	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Asherson, P.  et al. 2007	17403983				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Psychiatry    2007    164(4)    674-7	Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD		126455		CDC	2007	These data challenge results of meta-analyses suggesting that dopamine transporter variation does not have an effect on the risk for ADHD, and they indicate that further investigation of functional variation in the gene is required.											
153655		nicotine dependence smoking behavior	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Segman, R. H.  et al. 2007	17427187				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2007	Why do young women smoke? IV. Role of genetic variation in the dopamine transporter and lifetime traumatic experience		126455		CDC	2007			trauma									
153657		traumatic brain injury	NEUROLOGICAL	NEUR	Brain Injuries	5	5p15.3	SLC6A3	1445908	1498543		Wagner, A. K.  et al. 2007	17432702				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			J Neurosurg    2007    106(4)    538-47	Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury		126455		CDC	2007	In addition to systemic administration of DA, inherent factors such as sex and DAT genotype affect post-TBI CSF DA and DA metabolite levels, a phenomenon that may modulate susceptibility to DA-mediated oxidative injury.											
153658		alcohol abuse	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Guo, G.  et al. 2007	17440951				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2007	Gene-lifecourse interaction for alcohol consumption in adolescence and young adulthood		126455		CDC	2007												
153659		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Yang, B.  et al. 2007	17440978				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2007	A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention deficit hyperactivity disorder		126455		CDC	2007												
153660		antisocial personality disorder	CHEMDEPENDENCY	CHEM	Alcoholism	5	5p15.3	SLC6A3	1445908	1498543		Hoenicka, J.  et al. 2007	17449448				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Spain	CDC GDP info	6531	Hs.406			Neurotox Res    2007    11(1)    51-60	Association in alcoholic patients between psychopathic traits and the additive effect of allelic forms of the CNR1 and FAAH endocannabinoid genes, and the 3' region of the DRD2 gene		126455		CDC	2007												
153661		Parkinson's disease	NEUROLOGICAL	NEUR		5	5p15.3	SLC6A3	1445908	1498543		Dick, F.  et al. 2007	17449559				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	European		CDC GDP info	6531	Hs.406			Occup Environ Med    2007	Gene-environment interactions in parkinsonism and Parkinson's disease		126455		CDC	2007	Many small studies have reported associations between genetic polymorphisms and PD.		copper iron manganese pesticides solvents									
153663		neural reward sensitivity	NEUROLOGICAL	NEUR		5	5p15.3	SLC6A3	1445908	1498543		Yacubian, J.  et al. 2007	17483451				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Proc Natl Acad Sci U S A    2007	Gene-gene interaction associated with neural reward sensitivity		126455		CDC	2007												
153664	Y	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Laucht, M.  et al. 2007	17485610				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Arch Gen Psychiatry    2007    64(5)    585-90	Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample		126455		CDC	2007	These findings provide initial evidence that environmental risks as described by the Rutter Family Adversity Index moderate the impact of the DAT1 gene on ADHD symptoms, suggesting a DAT1 effect only in those individuals exposed to psychosocial adversity.		psychosocial adversity									
153665		smoking behavior	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Swan, G. E.  et al. 2007	17500623				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Health Psychol    2007    26(3)    361-8	Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR		126455		CDC	2007	Although these results are suggestive, a more compelling test is needed of the hypothesis that dopaminergic gene interaction underlies, in part, the likelihood of smoking following treatment with bupropion SR.											
153666		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Lasky-Su, J.  et al. 2007	17501935				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Ann Hum Genet    2007	Evidence for an Association of the Dopamine D5 Receptor Gene on Age at Onset of Attention Deficit Hyperactivity Disorder		126455		CDC	2007	await independent replication, these results suggest that a variant in DRD5 may affect age at onset for ADHD.											
153667		Tourette syndrome	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Tarnok, Z.  et al. 2007	17508355				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2007	Dopaminergic candidate genes in Tourette syndrome		126455		CDC	2007	allele frequencies did not differ between cases and controls, but DAT1 genotype accounted for variations of tic severity within the TS group.											
153669		impulsivity	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Congdon, E.  et al. 2007	17525955				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2007	Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults		126455		CDC	2007												
153670		alcohol abuse smoking behavior	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Preuss, U. W.  et al. 2007	17526637				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Alcohol Alcohol    2007    42(3)    258-266	D2 dopamine receptor gene haplotypes and their influence on alcohol and tobacco consumption magnitude in alcohol-dependent individuals		126455		CDC	2007												
153672		spatial bias	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Bellgrove, M. A.  et al. 2007	17549062				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Mol Psychiatry    2007	Dopaminergic genotype biases spatial attention in healthy children		126455		CDC	2007												
153673		antisocial personality disorder attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Langley, K.  et al. 2007	17579368				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2007	Testing for gene x environment interaction effects in attention deficit hyperactivity disorder and associated antisocial behavior		126455		CDC	2007			alcohol, maternal birth weight smoking (tobacco), maternal									
153675	N	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Banoei, M. M.  et al. 2007	17582621				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Iranian		CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2007	No association between the DAT1 10-repeat allele and ADHD in the Iranian population		126455		CDC	2007												
153676		behavior problems	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Becker, K.  et al. 2007	17608284				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Z Kinder Jugendpsychiatr Psychother    2007    35(2)    145-51	Dopaminergic polymorphisms and regulatory problems in infancy		126455		CDC	2007	The result must be replicated in an independent sample before any conclusions can be drawn.											
153677	Y	depression	PHARMACOGENOMIC	PHARM		5	5p15.3	SLC6A3	1445908	1498543		Lavretsky, H.  et al. 2007	17621383	VNTR 10/10			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Int J Geriatr Psychiatry    2007	The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression		126455		CDC	2007	DAT VNTR 10/10 genotype may be associated with an endophenotype of late-life depression with executive dysfunction that responds preferentially to methylphenidate added to a selective serotonin reuptake inhibitor, which warrants replication in a large sample. Copyright (c) 2007 John Wiley & Sons, Ltd.		citalopram									
153622		depression	PHARMACOGENOMIC	PHARM		5	5p15.3	SLC6A3	1445908	1498543		Kirchheiner, J.  et al. 2006	16702979				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Pharmacogenomics J    2006	A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment		126455		CDC	2006	the dopamine transporter VNTR polymorphism influenced rapid response to antidepressant therapy.		antidepressants									
153627	Y	schizophrenia	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Stober, G.  et al. 2006	16783497				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Eur Arch Psychiatry Clin Neurosci    2006	Family-based study of markers at the 5'-flanking region of the human dopamine transporter gene reveals potential association with schizophrenic psychoses		126455		CDC	2006	our present findings support the genetic involvement of distinct hSLC6A3 genotypes in schizophrenia.											
153642		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Neuman, R. J.  et al. 2006	17157268				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Biol Psychiatry    2006	Prenatal Smoking Exposure and Dopaminergic Genotypes Interact to Cause a Severe ADHD Subtype		126455		CDC	2006	Results indicate that smoking during pregnancy is associated with specific subtypes of ADHD in genetically susceptible children.		alcohol, maternal smoking (tobacco), maternal									
153648		sexual behavior	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Guo, G.  et al. 2007	17245411				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Eur J Hum Genet    2007	Dopamine transporter, gender, and number of sexual partners among young adults		126455		CDC	2007												
153662	N	smoking behavior	PHARMACOGENOMIC	PHARM		5	5p15.3	SLC6A3	1445908	1498543		Ton, T. G.  et al. 2007	17466074				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Behav Brain Funct    2007    3(1)    22	Genetic polymorphisms in dopamine-related genes and smoking cessation in women		126455		CDC	2007	 However, effect modification on smoking cessation was observed between DRD2 Taq1A and SLC6A3 VNTR polymorphisms, DRD3 Ser/Gly and d,1-fenfluramine, and DRD4 VNTR and d,1-fenfluramine.		1-fenfluramine									
153614		heroin abuse	CHEMDEPENDENCY	CHEM	Heroin Dependence	5	5p15.3	SLC6A3	1445908	1498543			16526040				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2006	The effect of dopamine D2, D5 receptor and transporter (SLC6A3) polymorphisms on the cue-elicited heroin craving in Chinese		126455		CDC	2006												
153616		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543			16545000				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Omani		CDC GDP info	6531	Hs.406			Genet Test    2006    10(1)    31-4	The VNTR Polymorphism in the Human Dopamine Transporter Gene		126455		CDC	2006												
153631		headache	NEUROLOGICAL	NEUR	Headache; Substance-Related Disorders	5	5p15.3	SLC6A3	1445908	1498543		Cevoli, S.  et al. 2006	16930369				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Eur J Neurol    2006    13(9)    1009-13	A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse		126455		CDC	2006												
153636		attention deficit hyperactivity disorder	PHARMACOGENOMIC	PHARM		5	5p15.3	SLC6A3	1445908	1498543		Joober, R.  et al. 2006	17063150				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Neuropsychopharmacology    2006	Dopamine Transporter 3'-UTR VNTR Genotype and ADHD		126455		CDC	2006			methylphenidate									
153644		lung cancer	CANCER	CAN	Lung Neoplasms	5	5p15.3	SLC6A3	1445908	1498543		Campa, D.  et al. 2006	17175058				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Caucasian;Norwegian		CDC GDP info	6531	Hs.406			Lung Cancer    2006	Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer		126455		CDC	2006	The dopamine receptor/transport gene polymorphisms are associated with the risk of NSCLC among smokers. The data show that the polymorphisms resulting in lower dopamine bioavailability were associated with increased risk of NSCLC.											
153652	N	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Laurin, N.  et al. 2007	17325714				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Mol Psychiatry    2007    12(3)    226-9	No preferential transmission of paternal alleles at risk genes in attention-deficit hyperactivity disorder		126455		CDC	2007												
153656		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Kim, J. W.  et al. 2007	17427194				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2007	Investigation of parent-of-origin effects in ADHD candidate genes		126455		CDC	2007												
153668	Y	smoking behavior	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Stapleton, J. A.  et al. 2007	17508996				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Addict Biol    2007    12(2)    221-6	Association between dopamine transporter genotypes and smoking cessation		126455		CDC	2007												
153671		migraine migraine with aura	NEUROLOGICAL	NEUR	Migraine Disorders	5	5p15.3	SLC6A3	1445908	1498543		McCallum, L. K.  et al. 2007	17539957			Intron	Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Eur J Neurol    2007    14(6)    706-7	Association study of a functional variant in intron 8 of the dopamine transporter gene and migraine susceptibility		126455		CDC	2007												
153674		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Friedel, S.  et al. 2007	17579611				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	German		CDC GDP info	6531	Hs.406			Mol Psychiatry    2007	Association and linkage of allelic variants of the dopamine transporter gene in ADHD		126455		CDC	2007												
154343	N	smoking behavior	PHARMACOGENOMIC	PHARM		11	11p15.5	TH	2141734	2149611		Ton, T. G.  et al. 2007	17466074				Tyrosine hydroxylase	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_199292.2			CDC GDP info	7054	Hs.435609			Behav Brain Funct    2007    3(1)    22	Genetic polymorphisms in dopamine-related genes and smoking cessation in women		191290		CDC	2007	 However, effect modification on smoking cessation was observed between DRD2 Taq1A and SLC6A3 VNTR polymorphisms, DRD3 Ser/Gly and d,1-fenfluramine, and DRD4 VNTR and d,1-fenfluramine.		1-fenfluramine									
123060		cancer	CANCER	CAN	Neoplasms|Breast Neoplasms|Ovarian Neoplasms|Fanconi Anemia|Bloom Syndrome|Genetic Predisposition to Disease|	9	9q22.3	FANCC	96901156	97119812		Koren-Michowitz, M.  et al. 2005	15726604				Fanconi anemia, complementation group C	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000136.2	Jewish	Israel	CDC GDPinfo	2176	Hs.494529			American journal of hematology. 2005 Mar;78(3):203-6	Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in riskmodification for cancer development.		227645	25998	2	2005	Coinheritance of FA and/or BS mutations seems to be more prevalent among BRCA mutation carriers, but a larger study encompassing more women may help in clarifying this issue.	Cohort 100 Ashkenazi women with known BRCA1 and BRCA2 mutations 										
121332		cleft lip with cleft palate; cleft lip without cleft palate	DEVELOPMENTAL	DEV		17	17q21	DLX3	45422367	45427587		Ichikawa, E.  et al. 2005	16247549				Distal-less homeo box 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_005220.2	Japanese		CDC GDPinfo	1747	Hs.134194			Journal of human genetics. 2006 ;51(1):38-46	PAX9 and TGFB3 are linked to susceptibility to nonsyndromic cleft lip with or without cleft palate in the Japanese: population-based and family-basedcandidate gene analyses.		600525	21145	2	2005												
120267	N	breast cancer; breast cancer, male	CANCER	CAN	Breast Neoplasms|Breast Neoplasms, Male	10	10q24.3	CYP17A1	104580277	104587280		Gudmundsdottir, K.  et al. 2003	12644832			promoter	Cytochrome P450, family 17, subfamily A, polypeptide 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000102.3			CDC GDPinfo	1586	Hs.438016			British journal of cancer. 2003 Mar;88(6):933-6	CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status.		202110	9722	2	2003	Our findings do not indicate a role for the CYP17 T-C polymorphism in female breast cancer, but a role in male carriers of a BRCA2 mutation could not be excluded because of the small sample size.	Control:309/395 male (n=309) and female (n=395) controls;Case:39/523 male (n=39) and female (n=523) breast cancer cases										
120056	Y	atherosclerosis, coronary	CARDIOVASCULAR	CARD	Coronary Stenosis|Myocardial Infarction	17	17p13	CXCL16	4583580	4589863		Lundberg, G. A.  et al. 2005	15836657				Chemokine (C-X-C motif) ligand 16	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_022059.1			CDC GDPinfo	58191	Hs.592117			Journal of internal medicine. 2005 May;257(5):415-22	Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene.		605398	9648	2	2005	 The present work provides evidence that CXCL16 is involved in processes leading to enhanced stenosis in atherosclerotic coronary arteries.	Control:387 sex- and age-matched controls;Case:387 unselected survivors of a first myocardial infarction aged <60 years:Cohort:468 patients undergoing percutaneous transluminal coronary angioplasty with stent implant										
119344		cleft lip with cleft palate; cleft lip without cleft palate	DEVELOPMENTAL	DEV		19	19q13.2-q13.3	CLPTM1	50150477	50188439		Ichikawa, E.  et al. 2005	16247549				Cleft lip and palate associated transmembrane protein 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001294.1	Japanese		CDC GDPinfo	1209	Hs.444441			Journal of human genetics. 2006 ;51(1):38-46	PAX9 and TGFB3 are linked to susceptibility to nonsyndromic cleft lip with or without cleft palate in the Japanese: population-based and family-basedcandidate gene analyses.		604783	18847	2	2005												
119265		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	22	22q11	CHEK2	27413730	27467822		Rajkumar, T.  et al. 2003	14507240				CHK2 checkpoint homolog (S. pombe)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007194.3	Indian	India	CDC GDPinfo	11200	Hs.291363			Asian Pacific journal of cancer prevention. 2003 Jul-Sep;4(3):203-8	BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.		604373	24145	2	2003	This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.	Control healthy blood donors;Case:22 breast cancer patients with a family history of breat and/or ovarian cancer and early onset breast:cancer South India										
119261		breast cancer	CANCER	CAN	Breast Neoplasms	22	22q11	CHEK2	27413730	27467822		Meijers-Heijboer, H.  et al. 2002	11967536				CHK2 checkpoint homolog (S. pombe)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007194.3			CDC GDPinfo	11200	Hs.291363			Nature genetics. 2002 May;31(1):55-9	Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations		604373	15805	2	2002	This suggests that the biological mechanisms underlying the elevated risk of breast cancer in CHEK2 mutation carriers are already subverted in carriers of BRCA1 or BRCA2 mutations, which is consistent with participation of the encoded proteins in the same pathway.	Cohort healthy individuals 										
119247		breast cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	22	22q11	CHEK2	27413730	27467822		Dufault, M. R.  et al. 2004	15095295				CHK2 checkpoint homolog (S. pombe)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007194.3			CDC GDPinfo	11200	Hs.291363			International journal of cancer. Journal international du cancer. 2004 Jun;110(3):320-5	Limited relevance of the CHEK2 gene in hereditary breast cancer.		604373	15790	2	2004	The low prevalence and penetrance of the exon 10 deletion mutations together with no, or an uncertain elevation in risk for other CHEK2 mutations suggests a limited relevance for CHEK2 mutations in familial breast cancer. Further evaluation of the unique variants observed in breast cancer is required to determine if they may play a role in a polygenic model of familial breast cancer. Nevertheless, it seems premature to include CHEK2 screening in genetic testing.	Case:30 unrelated patients from 516 breast cancer families negative for BRCA1 and BRCA2 gene mutations:German;Control:500 healthy women aged over 50 years										
119049		uveal melanoma	CANCER	CAN	Melanoma|Uveal Neoplasms	9	9p21	CDKN2B	21992901	21999312		Hearle, N.  et al. 2003	12556369				Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_004936.3			CDC GDPinfo	1030	Hs.72901			Investigative ophthalmology & visual science. 2003 Feb;44(2):458-62	Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.		600431	24134	2	2003	 These findings suggest that less than 2% of cases of uveal melanoma can be ascribed to germline mutations in BRCA2, P16(INK4A), P14(ARF), or P15. It is likely that mutations in other genes contribute to an inherited predisposition to uveal melanoma.	Cohort 385 patients with uveal melanoma 										
117963		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q22-q24	BRIP1	57114766	57295537		Sigurdson, A. J.  et al. 2004	15113441				BRCA1 interacting protein C-terminal helicase 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_032043.1			CDC GDPinfo	83990	Hs.532799			BMC cancer [electronic resource]. 2004 Mar;4:9	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.		605882	24098	2	2004	 Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.	Cohort 748 breast cancer cases identified within a cohort of femal US radiologic technologists and 2,430 female first-degree relatives of cases 										
117960		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Goode, E. L.  et al. 2002	12036913				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Cancer research. 2002 Jun;62(11):3052-7	Effect of germ-line genetic variation on breast cancer survival in a population-based study.		600185	25867	2	2002	Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.	Cohort 2430 cases of breast cancer from a population-based study for whom current vital status data were available 										
117958		breast cancer	CANCER	CAN	Breast Neoplasms|Neoplasms, Radiation-Induced|Neoplasms, Second Primary|Cocarcinogenesis|Genetic Predisposition to Disease	13	13q12.3	BRCA2	31787616	31871809		Bernstein, J. L.  et al. 2004	15084244				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Breast cancer research. 2004 ;6(3):R199-214	Study design: Evaluating gene-environmentinteractions in the etiology of breast cancer - the WECARE study		600185	24096	2	2004	 Our study design improves the potential for detecting gene-environment interactions for diseases when both gene mutations and the environmental exposures of interest are rare in the general population. This is particularly applicable to the study of bilateral breast cancer because both radiation dose and genetic susceptibility have important etiologic roles, possibly by interactive mechanisms. By using counter-matching, we optimized the informativeness of the collected dosimetry data by increasing the variability of radiation dose within the case-control sets and enhanced our ability to detect radiation-genotype interactions.	Control:1400 individually matched controls with unilateral breast cancer on date and age at diagnosis of the first breast cancer, race, and registry region, and counter-matched on radiation therapy;Case:700 women with asynchronous bilateral breast cancer										
117959		cancer	CANCER	CAN	Neoplasms|Breast Neoplasms|Ovarian Neoplasms|Fanconi Anemia|Bloom Syndrome|Genetic Predisposition to Disease|	13	13q12.3	BRCA2	31787616	31871809		Koren-Michowitz, M.  et al. 2005	15726604				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Jewish	Israel	CDC GDPinfo	675	Hs.34012			American journal of hematology. 2005 Mar;78(3):203-6	Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in riskmodification for cancer development.		600185	24097	2	2005	Coinheritance of FA and/or BS mutations seems to be more prevalent among BRCA mutation carriers, but a larger study encompassing more women may help in clarifying this issue.	Cohort 100 Ashkenazi women with known BRCA1 and BRCA2 mutations 										
117956		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	13	13q12.3	BRCA2	31787616	31871809		Menzel, H. J.  et al. 2004	15138483				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			British journal of cancer. 2004 May;90(10):1989-94	Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations.		600185	24094	2	2004	Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.	Control controls from Prague, Czech Republic;Case breast cancer cases Prague, Czech Republic;Control controls from Tyrol, Austria;Case breast cancer cases:Tyrol, Austria										
117957		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Dagan, E.  et al. 2002	12404104				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Jewish	Israel	CDC GDPinfo	675	Hs.34012			European journal of human genetics. 2002 Nov;10(11):724-8	Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers:association with breast/ovarian cancer phenotype.		600185	24095	2	2002	There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.	Cohort 227 BRCA1/2 mutation carriers 										
117953		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	13	13q12.3	BRCA2	31787616	31871809		Wang, W. W.  et al. 2001	11535547				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2		United States|Israel|Australia	CDC GDPinfo	675	Hs.34012			Cancer epidemiology, biomarkers & prevention. 2001 Sep;10(9):955-60	A Single Nucleotide Polymorphism in the 5' Untranslated Region of RAD51 and Risk of Cancer among BRCA1/2 Mutation Carriers		600185	20625	2	2001	We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers. The biochemical basis of this risk modifier is currently unknown.	Control:119 women without breast cancer;Case:67 breast cancer cases										
117954	Y	breast cancer	CANCER	CAN	Breast Neoplasms|DNA Damage|Genetic Predisposition to Disease|	13	13q12.3	BRCA2	31787616	31871809		Kadouri, L.  et al. 2004	15138485				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			British journal of cancer. 2004 May;90(10):2002-5	A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.		600185	20626	2	2004	These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found.	Control:152 women unaffected with breast cancer;Case:309/166 BRCA1/2 mutation carriers (n=309) and noncarrier breast cancer patients (n=166)										
117955		ovarian cancer	CANCER	CAN	Carcinoma|Breast Neoplasms|Ovarian Neoplasms|	13	13q12.3	BRCA2	31787616	31871809		Tong, D.  et al. 2003	12883740				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2		Austria	CDC GDPinfo	675	Hs.34012			Oncology reports. 2003 Sep-Oct;10(5):1551-3	Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.		600185	20627	2	2003	There are no statistically significant differences in the frequencies of the Rad52 mutations between the control group and sporadic ovarian cancer patients and between the control groups and familial breast/ovarian cancer patients, indicating that these two mutations of the Rad52 do not play a major role in the initiation of sporadic ovarian carcinoma and familial breast/ovarian cancer.	Control:128 healthy volunteers;Case:142 Austrian ovarian carcinoma patients										
117950		breast cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Hughes, D. J.  et al. 2005	15900600				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			International journal of cancer. Journal international du cancer. 2005 Nov;117(2):230-3	Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.		600185	20622	2	2005	These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.	Cohort 851/324 BRCA1 (n=851) and BRCA2 (n=32) female germline mutation carriers 										
117951		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	13	13q12.3	BRCA2	31787616	31871809		Runnebaum, I. B.  et al. 2001	11668223				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Pharmacogenetics. 2001 Oct;11(7):635-8	Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives		600185	20623	2	2001	Among the 214 carriers with no past exposure to oral contraceptives, the presence of one or more PROGINS alleles was associated with an OR of 2.4 for ovarian cancer, compared to women without ovarian cancer and with no PROGINS allele (P = 0.004; 95% CI 1.4-4.3). The association was present after adjustment for ethnic group and for year of birth.	Case:195 BRCA1 and BRCA2 carriers with a prior diagnosis of ovarian cancer;Control:249 carriers with neither cancer;Case:392 BRCA1 and BRCA2 carriers with a diagnosis of breast:cancer										
117952		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Levy-Lahad, E.  et al. 2001	11248061				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Proceedings of the National Academy of Sciences of the United States of America. 2001 Mar;98(6):3232-6	A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.		600185	20624	2	2001	These results show RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages.	Cohort 257 female Ashkenazi Jewish carriers of one of the common BRCA1 (185delAG, 5382insC) or BRCA2 (6174delT) mutations 										
117947		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Kotsopoulos, J.  et al. 2005	16049805				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Cancer causes & control. 2005 Aug;16(6):667-74	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.		600185	20619	2	2005			menarche									
117948		breast cancer	CANCER	CAN		13	13q12.3	BRCA2	31787616	31871809			16324400				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Zhonghua yi xue za zhi. 2005 Nov;85(43):3030-4	[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai.]		600185	20620	2	2005	 Four novel mutations in BRCA1 and one novel mutation in BRCA2 may be mutations characterized of early-onset breast cancer in Chinese population. Germline mutations in BRCA2 may contribute less than mutations in BRCA1 to early-onset breast cancer in Shanghai. These data contribute to information on spectrum of BRCA gene in Chinese population and also offer a recommended screening mode for clinical genetic testing programme in China.											
117949		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Rajkumar, T.  et al. 2003	14507240				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Indian	India	CDC GDPinfo	675	Hs.34012			Asian Pacific journal of cancer prevention. 2003 Jul-Sep;4(3):203-8	BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.		600185	20621	2	2003	This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.	Control healthy blood donors;Case:22 breast cancer patients with a family history of breat and/or ovarian cancer and early onset breast:cancer South India										
117944		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	13	13q12.3	BRCA2	31787616	31871809		Murday, V.  et al. 2004	15131403				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2		Great Britain	CDC GDPinfo	675	Hs.34012			Familial cancer. 2004 ;3(1):29-34	An audit of screening for familial breast cancer before 50 years in the South Thames Region - have we got it right?		600185	20616	2	2004	This audit suggests that screening below the age 50 years may be unnecessary in families with a low chance of having a BRCA1 or -2 mutation, but it is important to screen high-risk women at least annually and possibly under 35 years.	Cohort 192 women under 50 years of age attending family cancer clinics run by the South Thames genetic services 										
117945		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	13	13q12.3	BRCA2	31787616	31871809		Hallowell, N.  et al. 2004	15144764				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Social science & medicine (1982). 2004 Aug;59(3):553-65	Accommodating risk: responses to BRCA1/2 genetictesting of women who have had cancer.		600185	20617	2	2004	The data suggest that affected women understand their genetic risks of cancer within the context of their previous disease experiences. It is observed that women's responses to their genetic risk are influenced by the degree to which they have accommodated their risk status in their biography following their diagnosis and treatment of cancer.	Cohort 30 women (10 mutation carriers, 8 awaiting a result and 12 who received an inconclusive test result) 										
117946	Y	breast cancer, male	CANCER	CAN	Breast Neoplasms, Male|Occupational Diseases	13	13q12.3	BRCA2	31787616	31871809		Palli, D.  et al. 2004	15519522				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Eur J Cancer. 2004 Nov;40(16):2474-9	A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?		600185	20618	2	2004	The possible modifying effect on MBC risk in subjects carrying BRCA1/2 germ-line mutations of an occupation characterised by exposure to chemicals such as polycyclic aromatic hydrocarbons (PAH) that are capable of inducing DNA damage, may provide clues to the role of environmental exposures in modifying BC risk in mutation carriers in both genders.	Cohort 23 male breast cancer cases 	occupation									
117941		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Jara, L.  et al. 2002	12491828				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2		Chile	CDC GDPinfo	675	Hs.34012			Rev Med Chil. 2002 Oct;130(10):1113-23	[Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer]		600185	20613	2	2002	 The frequency of the 185delAG mutation in BRCA1 was 0.26% (1/382) in Chilean healthy women with a family history of breast cancer.	Cohort 382 Chilean healthy women with at least two relatives affected with breast cancer 										
117942	N	breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Robson, M. E.  et al. 2004	14680495				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Breast cancer research. 2004 ;6(1):R8-R17	A combined analysis of outcome following breast cancer: differences in survival based onBRCA1/BRCA2 mutation status and administration of adjuvant treatment.		600185	20614	2	2004	 BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. The risk for metachronous ipsilateral disease does not appear to be increased for either BRCA1 or BRCA2 mutation carriers, at least up to 10 years of follow up.	Cohort 584 Ashkenazi Jewish women from two retrospective cohorts undergoing breast-conserving treatment for invasive cancer 1980-1995 										
117943		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Zhou, Y. Z.  et al. 2004	15059511				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Chinese	China	CDC GDPinfo	675	Hs.34012			Zhonghua yi xue za zhi. 2004 Feb;84(4):294-8	[Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people]		600185	20615	2	2004	 Two pathogenic SNPs have been found in BRCA1 and may be related to early-onset breast cancer. One of them may be a novel mutation characterized of familial breast cancer in China.	Control:100 healthy controls;Case:15/76 inherited breast cancer patients (n=15) from 14 breast cancer families and sporadic breast cancer:patients (n=76):China										
117939		breast cancer	CANCER	CAN	Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Cella, D.  et al. 2002	12433008				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2		Ontario	CDC GDPinfo	675	Hs.34012			Health psychology. 2002 Nov;21(6):564-72	A brief assessment of concerns associated with genetic testing for cancer: the MultidimensionalImpact of Cancer Risk Assessment (MICRA) questionnaire		600185	20611	2	2002	Factor analysis supported the formation of 3	Cohort 158 women responding to questionnaire 1 month after receiving genetic test results 										
117940		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	13	13q12.3	BRCA2	31787616	31871809		Berrino, F.  et al. 2002	12484126				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2		Europe	CDC GDPinfo	675	Hs.34012			IARC scientific publications. 2002 ;156:63-5	A European case-only study on familial breast cancer		600185	20612	2	2002	The small size of the sudy does not permit any firm conclusions so far, but suggests that high parity and frequent x-ray exposure in childhood are associated with and increased risk of breast cancer in mutation carriers. Oral contraceptives do not seem to increase the risk and tobacco smoking does not seem to protect.	Case:103/356 genetic cases (n=103) and sporadic cases (n=356)	oral contraceptive parity radiation smoking (tobacco)									
117935		breast cancer, familial	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Antoniou, A. C.  et al. 2002	11857015				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			British journal of cancer. 2002 Jan;86(1):76-83	A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.		600185	20607	2	2002	The findings suggest that several common, low penetrance genes with multiplicative effects on risk may account for the residual non-BRCA1/2 familial aggregation of breast cancer. The modifying effect may explain the previously reported differences between population based estimates for BRCA1/2 penetrance and estimates based on high-risk families.	Cohort population based series of breast cancer cases 										
117936		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Miyoshi, Y.  et al. 2002	11977534				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Japanese		CDC GDPinfo	675	Hs.34012			Gan to kagaku ryoho Cancer & chemotherapy. 2002 Apr;29(4):512-22	[Genetic test and prophylactic treatment in breast cancer families]		600185	20608	2	2002	These results indicate that genetic testing and prophylactic surgery would be acceptable among a considerable number of Japanese women, and seem to support the establishment an infrastructure for genetic testing in Japan.	Cohort 113 Japanese breast cancer families Japan 										
117937		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Tereshchenko, I. V.  et al. 2002	12101561				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Voprosy onkologii. 2002 ;48(1):24-8	[Investigation of mutations of BRCA1 and BRCA2 genes in 52 breast cancer patients]		600185	20609	2	2002	The frequency of carriers of mutations among familial cancer cases was 16%, among cases of disease till 40 years--9%. 538insC BRCA1 was the most common genetic mutation among hereditary cases of breast cancer.	Case:52										
117932		breast cancer; ovarian cancer	CANCER	CAN	Carcinoma, Ductal, Breast|Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Pericay, C.  et al. 2001	11481082				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Med Clin (Barc). 2001 Jul;117(5):161-6	[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]		600185	20604	2	2001	 There were no differences in age at diagnosis and stage between BRCA1 and BRCA2 breast cancer. The mammographic pattern in BRCA2 was more heterogeneous. BRCA1 mutations were associated with more aggressive histopathologic findings and a higher risk of a second BC and OC.	Cohort 30 patients with breast cancer 										
117933		breast cancer	CANCER	CAN	Breast Neoplasms|Neoplasms, Multiple Primary|Neoplasm Recurrence, Local|Chromosome Deletion	13	13q12.3	BRCA2	31787616	31871809		Bremer, M.  et al. 2001	11505617				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Strahlentherapie und Onkologie. 2001 Jul;177(7):325-9	[Bilateral breast carcinoma and local recurrence:prevalence of BRCA-1 and BRCA-2 gene mutations in an unselected patient sample]		600185	20605	2	2001	 We failed to confirm an increased prevalence of BRCA 1/BRCA 2 mutations in our hospital-based series of patients with bilateral breast cancer. However, local relapse, especially when occurring after radiotherapy, may be predictive for an underlying pathogenic BRCA 1 and BRCA 2 gene mutation in patients with bilateral breast cancer.	Cohort 75 patients with bilateral breast cancer, who received posoperative radiotherapy 1995-2000 										
117929		pancreatic cancer	CANCER	CAN	Pancreatic Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Malats, N.   2001	12120227				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Pancreatology. 2001 ;1(5):472-6	Gene-environment interactions in pancreatic cancer.		600185	20601	2	2001	Review article		alcohol smoking (tobacco)									
117930		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Metcalfe, K. A.  et al. 2000	11073541				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Journal of medical genetics. 2000 Nov;37(11):866-74	An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.		600185	20602	2	2000	 These findings have a direct impact on the counselling and risk management of female BRCA mutation carriers. Age, education, and a previous diagnosis of cancer are important determinants in a woman's decision making after receiving positive genetic test results.	Cohort 79 women surveyed or 105 women who had received pre- and post-test genetic counselling for a positive BRCA1/2 result at the University of Toronto or at McGill University Montreal, Canada 										
117931	Y	breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Machackova, E.  et al. 2000	11192759				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Czech	Czech Republic	CDC GDPinfo	675	Hs.34012			Cas Lek Cesk. 2000 Oct;139(20):635-7	A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families		600185	20603	2	2000	 Molecular genetic testing of BRCA1 and BRCA2 genes in high-risk women with breast/ovarian cancer is effective in determining genetic predisposition to cancer. Spectrum of mutations found in both genes is variable and further investigation is needed for estimation of more frequent or founder mutations. The genetic counselling and preventive clinical follow-up of gene carriers has to be part of the genetic program.	Cohort 21 tested families in the South Moravian region of the Czech Republic 										
117926	Y	stomach cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Jakubowska, A.  et al. 2003	14647210				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Polish	Poland	CDC GDPinfo	675	Hs.34012			European journal of human genetics. 2003 Dec;11(12):955-8	A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer.		600185	15506	2	2003	The results of this study suggest that, in the Polish population, the constellation of ovarian and stomach cancer predicts the presence of a germ-line BRCA2 mutation and confirms that stomach cancer is part of the spectrum of BRCA2 mutations. It is expected that the penetrance of BRCA2 mutations for stomach cancer will vary from country to country, reflecting local environmental and lifestyle factors.	Case:34 women with ovarian cancer and a family history of stomach cancer:Poland;Control:75 women with ovarian cancer and a family history of ovarian cancer:Poland										
117927		breast cancer	CANCER	CAN		13	13q12.3	BRCA2	31787616	31871809		Gorski, B.  et al. 2005	16280055				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Breast cancer research. 2005 ;7(6):R1023-7	A common missense variant in BRCA2 predisposes to early onset breast cancer.		600185	15507	2	2005	 The BRCA2 C5972T allele is a common variant in Poland that increases the risk of DCIS with micro-invasion. The homozygous state is rare but increases the risk of breast cancer five-fold.											
117928		uveal melanoma	CANCER	CAN	Melanoma|Uveal Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Hearle, N.  et al. 2003	12556369				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Investigative ophthalmology & visual science. 2003 Feb;44(2):458-62	Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.		600185	15717	2	2003	 These findings suggest that less than 2% of cases of uveal melanoma can be ascribed to germline mutations in BRCA2, P16(INK4A), P14(ARF), or P15. It is likely that mutations in other genes contribute to an inherited predisposition to uveal melanoma.	Cohort 385 patients with uveal melanoma 										
117923		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Millikan, R. C.  et al. 2005	16214912				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Cancer epidemiology, biomarkers & prevention. 2005 Oct;14(10):2326-34	Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk.		600185	8951	2	2005			radiation									
117924		breast cancer	CANCER	CAN		13	13q12.3	BRCA2	31787616	31871809		Sliwinski, T.  et al. 2005	16261408				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Breast cancer research and treatment. 2005 Nov;94(2):105-9	Polymorphisms of the BRCA2 and RAD51 Genes in Breast Cancer.		600185	13444	2	2005				BRCA2	Met1915Thr Thr/Thr	BRCA2	Met784Val Met/Met	RAD51		Y		Breast Cancer
117925	Y	prenatal viability	CANCER	CAN	Breast Neoplasms|Neoplastic Syndromes, Hereditary|Fetal Death|Genetic Predisposition to Disease|Birth Weight	13	13q12.3	BRCA2	31787616	31871809		Healey, C. S.  et al. 2000	11062481				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Nature genetics. 2000 Nov;26(3):362-4	A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability.		600185	15505	2	2000	The N372H variant of BRCA2 appears also to affect fetal survival in a sex-dependent manner	Case not stated in abstract										
117920		esophageal cancer	CANCER	CAN	Carcinoma, Squamous Cell|Esophageal Neoplasms|Genetic Predisposition to Disease|	13	13q12.3	BRCA2	31787616	31871809		Hu N 2004	14647438				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			KGB	675	Hs.34012			Oncogene. 2004 Jan;23(3):852-8	Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer.		600185	1018	1	2004	We conclude that  germline mutations in BRCA2 in ESCC patients from this high-risk area of China are more frequent in FH+ than FH- cases, suggesting that BRCA2 may play a role in genetic susceptibility to familial ESCC.											
117921		spontaneous chromosomal instability	OTHER	OTH	Neoplasms|Wilms Tumor|Medulloblastoma|Brain Stem Neoplasms|Kidney Neoplasms|Anemia, Aplastic|	13	13q12.3	BRCA2	31787616	31871809		Hirsch B 2004	14670928				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			KGB	675	Hs.34012			Blood. 2004 Apr;103(7):2554-9	Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood.		600185	1019	1	2004												
117922	Y	lung cancer	CANCER	CAN	Lung Neoplasms|DNA Damage	13	13q12.3	BRCA2	31787616	31871809		Medina, P. P.  et al. 2003	12917199				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			Cancer epidemiology, biomarkers & prevention. 2003 Aug;12(8):699-704	Screening of Homologous Recombination Gene Polymorphisms in Lung Cancer Patients Reveals an Association of the NBS1-185Gln Variant and p53 Gene Mutations		600185	8950	2	2003	Germ-line variants in the NBS1 gene may play a role in the lung carcinogenesis in cigarette smokers.	Cohort 109 lung cancer patients 	smoking (tobacco)	NBS1	185Gln	p53				Y	cigarette smoking	lung cancer
117917	Y	breast cancer	CANCER	CAN	Medulloblastoma|Breast Neoplasms|Brain Neoplasms|Fanconi Anemia|Syndrome|Genetic Predisposition to Disease|	13	13q12.3	BRCA2	31787616	31871809		Offit K 2003	14559878				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			KGB	675	Hs.34012			Journal of the National Cancer Institute. 2003 Oct;95(20):1548-51	Shared genetic susceptibility to breast cancer, brain tumors~~~ and Fanconi anemia.		600185	1015	1	2003												
117918	Y	prophylactic breast surgery	OTHER	OTH	Genetic Predisposition to Disease	13	13q12.3	BRCA2	31787616	31871809		van Oostrom I 2003	14551306				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			KGB	675	Hs.34012			Journal of clinical oncology. 2003 Oct;21(20):3867-74	Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.		600185	1016	1	2003	 Our findings support the emerging consensus that genetic predisposition testing for BRCA1/2 does not pose major mental health risks, but our findings also show that the impact of prophylactic surgery on aspects such as body image and sexuality should not be underestimated, and that some women are at risk for high distress, and as a result, need more attentive care.											
117919		ovarian cancer	CANCER	CAN	Carcinoma|Peritoneal Neoplasms|Ovarian Neoplasms|	13	13q12.3	BRCA2	31787616	31871809		Rutter JL 2003	12865453				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Israeli	Israel	KGB	675	Hs.34012			Journal of the National Cancer Institute. 2003 Jul;95(14):1072-8	Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.		600185	1017	1	2003	 Both BRCA1/2 mutation carriers and non-carriers have reduced risk of ovarian or peritoneal cancer after gynecologic surgery. The magnitude of the reduction depends upon the type and extent of surgery.											
117914		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Goode, E. L.  et al. 2002	12036913				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Cancer research. 2002 Jun;62(11):3052-7	Effect of germ-line genetic variation on breast cancer survival in a population-based study.		113705	24093	2	2002	Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.	Cohort 2430 cases of breast cancer from a population-based study for whom current vital status data were available 										
117915	Y	breast cancer risk and prenatal viability	CANCER	CAN	Breast Neoplasms|Neoplastic Syndromes, Hereditary|Fetal Death|Genetic Predisposition to Disease|Birth Weight	13	13q12.3	BRCA2	31787616	31871809		Healey CS et al. 2000	11062481				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			KGB	675	Hs.34012			Nature genetics. 2000 Nov;26(3):362-4	A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability.		600185	1013	1	2000	The N372H variant of BRCA2 appears also to affect fetal survival in a sex-dependent manner	Case not stated in abstract										
117916		ovarian cancer	CANCER	CAN	Ovarian Neoplasms|Genetic Predisposition to Disease	13	13q12.3	BRCA2	31787616	31871809		Schwartz MD 2003	14581427				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2		District of Columbia	KGB	675	Hs.34012			Journal of clinical oncology. 2003 Nov;21(21):4034-41	Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.		600185	1014	1	2003	 These results demonstrate the significant behavioral impact of receiving a positive BRCA1/2 test result. The increased rate of oophorectomy among mutation carriers suggests that testing for BRCA1/2 mutations may ultimately impact ovarian cancer mortality.											
117912		breast cancer	CANCER	CAN	Breast Neoplasms|Neoplasms, Radiation-Induced|Neoplasms, Second Primary|Cocarcinogenesis|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Bernstein, J. L.  et al. 2004	15084244				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Breast cancer research. 2004 ;6(3):R199-214	Study design: Evaluating gene-environmentinteractions in the etiology of breast cancer - the WECARE study		113705	20599	2	2004	 Our study design improves the potential for detecting gene-environment interactions for diseases when both gene mutations and the environmental exposures of interest are rare in the general population. This is particularly applicable to the study of bilateral breast cancer because both radiation dose and genetic susceptibility have important etiologic roles, possibly by interactive mechanisms. By using counter-matching, we optimized the informativeness of the collected dosimetry data by increasing the variability of radiation dose within the case-control sets and enhanced our ability to detect radiation-genotype interactions.	Control:1400 individually matched controls with unilateral breast cancer on date and age at diagnosis of the first breast cancer, race, and registry region, and counter-matched on radiation therapy;Case:700 women with asynchronous bilateral breast cancer										
117913		cancer	CANCER	CAN	Neoplasms|Breast Neoplasms|Ovarian Neoplasms|Fanconi Anemia|Bloom Syndrome|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Koren-Michowitz, M.  et al. 2005	15726604				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Jewish	Israel	CDC GDPinfo	672	Hs.194143			American journal of hematology. 2005 Mar;78(3):203-6	Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in riskmodification for cancer development.		113705	20600	2	2005	Coinheritance of FA and/or BS mutations seems to be more prevalent among BRCA mutation carriers, but a larger study encompassing more women may help in clarifying this issue.	Cohort 100 Ashkenazi women with known BRCA1 and BRCA2 mutations 										
117910		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Menzel, H. J.  et al. 2004	15138483				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			British journal of cancer. 2004 May;90(10):1989-94	Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations.		113705	20597	2	2004	Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.	Control controls from Prague, Czech Republic;Case breast cancer cases Prague, Czech Republic;Control controls from Tyrol, Austria;Case breast cancer cases:Tyrol, Austria										
117911		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Dagan, E.  et al. 2002	12404104				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Jewish	Israel	CDC GDPinfo	672	Hs.194143			European journal of human genetics. 2002 Nov;10(11):724-8	Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers:association with breast/ovarian cancer phenotype.		113705	20598	2	2002	There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.	Cohort 227 BRCA1/2 mutation carriers 										
117907		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Freedman, M. L.  et al. 2005	16103107				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Cancer research. 2005 Aug;65(16):7516-22	A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.		113705	15503	2	2005												
117909		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Sigurdson, A. J.  et al. 2004	15113441				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			BMC cancer [electronic resource]. 2004 Mar;4:9	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.		113705	20596	2	2004	 Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.	Cohort 748 breast cancer cases identified within a cohort of femal US radiologic technologists and 2,430 female first-degree relatives of cases 										
117905		breast cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Hughes, D. J.  et al. 2005	15900600				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			International journal of cancer. Journal international du cancer. 2005 Nov;117(2):230-3	Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.		113705	15501	2	2005	These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.	Cohort 851/324 BRCA1 (n=851) and BRCA2 (n=32) female germline mutation carriers 								N		
117906		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Kotsopoulos, J.  et al. 2005	16049805				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Cancer causes & control. 2005 Aug;16(6):667-74	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.		113705	15502	2	2005			menarche									
117902	Y	breast cancer	CANCER	CAN	Breast Neoplasms|DNA Damage|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Bau, D. T.  et al. 2004	15256476				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Cancer research. 2004 Jul;64(14):5013-9	Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.		113705	15497	2	2004	Because BRCA1 is a well-documented breast cancer susceptibility gene, this association between NHEJ and BRCA1 not only suggests a role of BRCA1 in NHEJ but also provides essential support for the tumorigenic contribution of NHEJ in breast cancer development..	Case:469 breast cancer patients;Control:740 healthy controls		NHEJ		BRCA1				Y		breast cancer
117903	Y	breast cancer, male	CANCER	CAN	Breast Neoplasms, Male|Occupational Diseases	17	17q21	BRCA1	38449839	38530994		Palli, D.  et al. 2004	15519522				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Eur J Cancer. 2004 Nov;40(16):2474-9	A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?		113705	15498	2	2004	The possible modifying effect on MBC risk in subjects carrying BRCA1/2 germ-line mutations of an occupation characterised by exposure to chemicals such as polycyclic aromatic hydrocarbons (PAH) that are capable of inducing DNA damage, may provide clues to the role of environmental exposures in modifying BC risk in mutation carriers in both genders.	Cohort 23 male breast cancer cases 	occupation									
117900		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Murday, V.  et al. 2004	15131403				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Great Britain	CDC GDPinfo	672	Hs.194143			Familial cancer. 2004 ;3(1):29-34	An audit of screening for familial breast cancer before 50 years in the South Thames Region - have we got it right?		113705	15495	2	2004	This audit suggests that screening below the age 50 years may be unnecessary in families with a low chance of having a BRCA1 or -2 mutation, but it is important to screen high-risk women at least annually and possibly under 35 years.	Cohort 192 women under 50 years of age attending family cancer clinics run by the South Thames genetic services 										
117901		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Hallowell, N.  et al. 2004	15144764				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Social science & medicine (1982). 2004 Aug;59(3):553-65	Accommodating risk: responses to BRCA1/2 genetictesting of women who have had cancer.		113705	15496	2	2004	The data suggest that affected women understand their genetic risks of cancer within the context of their previous disease experiences. It is observed that women's responses to their genetic risk are influenced by the degree to which they have accommodated their risk status in their biography following their diagnosis and treatment of cancer.	Cohort 30 women (10 mutation carriers, 8 awaiting a result and 12 who received an inconclusive test result) 										
117898	Y	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Robson, M. E.  et al. 2004	14680495				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Breast cancer research. 2004 ;6(1):R8-R17	A combined analysis of outcome following breast cancer: differences in survival based onBRCA1/BRCA2 mutation status and administration of adjuvant treatment.		113705	15491	2	2004	 BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. The risk for metachronous ipsilateral disease does not appear to be increased for either BRCA1 or BRCA2 mutation carriers, at least up to 10 years of follow up.	Cohort 584 Ashkenazi Jewish women from two retrospective cohorts undergoing breast-conserving treatment for invasive cancer 1980-1995 										
117899	Y	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Zhou, Y. Z.  et al. 2004	15059511				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Chinese	China	CDC GDPinfo	672	Hs.194143			Zhonghua yi xue za zhi. 2004 Feb;84(4):294-8	[Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people]		113705	15492	2	2004	 Two pathogenic SNPs have been found in BRCA1 and may be related to early-onset breast cancer. One of them may be a novel mutation characterized of familial breast cancer in China.	Control:100 healthy controls;Case:15/76 inherited breast cancer patients (n=15) from 14 breast cancer families and sporadic breast cancer:patients (n=76):China										
117896		ovarian cancer	CANCER	CAN	Carcinoma|Breast Neoplasms|Ovarian Neoplasms|	17	17q21	BRCA1	38449839	38530994		Tong, D.  et al. 2003	12883740				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Austria	CDC GDPinfo	672	Hs.194143			Oncology reports. 2003 Sep-Oct;10(5):1551-3	Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.		113705	15489	2	2003	There are no statistically significant differences in the frequencies of the Rad52 mutations between the control group and sporadic ovarian cancer patients and between the control groups and familial breast/ovarian cancer patients, indicating that these two mutations of the Rad52 do not play a major role in the initiation of sporadic ovarian carcinoma and familial breast/ovarian cancer.	Control:128 healthy volunteers;Case:142 Austrian ovarian carcinoma patients										
117897		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Rajkumar, T.  et al. 2003	14507240				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Indian	India	CDC GDPinfo	672	Hs.194143			Asian Pacific journal of cancer prevention. 2003 Jul-Sep;4(3):203-8	BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.		113705	15490	2	2003	This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.	Control healthy blood donors;Case:22 breast cancer patients with a family history of breat and/or ovarian cancer and early onset breast:cancer South India										
117894		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Berrino, F.  et al. 2002	12484126				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Europe	CDC GDPinfo	672	Hs.194143			IARC scientific publications. 2002 ;156:63-5	A European case-only study on familial breast cancer		113705	15487	2	2002	The small size of the sudy does not permit any firm conclusions so far, but suggests that high parity and frequent x-ray exposure in childhood are associated with and increased risk of breast cancer in mutation carriers. Oral contraceptives do not seem to increase the risk and tobacco smoking does not seem to protect.	Case:103/356 genetic cases (n=103) and sporadic cases (n=356)	oral contraceptive parity radiation smoking (tobacco)									
117895		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Jara, L.  et al. 2002	12491828	185delAG			Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Chile	CDC GDPinfo	672	Hs.194143			Rev Med Chil. 2002 Oct;130(10):1113-23	[Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer]		113705	15488	2	2002	 The frequency of the 185delAG mutation in BRCA1 was 0.26% (1/382) in Chilean healthy women with a family history of breast cancer.	Cohort 382 Chilean healthy women with at least two relatives affected with breast cancer 										
117893	Y	breast cancer	CANCER	CAN	Neoplasms	17	17q21	BRCA1	38449839	38530994		Cella, D.  et al. 2002	12433008				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Ontario	CDC GDPinfo	672	Hs.194143			Health psychology. 2002 Nov;21(6):564-72	A brief assessment of concerns associated with genetic testing for cancer: the MultidimensionalImpact of Cancer Risk Assessment (MICRA) questionnaire		113705	15486	2	2002	Factor analysis supported the formation of 3	Cohort 158 women responding to questionnaire 1 month after receiving genetic test results 										
117890	Y	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Tereshchenko, I. V.  et al. 2002	12101561				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Voprosy onkologii. 2002 ;48(1):24-8	[Investigation of mutations of BRCA1 and BRCA2 genes in 52 breast cancer patients]		113705	15482	2	2002	The frequency of carriers of mutations among familial cancer cases was 16%, among cases of disease till 40 years--9%. 538insC BRCA1 was the most common genetic mutation among hereditary cases of breast cancer.	Case:52										
117891	N	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Ke, Y.  et al. 2002	12362311				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Chinese		CDC GDPinfo	672	Hs.194143			Zhonghua yi xue yi chuan xue za zhi. 2002 Oct;19(5):383-5	[Analysis of mutation sites of BRCA1 gene in Chinese patients with breast cancer]		113705	15483	2	2002	 The above results suggest this SNP may not be associated with the breast cancer in Chinese population, and indicates that the gene sequence of what we have studied doesn't account much for occurrence of the breast cancer in the population of China.	Control:controls;Case:86 patients with breast cancer without blood relationship randomly selected										
117888		breast cancer, familial	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Antoniou, A. C.  et al. 2002	11857015				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			British journal of cancer. 2002 Jan;86(1):76-83	A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.		113705	15479	2	2002	The findings suggest that several common, low penetrance genes with multiplicative effects on risk may account for the residual non-BRCA1/2 familial aggregation of breast cancer. The modifying effect may explain the previously reported differences between population based estimates for BRCA1/2 penetrance and estimates based on high-risk families.	Cohort population based series of breast cancer cases 										
117889		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Miyoshi, Y.  et al. 2002	11977534				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Japanese		CDC GDPinfo	672	Hs.194143			Gan to kagaku ryoho Cancer & chemotherapy. 2002 Apr;29(4):512-22	[Genetic test and prophylactic treatment in breast cancer families]		113705	15480	2	2002	These results indicate that genetic testing and prophylactic surgery would be acceptable among a considerable number of Japanese women, and seem to support the establishment an infrastructure for genetic testing in Japan.	Cohort 113 Japanese breast cancer families Japan 										
117886		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Hughes, C.  et al. 2002	11807889				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			American journal of medical genetics. 2002 Jan;107(2):143-50	All in the family: evaluation of the process andcontent of sisters' communication about BRCA1 and BRCA2 genetic test results.		113705	15477	2	2002	The results of this study suggest that probands are likely to quickly communicate their BRCA1/2 test results to relatives and that although needs for social support may motivate family communication, emotionally distant relationships may be a barrier to communication with relatives.	Cohort 81 sisters of 43 women who were the first family member to have genetic testing 										
117887		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Breast Neoplasms, Male|Ovarian Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Levin, T.  et al. 2001	11826460				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Norway	CDC GDPinfo	672	Hs.194143			Tidsskrift for den Norske laegeforening. 2001 Nov;121(28):3292-4	[Information to families with hereditary breast and ovarian cancer]		113705	15478	2	2001	The legislation constituted no barrier to offering health services to the target group. Information on our services had reached all close relatives who could benefit from them. This may be representative for curable inherited disorders. We examined inherited cancer limited to females; similar studies on inherited cancers in males and on other curable inherited disorders should be performed. Outside the framework of the present study, we are aware of rare examples of distant cousins who have not been properly informed through their families. One legally acceptable way of identifying mutation carrier families is to test all patients with breast or ovarian cancer for causative mutations. Health services should be monitored to make future decisions based on empirical evidence.	Cohort all first-degree relatives of all 75 BRCA1 mutation carriers diagnosed within a given period of time and asked them whether or not they had been informed by their relatives. 										
117884		breast cancer	CANCER	CAN	Breast Neoplasms|Neoplasms, Multiple Primary|Neoplasm Recurrence, Local|Chromosome Deletion	17	17q21	BRCA1	38449839	38530994		Bremer, M.  et al. 2001	11505617				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Strahlentherapie und Onkologie. 2001 Jul;177(7):325-9	[Bilateral breast carcinoma and local recurrence:prevalence of BRCA-1 and BRCA-2 gene mutations in an unselected patient sample]		113705	15475	2	2001	 We failed to confirm an increased prevalence of BRCA 1/BRCA 2 mutations in our hospital-based series of patients with bilateral breast cancer. However, local relapse, especially when occurring after radiotherapy, may be predictive for an underlying pathogenic BRCA 1 and BRCA 2 gene mutation in patients with bilateral breast cancer.	Cohort 75 patients with bilateral breast cancer, who received posoperative radiotherapy 1995-2000 										
117885		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Runnebaum, I. B.  et al. 2001	11668223				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Pharmacogenetics. 2001 Oct;11(7):635-8	Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives		113705	15476	2	2001	Among the 214 carriers with no past exposure to oral contraceptives, the presence of one or more PROGINS alleles was associated with an OR of 2.4 for ovarian cancer, compared to women without ovarian cancer and with no PROGINS allele (P = 0.004; 95% CI 1.4-4.3). The association was present after adjustment for ethnic group and for year of birth.	Case:195 BRCA1 and BRCA2 carriers with a prior diagnosis of ovarian cancer;Control:249 carriers with neither cancer;Case:392 BRCA1 and BRCA2 carriers with a diagnosis of breast:cancer		BRCA1		BRCA2		PGR		Y		Risk of Ovarian cancer
117882	Y	breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Machackova, E.  et al. 2000	11192759				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Czech	Czech Republic	CDC GDPinfo	672	Hs.194143			Cas Lek Cesk. 2000 Oct;139(20):635-7	A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families		113705	15473	2	2000	 Molecular genetic testing of BRCA1 and BRCA2 genes in high-risk women with breast/ovarian cancer is effective in determining genetic predisposition to cancer. Spectrum of mutations found in both genes is variable and further investigation is needed for estimation of more frequent or founder mutations. The genetic counselling and preventive clinical follow-up of gene carriers has to be part of the genetic program.	Cohort 21 tested families in the South Moravian region of the Czech Republic 										
117883		breast cancer; ovarian cancer	CANCER	CAN	Carcinoma, Ductal, Breast|Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Pericay, C.  et al. 2001	11481082				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Med Clin (Barc). 2001 Jul;117(5):161-6	[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]		113705	15474	2	2001	 There were no differences in age at diagnosis and stage between BRCA1 and BRCA2 breast cancer. The mammographic pattern in BRCA2 was more heterogeneous. BRCA1 mutations were associated with more aggressive histopathologic findings and a higher risk of a second BC and OC.	Cohort 30 patients with breast cancer 										
117879		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Gorski, B.  et al. 2005	15980987				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Polish	Poland	CDC GDPinfo	672	Hs.194143			Breast cancer research and treatment. 2005 Jul;92(1):19-24	Breast cancer predisposing alleles in Poland.		113705	8948	2	2005												
117880	Y	breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994			16161633				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Genetika. 2005 Aug;41(8):1115-24	[Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer]		113705	8949	2	2005												
117881		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Metcalfe, K. A.  et al. 2000	11073541				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Journal of medical genetics. 2000 Nov;37(11):866-74	An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.		113705	15472	2	2000	 These findings have a direct impact on the counselling and risk management of female BRCA mutation carriers. Age, education, and a previous diagnosis of cancer are important determinants in a woman's decision making after receiving positive genetic test results.	Cohort 79 women surveyed or 105 women who had received pre- and post-test genetic counselling for a positive BRCA1/2 result at the University of Toronto or at McGill University Montreal, Canada 										
117877	Y	breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Jakubowska, A.  et al. 2003	12750242				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Polish	Poland	CDC GDPinfo	672	Hs.194143			Cancer epidemiology, biomarkers & prevention. 2003 May;12(5):457-9	Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.		113705	8945	2	2003	This finding suggests that RAD51 is a genetic modifier of breast cancer risk in BRCA1 carriers in the Polish population. It will be of interest to confirm this in other populations as well.	Case:83 breast cancer cases who were carriers of the BRCA1 5382insC mutation;Control:83 women with the BRCA1 5382insC mutation but were:unaffected		BRCA1		RAD51				Y		breast cancer
117878	N	breast cancer	CANCER	CAN	Breast Neoplasms|DNA Damage|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Kadouri, L.  et al. 2004	15138485				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			British journal of cancer. 2004 May;90(10):2002-5	A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.		113705	8947	2	2004	These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found.	Control:152 women unaffected with breast cancer;Case:309/166 BRCA1/2 mutation carriers (n=309) and noncarrier breast cancer patients (n=166)		BRCA2		RAD51	135c			Y		breast cancer
117875		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Levy-Lahad, E.  et al. 2001	11248061				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Proceedings of the National Academy of Sciences of the United States of America. 2001 Mar;98(6):3232-6	A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.		113705	8943	2	2001	These results show RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages.	Cohort 257 female Ashkenazi Jewish carriers of one of the common BRCA1 (185delAG, 5382insC) or BRCA2 (6174delT) mutations 		BRCA2	6174delT	RAD51	135C			Y		breast cancer
117876		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Wang, W. W.  et al. 2001	11535547				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		United States|Israel|Australia	CDC GDPinfo	672	Hs.194143			Cancer epidemiology, biomarkers & prevention. 2001 Sep;10(9):955-60	A Single Nucleotide Polymorphism in the 5' Untranslated Region of RAD51 and Risk of Cancer among BRCA1/2 Mutation Carriers		113705	8944	2	2001	We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers. The biochemical basis of this risk modifier is currently unknown.	Control:119 women without breast cancer;Case:67 breast cancer cases										
117872		breast cancer	CANCER	CAN	Carcinoma, Ductal|Breast Neoplasms|Neoplasm Invasiveness|Fibrocystic Breast Disease	17	17q21	BRCA1	38449839	38530994		Cavalli LR 2004	15104281				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Cancer genetics and cytogenetics. 2004 Feb;149(1):38-43	Loss of heterozygosity in normal breast epithelial t and benign breast lesions in BRCA1/2 carriers with breast cancer.		113705	1010	1	2004												
117873		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Evans DG 2004	14680492				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Breast cancer research. 2004 ;6(1):E7	Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?		113705	1011	1	2004												
117874	Y	endometrial carcinoma	CANCER	CAN	Carcinoma, Endometrioid|Endometrial Neoplasms|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Levine DA et al. 2001	11263938				breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007295			KGB	672	Hs.194143			Gynecologic oncology. 2001 Mar;80(3):395-8	Risk of endometrial carcinoma associated with BRCA mutation.		113705	1012	1	2001	 For individuals with a germline BRCA mutation, the lifetime risk of endometrial carcinoma is not increased.											
117869		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Kadouri L 2004	14648706				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			International journal of cancer. Journal international du cancer. 2004 Jan;108(3):399-403	Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.		113705	1007	1	2004												
117870		colorectal cancer	CANCER	CAN	Colorectal Neoplasms	17	17q21	BRCA1	38449839	38530994		Kirchhoff T 2004	14709740				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		District of Columbia|Israel	KGB	672	Hs.194143			Journal of the National Cancer Institute. 2004 Jan;96(1):68-70	Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.		113705	1008	1	2004												
117871		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Foulkes WD 2004	14871808				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Cancer research. 2004 Feb;64(3):830-5	The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.		113705	1009	1	2004												
117866		colorectal cancer	CANCER	CAN	Breast Neoplasms|Colorectal Neoplasms|Genetic Predisposition to Disease|	17	17q21	BRCA1	38449839	38530994		Niell BL 2004	14709734				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Israel	KGB	672	Hs.194143			Journal of the National Cancer Institute. 2004 Jan;96(1):15-21	BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.		113705	1004	1	2004	 Although weak associations cannot be excluded, Ashkenazi BRCA founder mutations do not confer a strongly elevated risk of colorectal cancer. Similarly, a family history of breast cancer does not appear to be a strong risk factor for colorectal cancer in this population.											
117867		germline mutations	OTHER	OTH	Brenner Tumor|Carcinoma|Peritoneal Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Pautier P 2004	15026477				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Journal of the National Cancer Institute. 2004 Mar;96(6):488-9	Is systemic disease in the coelomic epithelium associated with BRCA1 germline mutations?		113705	1005	1	2004												
117868		ovarian cancer	CANCER	CAN	Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Malander S 2004	14746861				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Sweden	KGB	672	Hs.194143			Eur J Cancer. 2004 Feb;40(3):422-8	One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.		113705	1006	1	2004												
117863	Y	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Robson ME 2004	14680495				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Breast cancer research. 2004 ;6(1):R8-R17	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.		113705	1001	1	2004	 BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. The risk for metachronous ipsilateral disease does not appear to be increased for either BRCA1 or BRCA2 mutation carriers, at least up to 10 years of follow up.	Cohort 584 Ashkenazi Jewish women from two retrospective cohorts undergoing breast-conserving treatment for invasive cancer 1980-1995										
117865		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Rebbeck TR 2004	14981104				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		North America|Europe	KGB	672	Hs.194143			Journal of clinical oncology. 2004 Mar;22(6):1055-62	Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.		113705	1003	1	2004	 Bilateral prophylactic mastectomy reduces the risk of breast cancer in women with BRCA1/2 mutations by approximately 90%.											
117860	Y	breast cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		de la Hoya M 2003	12928470				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			JAMA. 2003 Aug;290(7):929-31	Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer~~~ or both.		113705	998	1	2003	 In these families with breast and/or ovarian cancer, mutations in BRCA1 but not BRCA2 were associated with a sex ratio skewed against male births.											
117861		ovarian cancer	CANCER	CAN	Carcinoma|Peritoneal Neoplasms|Ovarian Neoplasms|	17	17q21	BRCA1	38449839	38530994		Rutter JL 2003	12865453				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Israeli	Israel	KGB	672	Hs.194143			Journal of the National Cancer Institute. 2003 Jul;95(14):1072-8	Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.		113705	999	1	2003	 Both BRCA1/2 mutation carriers and non-carriers have reduced risk of ovarian or peritoneal cancer after gynecologic surgery. The magnitude of the reduction depends upon the type and extent of surgery.											
117862		ovarian cancer.	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Heimdal K 2003	14522380				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		Norway	KGB	672	Hs.194143			Eur J Cancer. 2003 Oct;39(15):2205-13	The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.		113705	1000	1	2003												
117858		ovarian cancer	CANCER	CAN	Ovarian Neoplasms|Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		Schwartz MD 2003	14581427				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2		District of Columbia	KGB	672	Hs.194143			Journal of clinical oncology. 2003 Nov;21(21):4034-41	Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.		113705	996	1	2003	 These results demonstrate the significant behavioral impact of receiving a positive BRCA1/2 test result. The increased rate of oophorectomy among mutation carriers suggests that testing for BRCA1/2 mutations may ultimately impact ovarian cancer mortality.											
117859		prophylactic breast surgery	OTHER	OTH	Genetic Predisposition to Disease	17	17q21	BRCA1	38449839	38530994		van Oostrom I 2003	14551306				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Journal of clinical oncology. 2003 Oct;21(20):3867-74	Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.		113705	997	1	2003	 Our findings support the emerging consensus that genetic predisposition testing for BRCA1/2 does not pose major mental health risks, but our findings also show that the impact of prophylactic surgery on aspects such as body image and sexuality should not be underestimated, and that some women are at risk for high distress, and as a result, need more attentive care.											
117854	Y	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Hadjisavvas A et al. 2002	11836613				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Oncology reports. 2002 Mar-Apr;9(2):383-6	Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family.		113705	992	1	2002												
117855	Y	ovarian cancer	CANCER	CAN	Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Buller RE et al. 2001	11309330				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Clinical cancer research. 2001 Apr;7(4):831-8	The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.		113705	993	1	2001	 Ovarian cancers containing somatic or germ-line BRCA1 mutations are uniformly accompanied by p53 dysfunction. This finding offers additional support to observations regarding the importance of p53/BRCA1 interactions in ovarian carcinogenesis.											
117856	Y	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Claus EB et al. 1998	9839523				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Journal of the National Cancer Institute. 1998 Dec;90(23):1824-9	Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.		113705	994	1	1998	 Among women with a moderate family history of breast cancer, i.e., predicted noncarriers of BRCA1 and/or BRCA2 mutations, family history remains a factor in predicting breast cancer risk. In families with breast and ovarian cancers, the aggregation of these two cancers appears to be explained by BRCA1/BRCA2 mutation-carrier probability.											
117852	Y	ovarian cancer	CANCER	CAN	Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Buller RE et al. 1999	10050867				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Journal of the National Cancer Institute. 1999 Feb;91(4):339-46	Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.		113705	990	1	1999	 Among individuals informative for the AR locus, nonrandom X-chromosome inactivation was found in the DNA of 53% of those with invasive cancer versus 28% of those with borderline cancer (P = .005) and 33% of healthy control subjects (P = .016). Nonrandom X-chromosome inactivation can be a heritable trait. Nine of 11 AR-informative carriers of germline BRCA1 mutations demonstrated nonrandom X-chromosome inactivation (.0002 < P < .008, for simultaneous occurrence of both). IMPLICATIONS: Nonrandom X-chromosome inactivation may be a predisposing factor for the development of invasive, but not borderline, ovarian cancer.											
117853	Y	germline BRCA1 mutation	CANCER	CAN	Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Buekers TE et al. 2000	10684722				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Gynecologic oncology. 2000 Mar;76(3):418-22	Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.		113705	991	1	2000	 Our data support the hypothesis that an Xp22.2-3 gene product interacts with or modifies the expression of BRCA1 in some hereditary ovarian cancers.											
117824		cancer	CANCER	CAN	Neoplasms|Breast Neoplasms|Ovarian Neoplasms|Fanconi Anemia|Bloom Syndrome|Genetic Predisposition to Disease|	15	15q26.1	BLM	89061582	89159690		Koren-Michowitz, M.  et al. 2005	15726604				Bloom syndrome	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000057.2	Jewish	Israel	CDC GDPinfo	641	Hs.169348			American journal of hematology. 2005 Mar;78(3):203-6	Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in riskmodification for cancer development.		604610	15499	2	2005	Coinheritance of FA and/or BS mutations seems to be more prevalent among BRCA mutation carriers, but a larger study encompassing more women may help in clarifying this issue.	Cohort 100 Ashkenazi women with known BRCA1 and BRCA2 mutations 										
117688		breast cancer	CANCER	CAN		2	2q34-q35	BARD1	215301521	215382611		Vahteristo, P.  et al. 2005	16333312	Cys557Ser and Val507Met			BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1			CDC GDPinfo	580	Hs.591642			European journal of human genetics. 2006 Feb;14(2):167-72	BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition		601593	15396	2	2005												
117685		uterine cancers	CANCER	CAN	Mixed Tumor, Mullerian|Sarcoma|Adenocarcinoma|Adenocarcinoma, Clear Cell|Carcinoma, Ductal, Breast	2	2q34-q35	BARD1	215301521	215382611		Thai TH et al. 1998	9425226				BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1			KGB	580	Hs.591642			Human molecular genetics. 1998 Feb;7(2):195-202	Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast ovarian and uterine cancers.		601593	930	1	1998												
117687		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	2	2q34-q35	BARD1	215301521	215382611		Ishitobi, M.  et al. 2003	14550946				BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1		Japan	CDC GDPinfo	580	Hs.591642			Cancer letters. 2003 Oct;200(1):7-Jan	Mutational analysis of BARD1 in familial breast cancer patients in Japan		601593	15395	2	2003	These results suggest that BARD1 mutations are responsible for, if any, a very small number of familial breast cancers. Genetic polymorphism of BARD1 (Val/Met 507) could be useful in the selection of postmenopausal women at a high risk for developing breast cancer.	Case:143 population based breast cancer patients;Control:155 healthy controls										
117683		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Breast Neoplasms, Male|Ovarian Neoplasms|	21	21q22.11	BACH1	29593090	29656086		Rutter, J. L.  et al. 2003	12872252				BTB and CNC homology 1, basic leucine zipper transcription factor 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_206866.1			CDC GDPinfo	571	Hs.154276			Human mutation. 2003 Aug;22(2):121-8	Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.		602751	15394	2	2003	Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to breast cancer in the general population.	Control:30 reference individuals;Case:58 early-onset breast cancer cases								N		breast cancer and ovarian cancer
117495		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	X	Xq11.2-q12	AR	66680598	66860844		Rebbeck TR et al. 1999	10205268				Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000044.2			KGB	367	Hs.496240			American journal of human genetics. 1999 May;64(5):1371-7	Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.		313700	881	1	1999												
117489	N	breast/ovarian cancer phenotype	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	X	Xq11.2-q12	AR	66680598	66860844		Dagan E et al. 2002	12404104				Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000044.2		Israel	KGB	367	Hs.496240			European journal of human genetics. 2002 Nov;10(11):724-8	Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.		313700	875	1	2002	There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.	Cohort 227 BRCA1/2 mutation carriers								N		
116690		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	14	14q11.2-q12	APEX1	19993129	19995766		Sigurdson, A. J.  et al. 2004	15113441				APEX nuclease (multifunctional DNA repair enzyme) 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001641.2			CDC GDPinfo	328	Hs.73722			BMC cancer [electronic resource]. 2004 Mar;4:9	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.		107748	15494	2	2004	 Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.	Cohort 748 breast cancer cases identified within a cohort of femal US radiologic technologists and 2,430 female first-degree relatives of cases 										
136126		cleft lip with cleft palate; cleft lip without cleft palate	DEVELOPMENTAL	DEV		14	14q24	TGFB3	75494194	75517242		Ichikawa, E.  et al. 2005	16247549				Transforming growth factor, beta 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_003239.1	Japanese		CDC GDPinfo	7043	Hs.592317			Journal of human genetics. 2006 ;51(1):38-46	PAX9 and TGFB3 are linked to susceptibility to nonsyndromic cleft lip with or without cleft palate in the Japanese: population-based and family-basedcandidate gene analyses.		190230	27851	2	2005												
135801		cleft lip with cleft palate; cleft lip without cleft palate	DEVELOPMENTAL	DEV		X	Xq21.1	TBX22	79156910	79173924		Ichikawa, E.  et al. 2005	16247549				T-box 22	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_016954.2	Japanese		CDC GDPinfo	50945	Hs.374253			Journal of human genetics. 2006 ;51(1):38-46	PAX9 and TGFB3 are linked to susceptibility to nonsyndromic cleft lip with or without cleft palate in the Japanese: population-based and family-basedcandidate gene analyses.		300307	27633	2	2005												
135793		cleft lip with cleft palate; cleft lip without cleft palate	DEVELOPMENTAL	DEV		11	11q13.2	TBX10	67155349	67163607		Ichikawa, E.  et al. 2005	16247549				T-box 10	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_005995.2	Japanese		CDC GDPinfo	347853	Hs.454480			Journal of human genetics. 2006 ;51(1):38-46	PAX9 and TGFB3 are linked to susceptibility to nonsyndromic cleft lip with or without cleft palate in the Japanese: population-based and family-basedcandidate gene analyses.		604648	27238	2	2005												
135374	N	oligospermia	REPRODUCTION	REP	Infertility, Male|Oligospermia	X	Xq26-q27	SOX3	139412817	139414891		Raverot, G.  et al. 2004	15292361				SRY (sex determining region Y)-box 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_005634.2			CDC GDPinfo	6658	Hs.157429			The Journal of clinical endocrinology and metabolism. 2004 Aug;89(8):4146-8	X-linked sex-determining region Y box 3 (SOX3) gene mutations are uncommon in men with idiopathic oligoazoospermic infertility.		313430	19678	2	2004	These data indicate that mutations in the SOX3 gene are not a common cause of male infertility.	Cohort 56 infertile men with idiopathic oligo-azoospermia 										
135375		hypospadias	DEVELOPMENTAL	DEV	Hypospadias	17	17q24.3-q25.1	SOX9	67628755	67634155		Wang, Y.  et al. 2004	15266301				SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000346.2	Chinese	China	CDC GDPinfo	6662	Hs.642674			European journal of human genetics. 2004 Sep;12(9):706-12	Mutation analysis of five candidate genes in Chinese patients with hypospadias.		608160	23532	2	2004	In conclusion, mutations are frequently found in genes that control androgen action and metabolism, but are seldom found in genes active in the early phase of sex determination and differentiation. Mutations in AR, SRD5A2 or WT1 seem to be associated not only with hypospadias but also with micropenis.	Control:controls;Case:90 Chinese hypospadias patients										
135373	Y	Myelin deficiencies	OTHER	OTH		22	22q13.1	SOX10	36698264	36713375		Inoue K et al. 1999	10482261				SRY (sex determining region Y)-box 10	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006941.3			KGB	6663	Hs.376984			Annals of neurology. 1999 Sep;46(3):313-8	Myelin deficiencies in both the central and the peripheral nervous systems associated with a SOX10 mutation.		602229	5605	1	1999												
134458	N	oral clefts	OTHER	OTH	Cleft Palate|Cleft Lip|Genetic Predisposition to Disease|	7	7q36	SHH	155285496	155297728		Orioli, I. M.  et al. 2002	11857543				Sonic hedgehog homolog (Drosophila)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000193.2	South American	South America	CDC GDPinfo	6469	Hs.164537			American journal of medical genetics. 2002 Feb;108(1):5-Dec	Mutational analysis of the Sonic Hedgehog gene in 220 newborns with oral clefts in a South American (ECLAMC) population.		600725	19446	2	2002	Thus, we did not identify any clearly disease-causing mutation in SHH in these patients, and conclude that SHH mutations are not a frequent cause of isolated oral clefts in humans	Case:220 newborn infants with nonsyndromic oral clefts South America										
134459		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease	7	7q36	SHH	155285496	155297728		Bak, M.  et al. 2004	15249145			promoter	Sonic hedgehog homolog (Drosophila)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000193.2			CDC GDPinfo	6469	Hs.164537			Brain research  Molecular brain research. 2004 Jul;126(2):207-11	Mutation analysis of the Sonic hedgehog promoter and putative enhancer elements in Parkinson's disease patients.		600725	19447	2	2004	None of the identified sequence variations were present at a significantly different frequency in PD patients compared to healthy individuals, suggesting that they are not involved in the pathogenesis of PD.	Control healthy individuals;Case patients with Parkinson's disease										
133585		breast cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q11	RAD51L3	30360243	30472625		Rodriguez-Lopez, R.  et al. 2004	15170666				RAD51-like 3 (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002878.2			CDC GDPinfo	5892	Hs.631757			International journal of cancer. Journal international du cancer. 2004 Jul;110(6):845-9	The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations.		602954	23327	2	2004	Finally, the structural prediction of the putative functional consequence of this change indicates that it can diminish protein stability and structure. This suggests a role for E233G as a low-penetrance susceptibility gene in the specific subgroup of high-risk familial breast cancer cases that are not related to BRCA1/2.	Case:174/765 familial breast cancer cases that are not associated with the BRCA1/2 genes (n=174) and another subset of breast cancer patients (n=765);Control:567:controls										
133583		breast cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	17	17q22-q23	RAD51C	54124961	54166691		Rodriguez-Lopez, R.  et al. 2004	15170666	E233G			RAD51 homolog C (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_058216.1			CDC GDPinfo	5889	Hs.412587			International journal of cancer. Journal international du cancer. 2004 Jul;110(6):845-9	The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations.		602774	13445	2	2004	Finally, the structural prediction of the putative functional consequence of this change indicates that it can diminish protein stability and structure. This suggests a role for E233G as a low-penetrance susceptibility gene in the specific subgroup of high-risk familial breast cancer cases that are not related to BRCA1/2.	Case:174/765 familial breast cancer cases that are not associated with the BRCA1/2 genes (n=174) and another subset of breast cancer patients (n=765);Control:567:controls										
133578	Y	breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	15	15q15.1	RAD51	38774660	38811646		Wang, W. W.  et al. 2001	11535547				RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002875.2		United States|Israel|Australia	CDC GDPinfo	5888	Hs.631709			Cancer epidemiology, biomarkers & prevention. 2001 Sep;10(9):955-60	A Single Nucleotide Polymorphism in the 5' Untranslated Region of RAD51 and Risk of Cancer among BRCA1/2 Mutation Carriers		179617	25481	2	2001	We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers. The biochemical basis of this risk modifier is currently unknown.	Control:119 women without breast cancer;Case:67 breast cancer cases										
133579	Y	breast cancer	CANCER	CAN	Breast Neoplasms|DNA Damage|Genetic Predisposition to Disease|	15	15q15.1	RAD51	38774660	38811646		Kadouri, L.  et al. 2004	15138485				RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002875.2			CDC GDPinfo	5888	Hs.631709			British journal of cancer. 2004 May;90(10):2002-5	A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.		179617	25482	2	2004	These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found.	Control:152 women unaffected with breast cancer;Case:309/166 BRCA1/2 mutation carriers (n=309) and noncarrier breast cancer patients (n=166)										
133577	Y	breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	15	15q15.1	RAD51	38774660	38811646		Levy-Lahad, E.  et al. 2001	11248061				RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002875.2			CDC GDPinfo	5888	Hs.631709			Proceedings of the National Academy of Sciences of the United States of America. 2001 Mar;98(6):3232-6	A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.		179617	25480	2	2001	These results show RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages.	Cohort 257 female Ashkenazi Jewish carriers of one of the common BRCA1 (185delAG, 5382insC) or BRCA2 (6174delT) mutations 										
133573	Y	breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	15	15q15.1	RAD51	38774660	38811646		Jakubowska, A.  et al. 2003	12750242				RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002875.2	Polish	Poland	CDC GDPinfo	5888	Hs.631709			Cancer epidemiology, biomarkers & prevention. 2003 May;12(5):457-9	Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.		179617	23323	2	2003	This finding suggests that RAD51 is a genetic modifier of breast cancer risk in BRCA1 carriers in the Polish population. It will be of interest to confirm this in other populations as well.	Case:83 breast cancer cases who were carriers of the BRCA1 5382insC mutation;Control:83 women with the BRCA1 5382insC mutation but were:unaffected										
133574		breast cancer	CANCER	CAN		15	15q15.1	RAD51	38774660	38811646		Sliwinski, T.  et al. 2005	16261408				RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002875.2			CDC GDPinfo	5888	Hs.631709			Breast cancer research and treatment. 2005 Nov;94(2):105-9	Polymorphisms of the BRCA2 and RAD51 Genes in Breast Cancer.		179617	23324	2	2005												
133370		Cowden syndrome	CANCER	CAN	Hamartoma Syndrome, Multiple|Breast Neoplasms	10	10q23.3	PTEN	89613174	89718512		Tsou HC et al. 1997	9345101				phosphatase and tensin homolog (mutated in multiple advanced cancers 1)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000314.3			KGB	5728	Hs.500466			American journal of human genetics. 1997 Nov;61(5)	The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases.		601728	5208	1	1997												
133363	Y	breast cancer	CANCER	CAN	Carcinoma, Ductal, Breast|Carcinoma, Lobular|Breast Neoplasms|Disease Susceptibility	9	9q22.3	PTCH	97246218	97310652		Chang-Claude, J.  et al. 2003	12516098	Pro1315Leu (C3944T)			Patched homolog (Drosophila)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000264.2		Germany|Great Britain	CDC GDPinfo	5727	Hs.494538			International journal of cancer. Journal international du cancer. 2003 Mar;103(6):779-83	The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk		601309	13376	2	2003	Our novel observation of a differential effect of OC use on breast cancer risk by PTCH1 1315Leu-carrier status suggests the interesting possibility of the Sonic hedgehog/Patched (SHH/PTCH1) signaling pathway being involved in hormone-induced development of breast carcinoma.	Control:1057 controls matched by age and study region in Germany for German patients;Case:611/1093 German breast cancer patients diagnosed by age 50 years (n=611) and 1093 breast cancer patients from United Kingdom;Case:611/1093 German breast cancer patients diagnosed by age 50 years (n=611) and 1093 breast cancer patients from United Kingdom	oral contraceptive									
132707		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	19	19q13.3	POLD1	55579407	55613082		Sigurdson, A. J.  et al. 2004	15113441				Polymerase (DNA directed), delta 1, catalytic subunit 125kDa	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002691.1			CDC GDPinfo	5424	Hs.279413			BMC cancer [electronic resource]. 2004 Mar;4:9	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.		174761	26502	2	2004	 Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.	Cohort 748 breast cancer cases identified within a cohort of femal US radiologic technologists and 2,430 female first-degree relatives of cases 										
132531	Y	breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	11	11q22-q23	PGR	100414312	100506465		Runnebaum, I. B.  et al. 2001	11668223				Progesterone receptor	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000926.2			CDC GDPinfo	5241	Hs.368072			Pharmacogenetics. 2001 Oct;11(7):635-8	Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives		607311	25415	2	2001	Among the 214 carriers with no past exposure to oral contraceptives, the presence of one or more PROGINS alleles was associated with an OR of 2.4 for ovarian cancer, compared to women without ovarian cancer and with no PROGINS allele (P = 0.004; 95% CI 1.4-4.3). The association was present after adjustment for ethnic group and for year of birth.	Case:195 BRCA1 and BRCA2 carriers with a prior diagnosis of ovarian cancer;Control:249 carriers with neither cancer;Case:392 BRCA1 and BRCA2 carriers with a diagnosis of breast:cancer										
132364	Y	hypodontia	DEVELOPMENTAL	DEV	Anodontia	14	14q12-q13	PAX9	36200655	36215621		Das P et al. 2002	11941488				Paired box gene 9	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006194.1			KGB	5083	Hs.132576			Human genetics. 2002 Apr;110(4):371-6	Haploinsufficiency of PAX9 is associated with autosomal dominant hypodontia.		167416	4896	1	2002												
132365		non-syndromic oligodontia	DEVELOPMENTAL	DEV	Anodontia	14	14q12-q13	PAX9	36200655	36215621		Jumlongras D 2004	14689302				Paired box gene 9	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006194.1			KGB	5083	Hs.132576			Human genetics. 2004 Feb;114(3):242-9	A novel missense mutation in the paired domain of PAX9 causes non-syndromic oligodontia.		167416	4897	1	2004												
132366		hypodontia	DEVELOPMENTAL	DEV		14	14q12-q13	PAX9	36200655	36215621		Peres, R. C.  et al. 2005	16137495			promoter	Paired box gene 9	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006194.1			CDC GDPinfo	5083	Hs.132576			Archives of oral biology. 2005 Oct;50(10):861-71	Association between PAX-9 promoter polymorphisms and hypodontia in humans.		167416	13064	2	2005												
132367		cleft lip with cleft palate; cleft lip without cleft palate	DEVELOPMENTAL	DEV		14	14q12-q13	PAX9	36200655	36215621		Ichikawa, E.  et al. 2005	16247549				Paired box gene 9	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006194.1	Japanese		CDC GDPinfo	5083	Hs.132576			Journal of human genetics. 2006 ;51(1):38-46	PAX9 and TGFB3 are linked to susceptibility to nonsyndromic cleft lip with or without cleft palate in the Japanese: population-based and family-basedcandidate gene analyses.		167416	25409	2	2005												
132360	N	diabetes, type 1	IMMUNE	IMM	Diabetes Mellitus, Type 1|Genetic Predisposition to Disease	7	7q32	PAX4	127037581	127043218		Hermann, R.  et al. 2005	16123375				Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1	Finnish	Hungary|Finland	CDC GDPinfo	5078	Hs.129706			Diabetes. 2005 Sep;54(9):2816-9	Lack of association of PAX4 gene with type 1 diabetes in the Finnish and Hungarian populations.		167413	18846	2	2005												
132361		epilepsy	NEUROLOGICAL	NEUR	Epilepsies, Myoclonic|Epilepsy, Generalized|Epilepsy, Absence|Genetic Predisposition to Disease	11	11p13	PAX6	31767033	31789455		Sander T et al. 1999	10463851			promoter	Paired box gene 6 (aniridia, keratitis)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000280.2			KGB	5080	Hs.591993			Epilepsy research. 1999 Aug;36(1):61-7	Association analysis of a regulatory promoter polymorphism of the PAX-6 gene with idiopathic generalized epilepsy.		607108	4894	1	1999												
132362		schizophrenia	PSYCH	PSY		11	11p13	PAX6	31767033	31789455		Stober G et al. 1999	10376119				Paired box gene 6 (aniridia, keratitis)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000280.2			KGB	5080	Hs.591993			Biological psychiatry. 1999 Jun;45(12):1585-91	Functional PAX-6 gene-linked polymorphic region: potential association with paranoid schizophrenia.		607108	4895	1	1999	 Our finding indicates that early developmental genes may be involved in the etiopathogenesis of schizophrenia subtypes via variable transcriptional regulation in the developing and adult human brain.											
132363		brain atrophy	NEUROLOGICAL	NEUR	Alcoholism|Atrophy	11	11p13	PAX6	31767033	31789455		Samochowiec, J.  et al. 2002	12043047			promoter	Paired box gene 6 (aniridia, keratitis)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000280.2			CDC GDPinfo	5080	Hs.591993			Psychiatria polska. 2002 ;36(2):303-10	[PAX-6 gene promoter polymorphism and other factors involved in brain atrophy in alcohol dependent patients]		607108	13063	2	2002	We found negative correlation between numbers of PAX-6 gene promoter B (AC)m (AG)n repeats and atrophy of the brain and the cerebellum. Occurrence of these lesions was correlated with a decrease of alcohol tolerance, withdrawal symptoms--especially delirium tremens.	Cohort 68 alcoholics 										
132357	Y	diabetes, type 2	METABOLIC	MET	Diabetes Mellitus, Type 2|Genetic Predisposition to Disease	7	7q32	PAX4	127037581	127043218		Shimajiri, Y.  et al. 2001	11723072				Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1	Japanese	Japan	CDC GDPinfo	5078	Hs.129706			Diabetes. 2001 Dec;50(12):2864-9	A missense mutation of Pax4 gene (R121W) is associated with type 2 diabetes in Japanese.		167413	18843	2	2001	This is the first report of a Pax4 gene mutation that exhibits loss of function and seems to be associated with type 2 diabetes. This work provides significant implications for the Pax4 gene as one of the predisposing genes for type 2 diabetes in the Japanese.	Cohort 200 unrelated Japanese type 2 diabetic patients 										
132358		diabetes, type 2; diabetes, type 1	UNKNOWN	UNK	Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Genetic Predisposition to Disease|	7	7q32	PAX4	127037581	127043218		Mauvais-Jarvis, F.  et al. 2004	15509590				Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1		Africa, Western	CDC GDPinfo	5078	Hs.129706			Human molecular genetics. 2004 Dec;13(24):3151-9	PAX4 gene variations predispose to ketosis-prone diabetes.		167413	18844	2	2004	Together these data provide the first evidence that ethnic-specific gene variants may contribute to the predisposition to this particular form of diabetes and suggests that KPD, like maturity onset diabetes of the young (MODY), is a rare, phenotypically-defined but genetically heterogeneous form of type 2 diabetes.	Case:101 subjects with ketosis-prone diabetes;Control:147/355 subjects with common type 2 or type 1 diabetes (n=147) and controls (n=355)										
132359	Y	diabetes, type 1	IMMUNE	IMM	Diabetes Mellitus, Type 1	7	7q32	PAX4	127037581	127043218		Biason-Lauber, A.  et al. 2005	15834548				Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1		Switzerland	CDC GDPinfo	5078	Hs.129706			Diabetologia. 2005 May;48(5):900-5	Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cellregenerative capacity.		167413	18845	2	2005	We have identified a link between beta cell regenerative capacity and susceptibility to type 1 diabetes. This finding could explain the fact that not all of the individuals who develop autoimmunity against beta cells actually contract the disease. The C/C genotype of the A1168C polymorphism in PAX4 can be viewed as a predisposition marker that can help to detect individuals prone to develop type 1 diabetes.	Control:1,070 controls from two distinct populations (n=1070) and children who had not developed type 1 diabetes, despite the presence of islet cell antibodies;Case:379 diabetic children from two distinct populations										
132353	Y	isolated colobomas or colobomas associated	OTHER	OTH	Coloboma|Urogenital Abnormalities|Vesico-Ureteral Reflux|Abnormalities, Multiple|Syndrome	10	10q24	PAX2	102495321	102579688		Cunliffe HE et al. 1998	9783702				Paired box gene 2				KGB	5076	Hs.155644			Journal of medical genetics. 1998 Oct;35(10):806-12	The prevalence of PAX2 mutations in patients with isolated colobomas or colobomas associated with urogenital anomalies.		167409	4890	1	1998	We conclude that  PAX2 mutations are unlikely to be common in patients with ocular colobomas in isolation or in patients with ocular colobomas and associated anomalies, except for patients with typical renal-coloboma syndrome where PAX2 is known to be the aetiological cause.											
132355	Y	diabetes, type 2	METABOLIC	MET	Diabetes Mellitus|Genetic Predisposition to Disease	7	7q32	PAX4	127037581	127043218	0.005	Shimajiri Y 2003	12604352				Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1	Japanese	Japan	KEW	5078	Hs.129706			Biochemical and biophysical research communications. 2003 Mar;302(2):342-4			167413	4892	1	2003	The R121W mutation in PAX4 is a predisposing factor for the development of type 2 diabetes in Okinawans.	Case:193; Control:372										
132356	Y	diabetes, type 2	METABOLIC	MET	Diabetes Mellitus, Type 2|Genetic Predisposition to Disease	7	7q32	PAX4	127037581	127043218		Shimajiri Y et al. 2001	11723072				Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1	Japanese	Japan	KGB	5078	Hs.129706			Diabetes. 2001 Dec;50(12):2864-9	A missense mutation of Pax4 gene (R121W) is associated with type 2 diabetes in Japanese.		167413	4893	1	2001	This is the first report of a Pax4 gene mutation that exhibits loss of function and seems to be associated with type 2 diabetes. This work provides significant implications for the Pax4 gene as one of the predisposing genes for type 2 diabetes in the Japanese.	Cohort 200 unrelated Japanese type 2 diabetic patients										
131531	N	Type II diabetes	METABOLIC	MET	Diabetes Mellitus, Type 2	2	2q32	NEUROD1	182249438	182253626	n	Dupont S et al. 1999	10230653				Neurogenic differentiation 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002500.1			KGB	4760	Hs.72981			Diabetologia. 1999 Apr;42(4):480-4	No evidence of linkage or diabetes-associated mutations in the transcription factors BETA2/NEUROD1 and PAX4 in Type II diabetes in France.		601724	4667	1	1999												
131496		breast cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	20	20q12	NCOA3	45564063	45719021		Hughes, D. J.  et al. 2005	15900600				Nuclear receptor coactivator 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_181659.1			CDC GDPinfo	8202	Hs.592142			International journal of cancer. Journal international du cancer. 2005 Nov;117(2):230-3	Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.		601937	25355	2	2005	These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.	Cohort 851/324 BRCA1 (n=851) and BRCA2 (n=32) female germline mutation carriers 										
131489	N	breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	20	20q12	NCOA3	45564063	45719021		Montgomery, K. G.  et al. 2005	15987430				Nuclear receptor coactivator 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_181659.1	Australian	Australia	CDC GDPinfo	8202	Hs.592142			Breast cancer research. 2005 ;7(3):R353-6	The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.		601937	12667	2	2005	 There was no evidence that risk of breast cancer depends on AIB1 CAG/CAA polymorphism status, even if affected women carry a mutation in BRCA1 or BRCA2.											
131237	Y	breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	8	8q24.12-q24.13	MYC	128816946	128822855		Wirtenberger, M.  et al. 2005	15929079				V-myc myelocytomatosis viral oncogene homolog (avian)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002467.3			CDC GDPinfo	4609	Hs.202453			International journal of cancer. Journal international du cancer. 2005 Nov;117(4):638-42	c-MYC Asn11Ser is associated with increased risk for familial breast cancer.		190080	18473	2	2005	The breast cancer risk associated with this genotype increases above the age of 50 years (OR = 2.24, 95% CI 1.20-4.21, p = 0.012). The wild-type amino acid Asn of this polymorphism is located in the N-terminal MYC transactivation domain and is highly conserved not only among most diverse species but also in the N-MYC homologue. Due to the pivotal role of c-MYC in diverse tumours, this variant might affect the genetic susceptibility of other cancers as well.	Case:349/356 Polish (n = 349) and German (n = 356) breast cancer cases tested negative for mutations in the BRCA1 and BRCA2 genes;Control:441/655 Polish (n = 441) and German (n = 655) controls										
131033		stomach cancer; pancreatic cancer; fallopian cancer	CANCER	CAN	Neoplasms|Neoplasms, Multiple Primary|Genetic Predisposition to Disease|Rare Diseases	2	2p22-p21	MSH2	47483766	47760014		Levene, S.  et al. 2003	14574163				MutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000251.1			CDC GDPinfo	4436	Hs.156519			Familial cancer. 2003 ;2(1):15-25	Does the occurrence of certain rare cancers indicate an inherited cancer susceptibility?		120435	22940	2	2003	This study supports the premise that the occurrence of rare (especially double primary) cancers does indicate an increased cancer susceptibility, although the numbers of cases ascertained were too small to draw firm conclusions.	Cohort 77 individuals with rare cancers which occur with increased relative risk in carriers of germline BRCA1/BRCA2 (fallopian, young-onset pancreatic) or HNPCC (biliary, small intestinal, urothelial, gallbladder, young-onset pancreatic) mutations 										
130561		stomach cancer; pancreatic cancer; fallopian cancer	CANCER	CAN	Neoplasms|Neoplasms, Multiple Primary|Genetic Predisposition to Disease|Rare Diseases	3	3p21.3	MLH1	37009982	37067341		Levene, S.  et al. 2003	14574163				MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000249.2			CDC GDPinfo	4292	Hs.195364			Familial cancer. 2003 ;2(1):15-25	Does the occurrence of certain rare cancers indicate an inherited cancer susceptibility?		120436	18279	2	2003	This study supports the premise that the occurrence of rare (especially double primary) cancers does indicate an increased cancer susceptibility, although the numbers of cases ascertained were too small to draw firm conclusions.	Cohort 77 individuals with rare cancers which occur with increased relative risk in carriers of germline BRCA1/BRCA2 (fallopian, young-onset pancreatic) or HNPCC (biliary, small intestinal, urothelial, gallbladder, young-onset pancreatic) mutations 										
129609	Y	breast cancer	CANCER	CAN	Breast Neoplasms|DNA Damage|Genetic Predisposition to Disease|	13	13q33-q34	LIG4	107657792	107668717		Bau, D. T.  et al. 2004	15256476				Ligase IV, DNA, ATP-dependent	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002312.3			CDC GDPinfo	3981	Hs.166091			Cancer research. 2004 Jul;64(14):5013-9	Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.		601837	22754	2	2004	Because BRCA1 is a well-documented breast cancer susceptibility gene, this association between NHEJ and BRCA1 not only suggests a role of BRCA1 in NHEJ but also provides essential support for the tumorigenic contribution of NHEJ in breast cancer development..	Case:469 breast cancer patients;Control:740 healthy controls										
137167	Y	ovarian cancer	CANCER	CAN	Ovarian Neoplasms	17	17p13.1	TP53	7505821	7531642		Buller RE et al. 2001	11309330				Tumor protein p53 (Li-Fraumeni syndrome)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000546.2			KGB	7157	Hs.408312			Clinical cancer research. 2001 Apr;7(4):831-8	The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.		191170	6190	1	2001	 Ovarian cancers containing somatic or germ-line BRCA1 mutations are uniformly accompanied by p53 dysfunction. This finding offers additional support to observations regarding the importance of p53/BRCA1 interactions in ovarian carcinogenesis.											
137192		ovarian cancer	CANCER	CAN	Ovarian Neoplasms	17	17p13.1	TP53	7505821	7531642		Wang-Gohrke S et al. 1999	10487631			intron	Tumor protein p53 (Li-Fraumeni syndrome)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000546.2			KGB	7157	Hs.408312			British journal of cancer. 1999 Sep;81(1):179-83	Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.		191170	6215	1	1999												
137265		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	17	17p13.1	TP53	7505821	7531642			16161633				Tumor protein p53 (Li-Fraumeni syndrome)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000546.2			CDC GDPinfo	7157	Hs.408312			Genetika. 2005 Aug;41(8):1115-24	[Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer]		191170	23777	2	2005												
138197		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	19	19q13.2	XRCC1	48739303	48771555		Sigurdson, A. J.  et al. 2004	15113441				X-ray repair complementing defective repair in Chinese hamster cells 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006297.1			CDC GDPinfo	7515	Hs.98493			BMC cancer [electronic resource]. 2004 Mar;4:9	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.		194360	27356	2	2004	 Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.	Cohort 748 breast cancer cases identified within a cohort of femal US radiologic technologists and 2,430 female first-degree relatives of cases 										
138688		uveal melanoma	CANCER	CAN	Melanoma|Uveal Neoplasms	9	9p21	CDKN2A	21957750	21965038		Hearle, N.  et al. 2003	12556369				Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000077.3			CDC GDPinfo	1029	Hs.512599			Investigative ophthalmology & visual science. 2003 Feb;44(2):458-62	Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.		600160	20766	2	2003	 These findings suggest that less than 2% of cases of uveal melanoma can be ascribed to germline mutations in BRCA2, P16(INK4A), P14(ARF), or P15. It is likely that mutations in other genes contribute to an inherited predisposition to uveal melanoma.	Cohort 385 patients with uveal melanoma 										
141721		cleft lip with cleft palate; cleft lip without cleft palate	DEVELOPMENTAL	DEV		11	11q23	PVRL1	119014017	119104645		Ichikawa, E.  et al. 2005	16247549				Hypothetical protein MGC16207	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002855.4	Japanese		CDC GDPinfo	5818	Hs.334846			Journal of human genetics. 2006 ;51(1):38-46	PAX9 and TGFB3 are linked to susceptibility to nonsyndromic cleft lip with or without cleft palate in the Japanese: population-based and family-basedcandidate gene analyses.		600644	26536	2	2005												
144856	P	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Song, C.  et al. 2006	16456781				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Zhonghua Yi Xue Yi Chuan Xue Za Zhi    2006    23(1)    27-31	BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China.		113705		CDC	2006	Two novel mutations in BRCA1 may be mutations characterized to familial breast cancer of Chinese Shanghai population.											
131493		breast cancer	CANCER	CAN		20	20q12	NCOA3	45564063	45719021		Colilla, S.  et al. 2005	16244359				Nuclear receptor coactivator 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_181659.1			CDC GDPinfo	8202	Hs.592142			Carcinogenesis. 2005	The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.		601937	18534	2	2005			smoking (tobacco)									
133362	Y	breast cancer	CANCER	CAN	Carcinoma, Ductal, Breast|Carcinoma, Lobular|Breast Neoplasms|Disease Susceptibility	9	9q22.3	PTCH	97246218	97310652		Chang-Claude J et al. 2003	12516098	Pro1315Leu (C3944T)			Patched homolog (Drosophila)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000264.2		Germany|Great Britain	KGB	5727	Hs.494538			International journal of cancer. Journal international du cancer. 2003 Mar;103(6):779-83	The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk.		601309	5205	1	2003	Our novel observation of a differential effect of OC use on breast cancer risk by PTCH1 1315Leu-carrier status suggests the interesting possibility of the Sonic hedgehog/Patched (SHH/PTCH1) signaling pathway being involved in hormone-induced development of breast carcinoma.	Control:1057 controls matched by age and study region in Germany for German patients;Case:611/1093 German breast cancer patients diagnosed by age 50 years (n=611) and 1093 breast cancer patients from United Kingdom;Case:611/1093 German breast cancer patie	oral contraceptive									
117908		breast cancer	CANCER	CAN		17	17q21	BRCA1	38449839	38530994			16324400				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDPinfo	672	Hs.194143			Zhonghua yi xue za zhi. 2005 Nov;85(43):3030-4	[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai.]		113705	15504	2	2005	 Four novel mutations in BRCA1 and one novel mutation in BRCA2 may be mutations characterized of early-onset breast cancer in Chinese population. Germline mutations in BRCA2 may contribute less than mutations in BRCA1 to early-onset breast cancer in Shanghai. These data contribute to information on spectrum of BRCA gene in Chinese population and also offer a recommended screening mode for clinical genetic testing programme in China.											
138329		breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	19	19q13.41	ZNF350	57159404	57181891		Sigurdson, A. J.  et al. 2004	15113441				Zinc finger protein 350	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_021632.3			CDC GDPinfo	59348	Hs.407694			BMC cancer [electronic resource]. 2004 Mar;4:9	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.		605422	27684	2	2004	 Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.	Cohort 748 breast cancer cases identified within a cohort of femal US radiologic technologists and 2,430 female first-degree relatives of cases 										
117686	N	breast cancer	CANCER	CAN	Breast Neoplasms|Genetic Predisposition to Disease	2	2q34-q35	BARD1	215301521	215382611		Ishitobi M 2003	14550946				BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1		Japan	KGB	580	Hs.591642			Cancer letters. 2003 Oct;200(1):7-Jan	Mutational analysis of BARD1 in familial breast cancer patients in Japan.		601593	931	1	2003	These results suggest that BARD1 mutations are responsible for, if any, a very small number of familial breast cancers. Genetic polymorphism of BARD1 (Val/Met 507) could be useful in the selection of postmenopausal women at a high risk for developing breast cancer.	Case:143 population based breast cancer patients;Control:155 healthy controls										
117864		cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Rodriguez JA 2004	14729053				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Experimental cell research. 2004 Feb;293(1):14-21	Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.		113705	1002	1	2004												
117551	N	breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms	X	Xq11.2-q12	AR	66680598	66860844		Dagan, E.  et al. 2002	12404104				Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000044.2	Jewish	Israel	CDC GDPinfo	367	Hs.496240			European journal of human genetics. 2002 Nov;10(11):724-8	Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers:association with breast/ovarian cancer phenotype.		313700	15485	2	2002	There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.	Cohort 227 BRCA1/2 mutation carriers 								N		
117904	Y	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Hu, Z.  et al. 2004	15777502				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Chinese	China	CDC GDPinfo	672	Hs.194143			Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2004 Nov;26(11):657-9	[Analysis of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.]		113705	15500	2	2004	 The incidence of BRCA1 mutations in Chinese patients with early onset breast cancer is similar to that reported from western countries, but the incidence of mutations in Chinese breast cancer patients with affected relatives is comparatively low.	Cohort 41 Chinse early onset breast cancer cases 										
117857	Y	tumor progression	CANCER	CAN	Carcinoma, Ductal, Breast|Breast Neoplasms|Chromosome Deletion|Disease Progression	17	17q21	BRCA1	38449839	38530994		Tirkkonen M et al. 1997	9102202				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			KGB	672	Hs.194143			Cancer research. 1997 Apr;57(7):1222-7	Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.		113705	995	1	1997												
117934		breast cancer; ovarian cancer	CANCER	CAN	Breast Neoplasms|Ovarian Neoplasms|Genetic Predisposition to Disease|	13	13q12.3	BRCA2	31787616	31871809		Hughes, C.  et al. 2002	11807889				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDPinfo	675	Hs.34012			American journal of medical genetics. 2002 Jan;107(2):143-50	All in the family: evaluation of the process andcontent of sisters' communication about BRCA1 and BRCA2 genetic test results.		600185	20606	2	2002	The results of this study suggest that probands are likely to quickly communicate their BRCA1/2 test results to relatives and that although needs for social support may motivate family communication, emotionally distant relationships may be a barrier to communication with relatives.	Cohort 81 sisters of 43 women who were the first family member to have genetic testing 										
132354	N	diabetes, type 2	METABOLIC	MET	Diabetes Mellitus, Type 2	7	7q32	PAX4	127037581	127043218	n	Dupont S et al. 1999	10230653				Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1			KGB	5078	Hs.129706			Diabetologia. 1999 Apr;42(4):480-4	No evidence of linkage or diabetes-associated mutations in the transcription factors BETA2/NEUROD1 and PAX4 in Type II diabetes in France.		167413	4891	1	1999	Our results indicate that NEUROD1 and PAX4 are not a common cause of either MODY or late-onset Type II diabetes in the French Caucasian population.											
134457		holoprosencephaly	NEUROLOGICAL	NEUR	Holoprosencephaly	7	7q36	SHH	155285496	155297728		Schell-Apacik C 2003	12709790				Sonic hedgehog homolog (Drosophila)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000193.2			KGB	6469	Hs.164537			Human genetics. 2003 Jul;113(2):170-7	SONIC HEDGEHOG mutations causing human holoprosencephaly impair neural patterning activity.		600725	5396	1	2003												
119675	N	breast cancer	CANCER	CAN	Breast Neoplasms|Neoplastic Syndromes, Hereditary	16	16q21-q22.3	CTCF	66153964	66230589		Zhou, X. L.  et al. 2004	15084242				CCCTC-binding factor (zinc finger protein)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006565.2		Sweden	CDC GDPinfo	10664	Hs.368367			Breast cancer research. 2004 ;6(3):R187-90	A screen for germline mutations in the gene encoding CCCTC-binding factor (CTCF) in familial non-BRCA1/BRCA2 breast cancer		604167	15910	2	2004	 The present study suggests that germline mutations in CTCF are not important as a risk factor for breast cancer.	Control:controls;Case:153 patients with familal non-BRCA1/BRCA2 breast cancer										
144648		breast cancer	CANCER	CAN		11	11q22-q23	ATM	107598768	107745036		Johnson, N.  et al. 2007	17341484				Ataxia telangiectasia mutated (includes complementation groups A, C and D)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000051.3			CDC GDP info	472	Hs.435561			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		607585		CDC	2007												
144650		breast cancer	CANCER	CAN		11	11q22-q23	ATM	107598768	107745036		Johnson, N.  et al. 2007	17409195				Ataxia telangiectasia mutated (includes complementation groups A, C and D)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000051.3			CDC GDP info	472	Hs.435561			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		607585		CDC	2007												
144679		breast cancer	CANCER	CAN		20	20q13.2-q13.3	AURKA	54377851	54400758		Vidarsdottir, L.  et al. 2006	17113223				aurora kinase A	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_198433.1			CDC GDP info	6790	Hs.250822			Cancer Lett    2006	Breast cancer risk associated with AURKA 91T-->A polymorphism in relation to BRCA mutations		603072		CDC	2006												
144697		breast cancer	CANCER	CAN	Breast Neoplasms; Genetic Predisposition to Disease	2	2q34-q35	BARD1	215301521	215382611		Onay, V. U.  et al. 2006	16672066				BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1			CDC GDP info	580	Hs.591642			BMC Cancer    2006    6(1)    114	SNP-SNP interactions in breast cancer susceptibility		601593		CDC	2006	The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.											
144698	Y	breast cancer	CANCER	CAN	Carcinoma in Situ; Breast Neoplasms	2	2q34-q35	BARD1	215301521	215382611		Stacey, S. N.  et al. 2006	16768547	Cys557Ser			BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1	Icelandic	Iceland	CDC GDP info	580	Hs.591642			PLoS Med    2006    3(7)    e217	The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland		601593		CDC	2006	Our findings suggest that BARD1 Cys557Ser is an ancient variant that confers risk of single and multiple primary breast cancers, and this risk extends to carriers of the BRCA2 999del5 mutation.											
144699	Y	breast cancer breast cancer, male colorectal cancer ovarian cancer prostate cancer	CANCER	CAN	Breast Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms	2	2q34-q35	BARD1	215301521	215382611		Karppinen, S. M.  et al. 2006	16825437				BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1	Norwegian		CDC GDP info	580	Hs.591642			J Med Genet    2006	Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 cancer cases		601593		CDC	2006	These results provide further evidence that BARD1 Cys557Ser confers a slightly increased risk of breast cancer in women.											
144700	Y	breast cancer	CANCER	CAN	Breast Neoplasms	2	2q34-q35	BARD1	215301521	215382611		Huo, X.  et al. 2006	17028982				BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1			CDC GDP info	580	Hs.591642			Breast Cancer Res Treat    2006	Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility		601593		CDC	2006												
144855			NORMALVARIATION	NV		17	17q21	BRCA1	38449839	38530994		Lee, J. K.  et al. 2003	12768436				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Japanese;Caucasian;Korean		CDC GDP info	672	Hs.194143			J Hum Genet    2003    48    213-6	Characterization of 458 single nucleotide polymorphisms of disease candidate genes in the Korean population.		113705		CDC	2003	Our data indicate that although many of the SNPs available in publicly available database, especially coding-region SNPs (cSNPs), can be used as informative genetic markers for disease association studies, an extensive verification of public SNPs in a particular population studied should be undertaken prior to their association studies. 											
144857		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Romanowicz-Makowska, H.  et al. 2005	16477874			5' untranslated region	Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Pol J Pathol    2005    56(4)    161-5	Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer		113705		CDC	2005												
144859	N	prostate cancer	CANCER	CAN	Prostatic Neoplasms	17	17q21	BRCA1	38449839	38530994		Damaraju, S.  et al. 2006	16638864				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Clin Cancer Res    2006    12(8)    2545-54	Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer		113705		CDC	2006	In this study, we identified SNPs in LIG4, ERCC2, and CYP2D6 genes as putative markers to predict individuals at risk for complications arising from radiation therapy in prostate cancer.											
144860		lymphoma lymphoma, non-Hodgkin	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Shen, M.  et al. 2006	16639601				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Hum Genet    2006	Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut		113705		CDC	2006												
144861		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Chang, T. W.  et al. 2006	16713266				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Breast    2006	Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan		113705		CDC	2006												
144862		benzene toxicity	PHARMACOGENOMIC	PHARM		17	17q21	BRCA1	38449839	38530994		Shen, M.  et al. 2006	16728435				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Carcinogenesis    2006	Polymorphisms in genes involved in DNA double strand break repair pathway and susceptibility to benzene-induced hematotoxicity		113705		CDC	2006												
144863		lymphoma, non-Hodgkin	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Shen, M.  et al. 2006	16738949				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Hum Genet    2006    119(6)    659-68	Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut		113705		CDC	2006												
144864		ovarian cancer	CANCER	CAN	Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994		Yazici, H.  et al. 2006	16783967				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Oncol Res    2006    16(1)    43-7	Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?		113705		CDC	2006			family history									
144865		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Romanowicz-Makowska, H.  et al. 2006	16837909				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Exp Oncol    2006    28(2)    156-9	Analysis of RAD51 polymorphism and BRCA1 mutations in polish women with breast cancer		113705		CDC	2006	Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and=or progression of breast cancer.											
144866		breast cancer	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Jakubowska, A.  et al. 2006	17004108			3' untranslated region	Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Breast Cancer Res Treat    2006	The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation		113705		CDC	2006												
144868		chemotherapy-related toxicity	PHARMACOGENOMIC	PHARM		17	17q21	BRCA1	38449839	38530994		Shanley, S.  et al. 2006	17145825				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Clin Cancer Res    2006    12(23)    7033-8	Acute Chemotherapy-Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom		113705		CDC	2006	This result has implications for therapy and indicates that women with mutations in BRCA1 and BRCA2 may be given the same doses of chemotherapy as noncarriers.											
144869		breast cancer ovarian cancer	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Pepe, C.  et al. 2006	17151928				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Breast Cancer Res Treat    2006	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers		113705		CDC	2006												
144871		menarche menstrual cycle length	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Henningson, M.  et al. 2007	17307805				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Mol Hum Reprod    2007	CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women		113705		CDC	2007	this study suggests that short menstrual cycles, age at first OC use and BRCA mutation status may need to be considered in studies exploring the relationships between CYP17 and risk factors for early onset breast cancer.											
144872		breast cancer	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Johnson, N.  et al. 2007	17341484				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		113705		CDC	2007												
144873		ovarian cancer	CANCER	CAN	Ovarian Neoplasms	17	17q21	BRCA1	38449839	38530994			17380889				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Russian		CDC GDP info	672	Hs.194143			Mol Biol (Mosk)    2007    41(1)    37-42	Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips		113705		CDC	2007												
144874		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Romanowicz-Makowska, H.  et al. 2006	17405295				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Pol Merkur Lekarski    2006    21(126)    548-50	Analysis of loss of heterozygosity and microsatellite instability RAD52, RAD54 and RAD54B gene and BRCA1 gene mutation in breast cancer		113705		CDC	2006	The results suggest that the microsatellite instability and LOH seems to be important in the development sporadic breast cancer.											
144876	N	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Baynes, C.  et al. 2007	17428325				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Breast Cancer Res    2007    9(2)    R27	Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk		113705		CDC	2007	It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.											
144878			NORMALVARIATION	NV		17	17q21	BRCA1	38449839	38530994		Henningson, M.  et al. 2007	17484040				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Fam Cancer    2007	Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families		113705		CDC	2007												
144879	Y	breast cancer	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Fu, X.  et al. 2007	17557253				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Zhonghua Yi Xue Yi Chuan Xue Za Zhi    2007    24(3)    341-4	Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang.		113705		CDC	2007	The mutation of BRCA1 gene may be related to Uigur women breast cancer and bilateral breast cancer.											
144880	P	breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Song, C.  et al. 2006	16456781				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Zhonghua Yi Xue Yi Chuan Xue Za Zhi    2006    23(1)    27-31	BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China.		600185		CDC	2006	Two novel mutations in BRCA1 may be mutations characterized to familial breast cancer of Chinese Shanghai population.											
144882	N	prostate cancer	CANCER	CAN	Prostatic Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Damaraju, S.  et al. 2006	16638864				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Clin Cancer Res    2006    12(8)    2545-54	Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer		600185		CDC	2006	In this study, we identified SNPs in LIG4, ERCC2, and CYP2D6 genes as putative markers to predict individuals at risk for complications arising from radiation therapy in prostate cancer.											
144883		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Chang, T. W.  et al. 2006	16713266				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Breast    2006	Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan		600185		CDC	2006												
144884		benzene toxicity	PHARMACOGENOMIC	PHARM		13	13q12.3	BRCA2	31787616	31871809		Shen, M.  et al. 2006	16728435				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Carcinogenesis    2006	Polymorphisms in genes involved in DNA double strand break repair pathway and susceptibility to benzene-induced hematotoxicity		600185		CDC	2006												
144885		lung cancer	CANCER	CAN	Lung Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Rudd, M. F.  et al. 2006	16741161				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Caucasian		CDC GDP info	675	Hs.34012			Genome Res    2006    16(6)    693-701	Variants in the GH-IGF axis confer susceptibilityto lung cancer		600185		CDC	2006												
144886	Y	breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Golshan, M.  et al. 2006	16769276				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Am J Surg    2006    192(1)    58-62	The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy		600185		CDC	2006	BRCA1 and BRCA2 mutations are common (9%) among unselected young breast cancer patients undergoing BCT.											
144887		ovarian cancer	CANCER	CAN	Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Yazici, H.  et al. 2006	16783967				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Oncol Res    2006    16(1)    43-7	Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?		600185		CDC	2006			family history									
144888		bladder cancer leukemia lung cancer	CANCER	CAN	Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Manuguerra, M. et al  et al. 2006	16956909				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Carcinogenesis    2006	Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions		600185		CDC	2006												
144890		chemotherapy-related toxicity	PHARMACOGENOMIC	PHARM		13	13q12.3	BRCA2	31787616	31871809		Shanley, S.  et al. 2006	17145825				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Clin Cancer Res    2006    12(23)    7033-8	Acute Chemotherapy-Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom		600185		CDC	2006	This result has implications for therapy and indicates that women with mutations in BRCA1 and BRCA2 may be given the same doses of chemotherapy as noncarriers.											
144891		breast cancer ovarian cancer	CANCER	CAN		13	13q12.3	BRCA2	31787616	31871809		Pepe, C.  et al. 2006	17151928				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Breast Cancer Res Treat    2006	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers		600185		CDC	2006												
144892	N	breast cancer	CANCER	CAN		13	13q12.3	BRCA2	31787616	31871809		Song, C. G.  et al. 2006	17217814				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Zhonghua Wai Ke Za Zhi    2006    44(19)    1310-3	Prevalence of Val158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer		600185		CDC	2006	Val158Met polymorphism in COMT gene could be a candidate for low penetrance breast cancer susceptibility in Shanghai population, especially among premenopausal women and early-onset breast cancer patients.											
144893		breast cancer	CANCER	CAN		13	13q12.3	BRCA2	31787616	31871809		Johnson, N.  et al. 2007	17341484				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		600185		CDC	2007												
144894		ovarian cancer	CANCER	CAN	Ovarian Neoplasms	13	13q12.3	BRCA2	31787616	31871809			17380889				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Russian		CDC GDP info	675	Hs.34012			Mol Biol (Mosk)    2007    41(1)    37-42	Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips		600185		CDC	2007												
144895		breast cancer	CANCER	CAN		13	13q12.3	BRCA2	31787616	31871809		Johnson, N.  et al. 2007	17409195				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		600185		CDC	2007												
144896	N	breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Baynes, C.  et al. 2007	17428325				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			Breast Cancer Res    2007    9(2)    R27	Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk		600185		CDC	2007	It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.											
144899		breast cancer	CANCER	CAN	Breast Neoplasms	17	17q22-q24	BRIP1	57114766	57295537		Seal, S.  et al. 2006	17033622				BRCA1 interacting protein C-terminal helicase 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_032043.1			CDC GDP info	83990	Hs.532799			Nat Genet    2006	Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles		605882		CDC	2006												
144900	N	breast cancer ovarian cancer	CANCER	CAN		17	17q22-q24	BRIP1	57114766	57295537		Song, H.  et al. 2007	17342202				BRCA1 interacting protein C-terminal helicase 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_032043.1			CDC GDP info	83990	Hs.532799			PLoS ONE    2007    2    e268	Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer		605882		CDC	2007	It is unlikely that common variants in BRIP1 contribute significantly to breast cancer susceptibility.											
144901		bladder cancer	CANCER	CAN		17	17q22-q24	BRIP1	57114766	57295537		Figueroa, J. D.  et al. 2007	17557904				BRCA1 interacting protein C-terminal helicase 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_032043.1			CDC GDP info	83990	Hs.532799			Carcinogenesis    2007	Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk		605882		CDC	2007	from this study provide evidence for associations between variants in genes in the DSBR pathway and bladder cancers risk that warrant replication in other study populations.											
145491		breast cancer	CANCER	CAN		22	22q11	CHEK2	27413730	27467822		Johnson, N.  et al. 2007	17341484				CHK2 checkpoint homolog (S. pombe)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007194.3			CDC GDP info	11200	Hs.291363			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		604373		CDC	2007												
145493		ovarian cancer	CANCER	CAN	Ovarian Neoplasms	22	22q11	CHEK2	27413730	27467822			17380889				CHK2 checkpoint homolog (S. pombe)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007194.3	Russian		CDC GDP info	11200	Hs.291363			Mol Biol (Mosk)    2007    41(1)    37-42	Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips		604373		CDC	2007												
145494		breast cancer	CANCER	CAN		22	22q11	CHEK2	27413730	27467822		Johnson, N.  et al. 2007	17409195				CHK2 checkpoint homolog (S. pombe)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007194.3			CDC GDP info	11200	Hs.291363			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		604373		CDC	2007												
145495	N	breast cancer	CANCER	CAN	Breast Neoplasms	22	22q11	CHEK2	27413730	27467822		Baynes, C.  et al. 2007	17428325				CHK2 checkpoint homolog (S. pombe)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007194.3			CDC GDP info	11200	Hs.291363			Breast Cancer Res    2007    9(2)    R27	Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk		604373		CDC	2007	It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.											
145727		breast cancer	CANCER	CAN		22	22q11.21-q11.23	COMT	18309308	18336530		Hu, Z.  et al. 2007	17562079				Catechol-O-methyltransferase	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000754.2			CDC GDP info	1312	Hs.370408			J Cancer Res Clin Oncol    2007	A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives		116790		CDC	2007			menopause									
146029		menarche menstrual cycle length	CANCER	CAN	Breast Neoplasms	10	10q24.3	CYP17A1	104580277	104587280		Henningson, M.  et al. 2007	17307805				Cytochrome P450, family 17, subfamily A, polypeptide 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000102.3			CDC GDP info	1586	Hs.438016			Mol Hum Reprod    2007	CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women		202110		CDC	2007	this study suggests that short menstrual cycles, age at first OC use and BRCA mutation status may need to be considered in studies exploring the relationships between CYP17 and risk factors for early onset breast cancer.											
146045	N	breast cancer	CANCER	CAN		15	15q21.1	CYP19A1	49288961	49418086		Song, C.  et al. 2006	16604491				Cytochrome P450, family 19, subfamily A, polypeptide 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000103.2			CDC GDP info	1588	Hs.511367			Zhonghua Yi Xue Yi Chuan Xue Za Zhi    2006    23(2)    181-3	Effect of R264C polymorphism in CYP19A1 gene on BRCA1/2-negative hereditary breast cancer from Shanghai population of China.		107910		CDC	2006	R264C polymorphism in CYP19A1 gene is not a candidate locus for low penetrance breast cancer susceptibility in Shanghai group of Chinese population and not recommended in clinical genetic test.											
146064		breast cancer	CANCER	CAN		15	15q21.1	CYP19A1	49288961	49418086		Hu, Z.  et al. 2007	17562079				Cytochrome P450, family 19, subfamily A, polypeptide 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000103.2			CDC GDP info	1588	Hs.511367			J Cancer Res Clin Oncol    2007	A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives		107910		CDC	2007			menopause									
146160	Y	breast cancer	CANCER	CAN		15	15q24	CYP1A2	72828236	72835994		Kotsopoulos, J.  et al. 2007	17507615				Cytochrome P450, family 1, subfamily A, polypeptide 2	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000761.3			CDC GDP info	1544	Hs.1361			Cancer Epidemiol Biomarkers Prev    2007    16(5)    912-6	The CYP1A2 Genotype Modifies the Association Between Coffee Consumption and Breast Cancer Risk Among BRCA1 Mutation Carriers		124060		CDC	2007			coffee									
146922		breast cancer, male	CANCER	CAN		7	7q21.3-q22.1	DSS1	96156014	96177139		Syrjakoski, K.  et al. 2007	17066443				split hand/foot malformation (ectrodactyly) type 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AK094899			CDC GDP info	7979				Int J Cancer    2007    120(2)    444-6	Mutations in the BRCA2 interacting DSS1 are not a risk factor for male breast cancer		601285		CDC	2007												
147161	Y	breast cancer	CANCER	CAN		17	17q11.2-q12	ERBB2	35097918	35138441		Tommasi, S.  et al. 2007	17452776				V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_004448.2	Caucasian		CDC GDP info	2064	Hs.446352			Cell Oncol    2007    29(3)    241-8	655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations		164870		CDC	2007	these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.		family history									
149504	P		NORMALVARIATION	NV		12	12q22-q23	IGF1	101313805	101398454		Henningson, M.  et al. 2007	17484040				Insulin-like growth factor 1 (somatomedin C)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000618.2			CDC GDP info	3479	Hs.160562			Fam Cancer    2007	Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families		147440		CDC	2007												
150368	Y	breast cancer ovarian cancer	CANCER	CAN	Breast Neoplasms; Ovarian Neoplasms	17	17q21.32	ITGB3	42686206	42745076		Jakubowska, A.  et al. 2007	17220212				Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000212.2	Polish		CDC GDP info	3690	Hs.218040			J Med Genet    2007	Integrin {beta}3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk		173470		CDC	2007												
151351		breast cancer ovarian cancer	CANCER	CAN				MS				Pepe, C.  et al. 2006	17151928				multiple sclerosis				CDC GDP info	4397				Breast Cancer Res Treat    2006	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers		126200		CDC	2006												
151478		breast cancer ovarian cancer	CANCER	CAN		1	1p36.3	MTHFR	11768373	11788702		Pepe, C.  et al. 2006	17151928				Chromosome 1 open reading frame 167	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_005957.3			CDC GDP info	4524	Hs.214142			Breast Cancer Res Treat    2006	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers		607093		CDC	2006												
151577		breast cancer ovarian cancer	CANCER	CAN		1	1q43	MTR	235025340	235130583		Pepe, C.  et al. 2006	17151928				5-methyltetrahydrofolate-homocysteine methyltransferase	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000254.1			CDC GDP info	4548	Hs.498187			Breast Cancer Res Treat    2006	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers		156570		CDC	2006												
151769	N	breast cancer	CANCER	CAN	Breast Neoplasms	20	20q12	NCOA3	45564063	45719021		Spurdle, A. B.  et al. 2006	16434590				Nuclear receptor coactivator 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_181659.1			CDC GDP info	8202	Hs.592142			Cancer Epidemiol Biomarkers Prev    2006    15(1)    76-9	The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers		601937		CDC	2006	the AIB1 glutamine repeat does not substantially modify risk of breast cancer in BRCA1 and BRCA2 mutation carriers.											
152412	Y	kidney volume, newborn	RENAL	REN		10	10q24	PAX2	102495321	102579688		Quinlan, J.  et al. 2007	17513325				Paired box gene 2	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_003988			CDC GDP info	5076	Hs.155644			J Am Soc Nephrol    2007	A Common Variant of the PAX2 Gene Is Associated with Reduced Newborn Kidney Size		167409		CDC	2007												
152413	N	neural tube defects	DEVELOPMENTAL	DEV	Spinal Dysraphism	2	2q35-q37|2q35	PAX3	222772850	222871944		Lu, W.  et al. 2006	17149730				Paired box 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_181458			CDC GDP info	5077	Hs.42146			Birth Defects Res A Clin Mol Teratol    2006	Screening for novel PAX3 polymorphisms and risks of spina bifida		606597		CDC	2006	Our analyses indicated that PAX3 SNPs were not strong risk factors for human spina bifida.											
152414	Y	diabetes, type 2	METABOLIC	MET		7	7q32	PAX4	127037581	127043218			16423628	PAX4  Arg121Trp			Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1			CDC GDP info	5078	Hs.129706			Metabolism    2006    55(2)    213-6	The Arg121Trp variant in PAX4 gene is associated with beta-cell dysfunction in Japanese subjects with type 2 diabetes mellitus		167413		CDC	2006												
152415	N	diabetes, type 1	IMMUNE	IMM	Genetic Predisposition to Disease	7	7q32	PAX4	127037581	127043218		Martin, R. J.  et al. 2006	16911636	PAX4  A1168C			Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1			CDC GDP info	5078	Hs.129706			Diabet Med    2006    23(8)    927-8	The PAX4 gene variant A1168C is not associated with early onset Type 1 diabetes in a UK population		167413		CDC	2006												
152416		diabetes, type 2	METABOLIC	MET		7	7q32	PAX4	127037581	127043218		Plengvidhya, N.  et al. 2007	17426099				Paired box gene 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006193.1	Thai		CDC GDP info	5078	Hs.129706			J Clin Endocrinol Metab    2007	PAX4 Mutations in Thais with Maturity-Onset Diabetes of the Young		167413		CDC	2007	Eight sequence differences were identified.											
152417	N	optic nerve malformation	DEVELOPMENTAL	DEV	Abnormalities	11	11p13	PAX6	31767033	31789455		Nallathambi, J.  et al. 2006	16604056				Paired box gene 6 (aniridia, keratitis)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000280.2	Indian		CDC GDP info	5080	Hs.591993			Mol Vis    2006    12    236-42	PAX6 missense mutations associated in patients with optic nerve malformation		607108		CDC	2006	In this study, we have been able to identify two sequence variations in the PAX6 gene.											
152418		diabetes, type 2	METABOLIC	MET		11	11p13	PAX6	31767033	31789455		Yokoi, N.  et al. 2006	16873704				Paired box gene 6 (aniridia, keratitis)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000280.2	Japanese;European		CDC GDP info	5080	Hs.591993			Diabetes    2006    55(8)    2379-86	Association Studies of Variants in the Genes Involved in Pancreatic {beta}-Cell Function in Type 2 Diabetes in Japanese Subjects		607108		CDC	2006												
152419	Y	hypothyroidism, congenital	METABOLIC	MET	Congenital Hypothyroidism	2	2q12-q14	PAX8	113690044	113752968		Lanzerath, K.  et al. 2006	16763387				Paired box 8	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_003466	German		CDC GDP info	7849	Hs.469728			Horm Res    2006    66(2)    96-100	Screening for Pax8 Mutations in Patients with Congenital Hypothyroidism in South-West Germany		167415		CDC	2006	These findings confirm the contribution of mutations in the Pax8 gene to the etiology of thyroid dysgenesis with a variable penetrance, but also demonstrate the rare overall incidence in CH.											
152521		breast cancer	CANCER	CAN		17	17q21	PHB	44836418	44847241		Jakubowska, A.  et al. 2006	17004108			3' untranslated region	Prohibitin	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002634.2			CDC GDP info	5245	Hs.514303			Breast Cancer Res Treat    2006	The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation		176705		CDC	2006												
152913	Y	ovarian cancer	CANCER	CAN	Ovarian Neoplasms	10	10q23.3	PTEN	89613174	89718512		Kolasa, I. K.  et al. 2006	16793127				Phosphatase and tensin homolog (mutated in multiple advanced cancers 1)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000314.3			CDC GDP info	5728	Hs.500466			Gynecol Oncol    2006	PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations		601728		CDC	2006	Our results suggest that PTEN mutations may play a role in a development of low-grade endometrioid tumors. PTEN haploinsufficiency caused by LOH or epigenetic events may possibly contribute to development of other histological types and may be an adverse prognostic factor.											
153077		breast cancer	CANCER	CAN	Breast Neoplasms	15	15q15.1	RAD51	38774660	38811646		Romanowicz-Makowska, H.  et al. 2005	16477874			5' untranslated region	RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002875.2			CDC GDP info	5888	Hs.631709			Pol J Pathol    2005    56(4)    161-5	Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer		179617		CDC	2005												
153081	N	breast cancer	CANCER	CAN	Breast Neoplasms	15	15q15.1	RAD51	38774660	38811646		Romanowicz-Makowska, H.  et al. 2006	16837909				RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002875.2			CDC GDP info	5888	Hs.631709			Exp Oncol    2006    28(2)    156-9	Analysis of RAD51 polymorphism and BRCA1 mutations in polish women with breast cancer		179617		CDC	2006	Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and=or progression of breast cancer.											
153116		breast cancer	CANCER	CAN	Breast Neoplasms			RCA1				Golshan, M.  et al. 2006	16769276				von Hippel-Lindau tumor suppressor	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000551			CDC GDP info	7428	Hs.517792			Am J Surg    2006    192(1)    58-62	The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy		603046		CDC	2006	BRCA1 and BRCA2 mutations are common (9%) among unselected young breast cancer patients undergoing BCT.											
153994		Hirschsprung's disease	OTHER	OTH	Hirschsprung Disease	22	22q13.1	SOX10	36698264	36713375		Sangkhathat, S.  et al. 2006	17009072				SRY (sex determining region Y)-box 10	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006941.3	Asian		CDC GDP info	6663	Hs.376984			J Hum Genet    2006	Mutations and polymorphisms of Hirschsprung disease candidate genes in Thai patients		602229		CDC	2006												
153995	Y	schizophrenia	PSYCH	PSY		22	22q13.1	SOX10	36698264	36713375		Maeno, N.  et al. 2007	17621166				SRY (sex determining region Y)-box 10	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006941.3			CDC GDP info	6663	Hs.376984			Psychiatr Genet    2007    17(4)    227-231	Association of SOX10 with schizophrenia in the Japanese population		602229		CDC	2007	This study suggests that the SOX10 gene is related to the development of schizophrenia in the Japanese population.											
154737		breast cancer	CANCER	CAN		17	17p13.1	TP53	7505821	7531642		Johnson, N.  et al. 2007	17341484				Tumor protein p53 (Li-Fraumeni syndrome)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000546.2			CDC GDP info	7157	Hs.408312			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		191170		CDC	2007												
154740		breast cancer	CANCER	CAN		17	17p13.1	TP53	7505821	7531642		Johnson, N.  et al. 2007	17409195				Tumor protein p53 (Li-Fraumeni syndrome)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000546.2			CDC GDP info	7157	Hs.408312			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		191170		CDC	2007												
154742	N	breast cancer	CANCER	CAN	Breast Neoplasms	17	17p13.1	TP53	7505821	7531642		Baynes, C.  et al. 2007	17428325				Tumor protein p53 (Li-Fraumeni syndrome)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000546.2			CDC GDP info	7157	Hs.408312			Breast Cancer Res    2007    9(2)    R27	Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk		191170		CDC	2007	It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.											
155276	N	breast cancer	CANCER	CAN	Breast Neoplasms; DNA Damage	7	7q36.1	XRCC2	151974519	152004183		Garcia-Closas, M.  et al. 2006	16485136				X-ray repair complementing defective repair in Chinese hamster cells 2	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=CR749256	Caucasian		CDC GDP info	7516	Hs.129727			Hum Genet    2006	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer		600375		CDC	2006	the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.											
155285	N	breast cancer	CANCER	CAN	Breast Neoplasms; DNA Damage	14	14q32.3	XRCC3	103233706	103251549		Garcia-Closas, M.  et al. 2006	16485136				X-ray repair complementing defective repair in Chinese hamster cells 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_005432.2	Caucasian		CDC GDP info	7517	Hs.592325			Hum Genet    2006	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer		600675		CDC	2006	the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.											
155336	N	breast cancer	CANCER	CAN	Breast Neoplasms; DNA Damage	19	19q13.41	ZNF350	57159404	57181891		Garcia-Closas, M.  et al. 2006	16485136				Zinc finger protein 350	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_021632.3	Caucasian		CDC GDP info	59348	Hs.407694			Hum Genet    2006	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer		605422		CDC	2006	the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.											
144877	N	breast cancer	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Tommasi, S.  et al. 2007	17452776				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2	Caucasian		CDC GDP info	672	Hs.194143			Cell Oncol    2007    29(3)    241-8	655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations		113705		CDC	2007	these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.		family history									
150716	N	breast cancer	CANCER	CAN	Breast Neoplasms; DNA Damage	13	13q33-q34	LIG4	107657792	107668717		Garcia-Closas, M.  et al. 2006	16485136				Ligase IV, DNA, ATP-dependent	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002312.3	Caucasian		CDC GDP info	3981	Hs.166091			Hum Genet    2006	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer		601837		CDC	2006	the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.											
144651	N	breast cancer	CANCER	CAN	Breast Neoplasms	11	11q22-q23	ATM	107598768	107745036		Baynes, C.  et al. 2007	17428325				Ataxia telangiectasia mutated (includes complementation groups A, C and D)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000051.3			CDC GDP info	472	Hs.435561			Breast Cancer Res    2007    9(2)    R27	Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk		607585		CDC	2007	It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.											
144701	N	breast cancer	CANCER	CAN		2	2q34-q35	BARD1	215301521	215382611		Jakubowska, A.  et al. 2007	17333333				BRCA1 associated RING domain 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000465.1	Polish		CDC GDP info	580	Hs.591642			Breast Cancer Res Treat    2007	BARD1 and breast cancer in Poland		601593		CDC	2007	There was no clear association between the presence of the BARD1 Cys557Ser allele and breast cancer in Poland.		family history									
144858	N	breast cancer	CANCER	CAN	Breast Neoplasms	17	17q21	BRCA1	38449839	38530994		Copson, E. R.  et al. 2006	16563154				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			BMC Cancer    2006    6(1)    80	Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers		113705		CDC	2006	We found no evidence that the MDM2 SNP309 accelerates tumour development in carriers of known pathogenic germline mutations of BRCA1.											
144867		cytogenetic studies	OTHER	OTH		17	17q21	BRCA1	38449839	38530994		Laczmanska, I.  et al. 2006	17078101				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Environ Mol Mutagen    2006	Influence of polymorphisms in xenobiotic-metabolizing genes and DNA-repair genes on diepoxybutane-induced SCE frequency		113705		CDC	2006												
144870	N	breast cancer	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Song, C. G.  et al. 2006	17217814				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Zhonghua Wai Ke Za Zhi    2006    44(19)    1310-3	Prevalence of Val158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer		113705		CDC	2006	Val158Met polymorphism in COMT gene could be a candidate for low penetrance breast cancer susceptibility in Shanghai population, especially among premenopausal women and early-onset breast cancer patients.											
144875		breast cancer	CANCER	CAN		17	17q21	BRCA1	38449839	38530994		Johnson, N.  et al. 2007	17409195				Breast cancer 1, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_007294.2			CDC GDP info	672	Hs.194143			Hum Mol Genet    2007	Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility		113705		CDC	2007												
144881	N	breast cancer	CANCER	CAN	Breast Neoplasms; DNA Damage	13	13q12.3	BRCA2	31787616	31871809		Garcia-Closas, M.  et al. 2006	16485136				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2	Caucasian		CDC GDP info	675	Hs.34012			Hum Genet    2006	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer		600185		CDC	2006	the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.											
144889		breast cancer	CANCER	CAN	Breast Neoplasms	13	13q12.3	BRCA2	31787616	31871809		Breast Cancer Association, = Consortium  et al. 2006	17018785				Breast cancer 2, early onset	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000059.2			CDC GDP info	675	Hs.34012			J Natl Cancer Inst    2006    98(19)    1382-96	Commonly studied single-nucleotide polymorphisms and breast cancer		600185		CDC	2006	Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.											
144898	N	breast cancer	CANCER	CAN	Breast Neoplasms; DNA Damage	17	17q22-q24	BRIP1	57114766	57295537		Garcia-Closas, M.  et al. 2006	16485136				BRCA1 interacting protein C-terminal helicase 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_032043.1	Caucasian		CDC GDP info	83990	Hs.532799			Hum Genet    2006	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer		605882		CDC	2006	the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.											
145711	Y	breast cancer	CANCER	CAN		22	22q11.21-q11.23	COMT	18309308	18336530		Song, C. G.  et al. 2006	17217814	COMT  Val158Met			Catechol-O-methyltransferase	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000754.2			CDC GDP info	1312	Hs.370408			Zhonghua Wai Ke Za Zhi    2006    44(19)    1310-3	Prevalence of Val158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer		116790		CDC	2006	Val158Met polymorphism in COMT gene could be a candidate for low penetrance breast cancer susceptibility in Shanghai population, especially among premenopausal women and early-onset breast cancer patients.											
147341		breast cancer	CANCER	CAN		6	6q25.1	ESR1	152053407	152466099		Hu, Z.  et al. 2007	17562079				Estrogen receptor 1	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000125.2			CDC GDP info	2099	Hs.208124			J Cancer Res Clin Oncol    2007	A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives		133430		CDC	2007			menopause									
151033	N	breast cancer	CANCER	CAN	Breast Neoplasms	12	12q14.3-q15	MDM2	67488246	67520481		Copson, E. R.  et al. 2006	16563154				Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse)	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_002392.2			CDC GDP info	4193	Hs.567303			BMC Cancer    2006    6(1)    80	Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers		164785		CDC	2006	We found no evidence that the MDM2 SNP309 accelerates tumour development in carriers of known pathogenic germline mutations of BRCA1.											
152411		Henoch-Schonlein purpura nephritis	CARDIOVASCULAR	CARD	Nephritis	10	10q24	PAX2	102495321	102579688		Yi, Z. W.  et al. 2006	16509931				Paired box gene 2	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_003988			CDC GDP info	5076	Hs.155644			Nephrology (Carlton)    2006    11(1)    42-8	Role of PAX2 gene polymorphisms in Henoch-Schonlein purpura nephritis		167409		CDC	2006	The 1410CT/1521AC PAX2 genotype does not increase susceptibility for HSP, but is likely to increase the susceptibility of kidney involvement, resulting in a HSPN diagnosis.											
153993		schizophrenia	PSYCH	PSY		22	22q13.1	SOX10	36698264	36713375		Iwamoto, K.  et al. 2006	16741945				SRY (sex determining region Y)-box 10	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_006941.3			CDC GDP info	6663	Hs.376984			Am J Med Genet B Neuropsychiatr Genet    2006	A family-based and case-control association study of SOX10 in schizophrenia		602229		CDC	2006												
155317	N	breast cancer	CANCER	CAN	Breast Neoplasms; DNA Damage	5	5q13-q14	XRCC4	82409072	82685335		Garcia-Closas, M.  et al. 2006	16485136				X-ray repair complementing defective repair in Chinese hamster cells 4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_003401.2	Caucasian		CDC GDP info	7518	Hs.567359			Hum Genet    2006	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer		194363		CDC	2006	the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.											
121508		smoking behavior	CHEMDEPENDENCY	CHEM		11	11q23	DRD2	112785526	112851091		Erblich, J.  et al. 2005	15381926				Dopamine receptor D2	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000795.2	African American		CDC GDPinfo	1813	Hs.73893			Molecular psychiatry. 2005 Apr;10(4):407-14	Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers.		126450	13820	2	2005				DRD2	D2 dopamine receptor	TaqI	A1 RFLP	SLC6A3	9-repeat VNTR	Y	smoking (cigarettes)	Cigarette craving among African-American smokers.
134781		cirrhosis, alcoholic; alcoholism	UNKNOWN	UNK	Alcoholism	5	5p15.3	SLC6A3	1445908	1498543		Foley, P. F.  et al. 2004	15542698				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Caucasian		CDC GDPinfo	6531	Hs.406			Annals of the New York Academy of Sciences. 2004 Oct;1025:39-46	Association studies of neurotransmitter gene polymorphisms in alcoholic Caucasians.		126455	27836	2	2004	Combined DRD2TaqI A or B with GABA(A)-beta2 or EAAT2 G603A genotypes may have a concerted influence in the predisposition to alcoholism.	Case:alcoholics;Control:controls										
134782		smoking behavior	CHEMDEPENDENCY	CHEM	Tobacco Use Disorder|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Batra, V.  et al. 2003	12740294				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Chest. 2003 May;123(5):1730-9	The genetic determinants of smoking.		126455	27837	2	2003	Review article											
134783		smoking behavior	CHEMDEPENDENCY	CHEM	Tobacco Use Disorder|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Lerman, C.  et al. 2003	12627466				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2003 Apr;118(1):48-54	Elucidating the role of genetic factors in smoking behavior and nicotine dependence.		126455	28259	2	2003	Review article											
134778		schizophrenia	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Zhang, M.  et al. 2003	12579508				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Chinese		CDC GDPinfo	6531	Hs.406			Zhonghua yi xue yi chuan xue za zhi. 2003 Feb;20(1):69-71	[Associations between six functional genes and schizophrenia]		126455	27216	2	2003	 The 480 bp allele of DAT1 gene is negatively associated with schizophrenia in Chinese Han population, which stands for the dopamine hypothesis of schizophrenia.	Control:controls;Case:67 Chinese Han schizophrenic patients										
134779		Tourette syndrome	PSYCH	PSY	Tourette Syndrome	5	5p15.3	SLC6A3	1445908	1498543		Diaz-Anzaldua, A.  et al. 2004	15094788				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Canadian	Quebec	CDC GDPinfo	6531	Hs.406			Molecular psychiatry. 2004 Mar;9(3):272-7	Tourette syndrome and dopaminergic genes: afamily-based association study in the French Canadian founder population.		126455	27217	2	2004	These data support the notion that DRD4 and MOA-A genes may confer an increased risk for developing TS in the French Canadian population.	Cohort 110 French Canadian Tourette syndrome patients 										
134780		obsessive compulsive disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Hemmings, S. M.  et al. 2003	12650952				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			European neuropsychopharmacology. 2003 Mar;13(2):93-8	Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder.		126455	27218	2	2003	Although no statistically significant genotypic or allelic associations were detected, the data yielded interesting preliminary results that warrant further discussion and investigation.	Control:129 control individuals;Case:71 obsessive compulsive disorder patients in the genetically homogeneous Afrikaner population										
134775		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease	5	5p15.3	SLC6A3	1445908	1498543		Goudreau, J. L.  et al. 2002	12465073				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Midwestern United States	CDC GDPinfo	6531	Hs.406			Movement disorders. 2002 Nov;17(6):1305-11	Case-Control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease		126455	25554	2	2002	We found statistically significant associations of PD with MAO-B polymorphisms in older patients and with a COMT polymorphism in younger subjects and in women. These significant differences at the two-tailed alpha level of 0.05 and restricted to subgroup analyses may have a biological basis or may be chance findings.	Control:196 control subjects;Case:319 unrelated Parkinson's disease cases										
134776		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease|Disease Progression	5	5p15.3	SLC6A3	1445908	1498543		Lynch, D. R.  et al. 2003	12815660				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Movement disorders. 2003 Jul;18(7):804-12	Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease.		126455	25555	2	2003	These results demonstrate that these specific genetic variations do not alter the fidelity of (99)Tc-TRODAT-1 as a measure of dopaminergic function in asymptomatic volunteer individuals or patients with PD.	Case patients with Parkinsons' disease;Control asymptomatic volunteers										
134777		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543			16389711				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Encephale. 2005 Jul-Aug;31(4 Pt 1):437-47	[Meta-analysis of candidate genes in attention-deficit hyperactivity disorder]		126455	26575	2	2005												
134772		alcohol abuse	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Hopfer, C. J.  et al. 2005	15845322				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Drug and alcohol dependence. 2005 May;78(2):187-93	Genetic influences on quantity of alcohol consumed by adolescents and young adults.		126455	25551	2	2005	 Genetic influence on drinking behavior was common in adolescents longitudinally assessed 1 year apart, but was less correlated between these adolescents and their assessment as young adults at a subsequent time point. Polymorphisms in genes of the dopaminergic system appear to influence variation in drinking behavior.	Cohort 4,432 youth assessed during adolescence (mean age of 16) and then 1 and 6 years later 										
134773	N	P300 event-related potentials	NEUROLOGICAL	NEUR		5	5p15.3	SLC6A3	1445908	1498543		Tsai, S. J.  et al. 2003	12605102				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Psychiatric genetics. 2003 Mar;13(1):51-3	Association analysis for dopamine D3 receptor, dopamine D4 receptor and dopamine transporter genetic polymorphisms and P300 event-related potentials for normal young females.		126455	25552	2	2003	 Our negative findings suggest that these genetic polymorphisms do not play a major role in the modulation of P300 event-related potentials.	Cohort 120 normal young Han-Chinese females 										
134774		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Bobb, A. J.  et al. 2004	15457500				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			American journal of medical genetics. 2004 Sep;{}:	Molecular genetic studies of ADHD: 1991 to 2004.		126455	25553	2	2004	All candidate gene approaches continue to face the problem of relatively low power, given modest odds ratios for even the best replicated genes.	Control:controls;Case attention deficit hyperactivity disorder cases										
134769		attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Todd, R. D.  et al. 2005	16178930				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		United States	CDC GDPinfo	6531	Hs.406			Journal of child psychology and psychiatry, and allied disciplines. 2005 Oct;46(10):1067-73	Collaborative analysis of DRD4 and DAT genotypes in population-defined ADHD subtypes.		126455	23461	2	2005	 Use of alternative population-based defined ADHD subtypes may help resolve some of the variable results presented for candidate gene association studies in ADHD.											
134770		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Meulen, E. M.  et al. 2005	16178931				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Dutch		CDC GDPinfo	6531	Hs.406			Journal of child psychology and psychiatry, and allied disciplines. 2005 Oct;46(10):1074-80	High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD.		126455	23462	2	2005	 The sibling correlation may indicate a familial clustering of methylphenidate response. This response is possibly associated with the presence of one or two alleles at the DRD4-7R locus, but not with DAT1-10R homozygosity in the Dutch population.											
134771		smoking behavior	CHEMDEPENDENCY	CHEM	Tobacco Use Disorder|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Munafo, M.  et al. 2004	15370155				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Nicotine & tobacco research. 2004 Aug;6(4):583-97	The genetic basis for smoking behavior: asystematic review and meta-analysis.		126455	25550	2	2004	The evidence for a contribution of specific genes to smoking behavior remains modest. Implications for the design of future studies are discussed, such as the need for the development of more specific phenotypes to increase the genetic signal in candidate gene studies.	Cohort individuals from 28 studies on smoking behavior 										
134766		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Roman, T.  et al. 2001	11449401				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			American journal of medical genetics. 2001 Jul;105(5):471-8	Attention-deficit hyperactivity disorder: a studyof association with both the dopamine transporter gene and the dopamine D4 receptor gene.		126455	23458	2	2001	These results add to the group of studies that together suggest a small effect of these genes in the susceptibility to ADHD	Control ethnically matched control sample;Case:81 Attention-deficit hyperactivity disorder children and adolescents and their parents:Brazil										
134767		attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		DiMaio, S.  et al. 2003	12587848				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Journal of psychiatry & neuroscience. 2003 Jan;28(1):27-38	Dopamine genes and attention-deficit hyperactivity disorder: a review.		126455	23459	2	2003	 The implication of SLC6A3 and DRD4 genes in ADHD appears to be one of the most replicated in psychiatric genetics and strongly suggests the involvement of the brain dopamine systems in the pathogenesis of ADHD. However, more work is required to further these findings by genotype-to-phenotype correlations and identify the functional allelic variants/mutations that are responsible for these associations. The role of other dopamine genes, which may have smaller effects than SLC6A3 and DRD4, needs also to be determined.											
134768		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Durston, S.  et al. 2005	15724142				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Molecular psychiatry. 2005 Jul;10(7):678-85	Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls.		126455	23460	2	2005	This demonstrates that, by constraining our investigations by prior knowledge of gene expression, including samples in which the distribution of phenotypic variance is wide and under heritable influences, and by using intermediate phenotypes, such as neuroimaging, we may begin to map out the pathways by which genes influence behavior.	Case subjects with attention deficit hyperactivity:disorder;Control:controls										
134763		attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Qian, Q.  et al. 2004	15211638				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Chinese	China	CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2004 Jul;128(1):84-9	Family-based and case-control association studies of DRD4 and DAT1 polymorphisms in Chinese attention deficit hyperactivity disorder patients suggest long repeats contribute to genetic risk for the disorder		126455	23455	2	2004	he long-repeat alleles of DRD4 (ranging from 4 to 6 repeats) and DAT1 (ranging from 11 to 12 repeats), were present more frequently in ADHD probands than controls (P < 0.05), although there was no significant allelic association when the alleles were analyzed separately from each other and there findings were not supported by within family tests of association. An exploratory stratification by gender suggests that long-repeat alleles of DRD4 and DAT1 may increase the risk for ADHD in Han Chinese children.	Control:226:controls;Case:340 Han Chinese attention deficit hyperactivity disorder cases										
134764		attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Kim, Y. S.  et al. 2005	16165273				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Korean	Korea	CDC GDPinfo	6531	Hs.406			Neuroscience letters. 2005 Dec;390(3):176-81	Family-based association study of DAT1 and DRD4 polymorphism in Korean children with ADHD.		126455	23456	2	2005												
134765		alcoholism	CHEMDEPENDENCY	CHEM	Alcoholism	5	5p15.3	SLC6A3	1445908	1498543		Bau, C. H.  et al. 2001	11244477				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Molecular psychiatry. 2001 Jan;6(1):9-Jul	DRD4 and DAT1 as modifying genes in alcoholism:interaction with novelty seeking on level of alcohol consumption		126455	23457	2	2001	The possible presence of an interaction effect between DRD4 and DAT1 gnotypes with novelty seeking on the level of consumption suggests that these genotypes may increase the alcohol-seeking behavior in high novelty seeking individuals, supporting that model.	Control:112:controls;Case:114:alcoholics										
134760		schizophrenia	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Szekeres, G.  et al. 2004	14681904				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2004 Jan;124(1):5-Jan	Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.		126455	23452	2	2004	These results suggest that the S/S genotype of the DRD3 is associated with worse therapeutic response and more severe executive dysfunctions in patients with schizophrenia.	Cohort patients with schizophrenia 	clozapine olanzapine quetiapine risperidone									
134761		schizophrenia	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Joober, R.  et al. 2000	11104840				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Journal of psychiatric research. 2000 Jul-Oct;34(5-Apr):285-91	DRD3 and DAT1 genes in schizophrenia: anassociation study		126455	23453	2	2000	 These results do not support the role of either of these genes in increasing susceptibility to schizophrenia or in modulating its phenotype in the studied population.	Case:42 two groups of schizophrenic patients, one of excellent neuroleptic responders and one of:nonresponders (N=64);Control:89 A group of healthy volunteers screened for major psychiatric disorders was also included	neuroleptic response									
134762		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Qian, Q.  et al. 2003	12947560				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Chinese		CDC GDPinfo	6531	Hs.406			Beijing da xue xue bao Yi xue ban. 2003 Aug;35(4):412-8	[Association studies of dopamine D4 receptor gene and dopamine transporter gene polymorphisms in Han Chinese patients with attention deficit hyperactivity disorder]		126455	23454	2	2003	 The long-repeat alleles of DRD4 (after a stratification by gender) and DAT1 may increase the risk for ADHD in Han Chinese children.	Control:226 unrelated controls;Case:340 Chinese attention deficit hyperactivity disorder:children										
134757		smoking behavior	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Lerman, C.  et al. 2003	14570538				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Health psychology. 2003 Sep;22(5):541-8	Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.		126455	23449	2	2003	These results provide the first evidence from a prospective clinical trial that genes that alter dopamine function may influence smoking cessation and relapse during the treatment phase.	Cohort 418 smokers of European ancestry 	bupropion									
134758		smoking behavior	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Erblich, J.  et al. 2005	15381926				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	African American		CDC GDPinfo	6531	Hs.406			Molecular psychiatry. 2005 Apr;10(4):407-14	Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers.		126455	23450	2	2005												
134759		smoking behavior	CHEMDEPENDENCY	CHEM	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Audrain-McGovern, J.  et al. 2004	15229055				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Virginia	CDC GDPinfo	6531	Hs.406			The American journal of psychiatry. 2004 Jul;161(7):1224-30	Interacting effects of genetic predisposition and depression on adolescent smoking progression.		126455	23451	2	2004	 These results provide the first evidence, to the authors' knowledge, for an association of the DRD2 A1 allele with smoking progression among adolescents. This effect is potentiated by depression symptoms. These effects appear to be specific to adolescents who have had at least some nicotine exposure (i.e., at least a puff of a cigarette).	Cohort 615 adolescents, including those who had never smoked, and in a subgroup including only adolescents who had been exposed to nicotine (i.e., smoked at least a puff of a cigarette) (N=292) 										
134754		alcoholism	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Choi, I. G.  et al. 2005	16125912				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			European neuropsychopharmacology. 2006 Feb;16(2):123-8	Genetic polymorphisms of alcohol and aldehyde dehydrogenase, dopamine and serotonin transporters in familial and non-familial alcoholism.		126455	23446	2	2005			family history									
134755		alcoholism	CHEMDEPENDENCY	CHEM	Alcoholism|Substance Withdrawal Syndrome	5	5p15.3	SLC6A3	1445908	1498543		Chen, W. J.  et al. 2001	11807408				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Chinese	China	CDC GDPinfo	6531	Hs.406			Psychiatric genetics. 2001 Dec;11(4):187-95	Genetic polymorphisms of the promoter region of dopamine D2 receptor and dopamine transporter genes and alcoholism among four aboriginal groups and Han Chinese in Taiwan.		126455	23447	2	2001	The results suggest that both the DRD2 promoter region and the DAT gene do not play a significant role in conferring vulnerability to alcoholism.	Case:203 alcohol dependents with withdrawal symptoms among four aboriginal groups (Atayal, Ami, Bunun, and Paiwan) and Han Chinese in Taiwan.:Taiwan;Control:213 sex- and ethnicity-matched individuals who were screened to exclude those with alcohol problems among four aboriginal groups (Atayal, Ami, Bunun, and Paiwan) and Han Chinese in Taiwan.										
134756		schizophrenia; opium abuse	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Vieyra, G.  et al. 2003	12708251				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Rev Med Chil. 2003 Feb;131(2):135-43	[Distribution of DRD4 and DAT1 alleles from dopaminergic system in a mixed Chilean population]		126455	23448	2	2003	In a Chilean population sample, the frequency of DRD4 and DAT1 alleles was very similar to that of European populations.	Cohort 100 blood donors in two public hospitals in Santiago Santiago, Chile 										
134750		attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Bellgrove, M. A.  et al. 2005	16168728				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Neuropsychologia. 2005 ;43(13):1847-57	Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: sustained attention,response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype.		126455	19537	2	2005												
134751		bipolar disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Greenwood, T. A.  et al. 2005	16261167				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Molecular psychiatry. 2006 Feb;11(2):125-33	Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples.		126455	19538	2	2005												
134752		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543			16368111				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Journal of psychiatric research. 2005	The dopamine transporter gene and the impulsivity phenotype in attention deficit hyperactivity disorder: A case-control association study in aKorean sample		126455	19539	2	2005												
134747	N	Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease	5	5p15.3	SLC6A3	1445908	1498543		Kelada, S. N.  et al. 2005	16041244				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Pharmacogenetics and genomics. 2005 Sep;15(9):659-68	Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease.		126455	19534	2	2005	We conclude that  although DAT 5' region SNPs haplotypes significantly alter in vitro transcriptional activity, they are not related to PD risk. In addition, our findings provide further evidence supporting an association of PD with the VNTR polymorphism.											
134748	N	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Langley, K.  et al. 2005	16082688				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2005 Nov;139(1):10-Jul	No support for association between the dopamine transporter (DAT1) gene and ADHD.		126455	19535	2	2005	We conclude that  the 3' VNTR and three additional promoter variants in DAT1 do not appear to be associated with ADHD, or response to stimulant mediation in our sample.		stimulant									
134749	Y	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Bellgrove, M. A.  et al. 2005	16123773				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Neuropsychopharmacology. 2005 Dec;30(12):2290-7	Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.		126455	19536	2	2005												
134743	Y	drug hypersensitivity	METABOLIC	MET		5	5p15.3	SLC6A3	1445908	1498543		Lott, D. C.  et al. 2004	15602501				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Neuropsychopharmacology. 2005 Mar;30(3):602-9	Dopamine transporter gene associated with diminished subjective response to amphetamine.		126455	19530	2	2004	The current findings have important implications for understanding the genetic determinants of variability in stimulant response and risk of abuse.	Cohort 96 healthy adult volunteers 	amphetamine									
134744		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Cornish, K. M.  et al. 2005	15809660				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Molecular psychiatry. 2005 Jul;10(7):686-98	Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample.		126455	19531	2	2005	The results suggest that DAT1 is a QTL for continuously distributed ADHD behaviours in the general population and the cognitive endophenotype of response inhibition.	Case:58 boys recruited from an epidemiological sample of 872 boys aged 6-11 years who scored above 90th percentile for teacher reported ADHD symptoms;Control:68 boys scoring below the 10th percentile										
134745		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Stein, M. A.  et al. 2005	15827573				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Neuropsychopharmacology. 2005 Jul;30(7):1374-82	Dopamine transporter genotype and methylphenidate dose response in children with ADHD.		126455	19532	2	2005	Further research is needed to determine the mechanisms related to poor response in patients with the 9/9-repeat genotype, and to determine if this group responds differentially to alternative treatments.	Cohort 47 children with attention deficit hyperactivity disorder,, ages 5-16 years (mean=9.02 years) 	methylphenidate									
134740		behavioral disorder	OTHER	OTH	Prenatal Exposure Delayed Effects	5	5p15.3	SLC6A3	1445908	1498543		Kahn, R. S.  et al. 2003	12915833				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			The Journal of pediatrics. 2003 Jul;143(1):104-10	Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors		126455	19524	2	2003	 Child hyperactivity-impulsivity and oppositional behaviors were associated with a DAT polymorphism but only when the child also had exposure to maternal prenatal smoking. This study emphasizes the importance of incorporating environmental cofactors in genetic studies of attention deficit hyperactivity disorder.	Cohort 161 children was followed prospectively from age 6 months to 60 months 	smoking (tobacco), maternal									
134741		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Oh, K. S.  et al. 2003	14584093				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Korean		CDC GDPinfo	6531	Hs.406			Yonsei medical journal. 2003 Oct;44(5):787-92	Dopamine transporter genotype influences the attention deficit in Korean boys with ADHD.		126455	19525	2	2003	This study found that the 10/10 genotype made less omission errors on the T.O.V.A. This suggests that the dopamine transporter genotype influences the attention deficits measured by T.O.V.A.	Cohort 44 unrelated attention deficit hyperactivity disorder patients recruited from the psychiatric outpatients' clinic at Kangbuk Samsung Hospital Korea 										
134742		depression; alcohol withdrawal	PSYCH	PSY	Alcoholism	5	5p15.3	SLC6A3	1445908	1498543		Heinz, A.  et al. 2004	15148564				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Psychopharmacology. 2004 Aug;174(4):561-70	Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence.		126455	19526	2	2004	 Genetic constitution interacts with the in vivo availability of central dopamine and serotonin transporters during alcohol detoxification and may affect the severity of alcohol withdrawal and clinical depression.	Case detoxified alcoholics;Control healthy controls										
134737		obesity	METABOLIC	MET	Obesity|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Epstein, L. H.  et al. 2002	12490667				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		United States	CDC GDPinfo	6531	Hs.406			Obesity research. 2002 Dec;10(12):1232-40	Dopamine transporter genotype as a risk factor for obesity in African-American smokers.		126455	19520	2	2002	These results suggest that variants of the dopamine transporter gene may be related to obesity in African-American smokers. Possible mechanisms responsible for the association between dopamine transport and obesity in African-American smokers are discussed.	Cohort 510 smokers of African-American (n=90) and non-Hispanic Caucasians (n=420) 										
134738		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Lin, J. J.  et al. 2003	12686408				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Taiwan	CDC GDPinfo	6531	Hs.406			Journal of the neurological sciences. 2003 May;209(2-Jan):87-92	The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not to female patients.		126455	19521	2	2003	In conclusion, the results of our study show that homozygote 10-copy genotype of the VNTR polymorphism within the DAT may confer a protective factor for male PD patients, but not for female PD patients.	Case:193 sporadic Parkinson's disease patients;Control:254 controls, matched by age and sex										
134739		attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Smith, K. M.  et al. 2003	12707943				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Wisconsin	CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2003 May;119(1):77-85	Association of the dopamine beta hydroxylase gene with attention deficit hyperactivity disorder:genetic analysis of the Milwaukee longitudinal study.		126455	19522	2	2003	These results indicate that the DBH TaqI A allele, or another polymorphism in linkage disequilibrium with this allele, may confer increased susceptibility towards ADHD.	Case:158 Attention deficit hyperactivity disorder adult subjects followed longitudinally since childhood in the Milwaukee study;Control:81 control adult subjects										
134734		attention deficit disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Roman, T.  et al. 2002	12172219				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Pharmacogenetics. 2002 Aug;12(6):497-9	Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder.		126455	19517	2	2002	Our findings support an association between homozygosity for the 10-repeat allele at dopamine transporter gene locus and poor response to MPH.	Cohort 50 male ADHD youths 	methylphenidate									
134735	Y	post-traumatic stress disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Segman, R. H.  et al. 2002	12232785				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Molecular psychiatry. 2002 ;7(8):903-7	Association between the dopamine transporter gene and posttraumatic stress disorder.		126455	19518	2	2002	These findings suggest that genetically determined changes in dopaminergic reactivity may contribute to the occurrence of PTSD among trauma survivors.	Case:102 chronic PTSD patients;Control:104 carefully-documented trauma survivors (TS) who did not develop PTSD										
134736		alcohol abuse	CHEMDEPENDENCY	CHEM	Alcoholism|Substance Withdrawal Syndrome	5	5p15.3	SLC6A3	1445908	1498543		Wernicke, C.  et al. 2002	12401557				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	German	Germany	CDC GDPinfo	6531	Hs.406			Neuroscience letters. 2002 Nov;333(1):45-8	Evidence for the importance of the human dopamine transporter gene for withdrawal symptomatology of alcoholics in a German population.		126455	19519	2	2002	Our findings provide further evidence that the 3'UTR of the DAT1 gene affects vulnerability to severe alcohol withdrawal.	Case:alcoholics;Control:control	family history									
134730	Y	dopamine transporter availability	UNKNOWN	UNK		5	5p15.3	SLC6A3	1445908	1498543		van Dyck, C. H.  et al. 2005	15872345	9 repeat			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	European American		CDC GDPinfo	6531	Hs.406			Journal of nuclear medicine. 2005 May;46(5):745-51	Increased Dopamine Transporter Availability Associated with the 9-Repeat Allele of the SLC6A3 Gene		126455	13826	2	2005	 These results support the interpretation of higher DAT levels in association with the *9R allele in European Americans and may relate to previously observed associations between DAT genotype and neuropsychiatric diseases.	Cohort 96 healthy European Americans (age range, 18-88 y) 										
134732		suicide; heroin abuse	PSYCH	PSY	Heroin Dependence	5	5p15.3	SLC6A3	1445908	1498543		Gerra, G.  et al. 2005	16109590				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Addiction biology. 2005 Sep;10(3):275-81	Allelic association of a dopamine transporter gene polymorphism with antisocial behaviour in heroin-dependent patients.		126455	13828	2	2005												
134733		schizophrenia; methamphetamine abuse	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Simsek, M.  et al. 2005	16201143				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Human biology; an international record of research. 2005 Apr;77(2):281-6	DAT1 VNTR allele frequencies in the Omani population.		126455	13830	2	2005												
134727	N	schizophrenia	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Cordeiro, Q.  et al. 2004	15608954				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Brazil	CDC GDPinfo	6531	Hs.406			Arquivos de neuro-psiquiatria. 2004 Dec;62(4):973-6	Lack of association between VNTR polymorphism of dopamine transporter gene (SLC6A3) and schizophrenia in a Brazilian sample		126455	13823	2	2004	Thus, our results do not support an association of the SLC6A3 VNTR with schizophrenia in our sample.	Case:220 schizophrenic patients;Control:226 gender and ethnic matched controls										
134728		bipolar disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Keikhaee, M. R.  et al. 2005	15768394	(DAT1)-67A/T			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Iranian		CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2005 May;135(1):47-9	Association analysis of the dopamine transporter (DAT1)-67A/T polymorphism in bipolar disorder.		126455	13824	2	2005	For the first time, these findings provide tentative evidence of the contribution of the DAT1 gene core promoter polymorphism to the etiopathophysiology of bipolar disorder at least in the Iranian population that we have studied. Interestingly, no allelic or genotype association was observed in the female patients (P	Case:136 Iranian bipolar disorder patients;Control:163 controls matched on sex, age and ethnicity										
134729		delusional disorder	PSYCH	PSY	Delirium	5	5p15.3	SLC6A3	1445908	1498543		Kim, J. Y.  et al. 2005	15823165				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Korea	CDC GDPinfo	6531	Hs.406			Psychiatry and clinical neurosciences. 2005 Apr;59(2):183-8	Antipsychotics and dopamine transporter gene polymorphisms in delirium patients.		126455	13825	2	2005	The response rates at the 3rd and 7th days after medication did not differ with either the drug group or the dopamine transporter polymorphism. Relatively low doses of risperidone and haloperidol exhibited similar efficacies, and dopamine transporter polymorphisms do not appear to play a major role in the action of antipsychotics on delirium.	Cohort 42 delerium patients 	haloperidol risperidone									
134724		schizophrenia	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Jeong, S. H.  et al. 2004	15380858				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Korean	Korea	CDC GDPinfo	6531	Hs.406			Progress in neuro-psychopharmacology & biological psychiatry. 2004 Sep;28(6):975-83	Association study of dopamine transporter gene and schizophrenia in Korean population using multiple single nucleotide polymorphism markers		126455	13819	2	2004	In accordance with the previous literature, we could not find any evidence of association between DAT1 gene and schizophrenia. This result acquired more certainty because not only the VNTR but several SNPs present in DAT1 gene and newly constructed haplotypes were also used as additional markers. However, the finding of weak association between one of the SNP markers (1398C>T) and the specific subgroups of schizophrenia patients added further support to the importance of defining more homogenous subgroups in association studies.	Case:252 schizophrenic patients:Korea;Control:271:controls										
134725	N	schizophrenia	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Gamma, F.  et al. 2005	15567077	40 bp			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Schizophrenia research. 2005 Feb;73(1):55-8	Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene.		126455	13821	2	2005	 Despite over 90% power to detect a significant odds ratio as small as 1.3, no association was observed. Considering the cumulative evidence from six case-control studies and results from additional family-based studies, it seems unlikely that the 40-base-pair VTNR polymorphism of the SLC6A3 gene influences risk for schizophrenia.	Control controls from six case-control studies;Case schizophrenic patients from six case-control:studies										
134726	N	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Qian, Q. J.  et al. 2004	15605097	G352A			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Chinese		CDC GDPinfo	6531	Hs.406			Beijing da xue xue bao Yi xue ban. 2004 Dec;36(6):626-9	[Association studies of G352A polymorphism of dopamine transporter gene in Han Chinese attention deficit hyperactivity disorder patients.]		126455	13822	2	2004	 There is no association between G352A, the new polymorphism, in exon 15 of DAT1 and ADHD. The 352G allele has a tendency to be preferentially transmitted to ADHD girls, but the findings require replication before drawing a definitive conclusion.	Control:207 unrelated controls;Case:337 Han Chinese attention deficit hyperactivity:disorder										
134721		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease	5	5p15.3	SLC6A3	1445908	1498543		Contin, M.  et al. 2004	15190232				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Clinical neuropharmacology. 2004 May-Jun;27(3):111-5	Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease.		126455	13816	2	2004	 The study did not identify clinically relevant in vivo DAT neurochemical function phenotypes or levodopa response patterns associated with the DAT polymorphism.	Cohort 36 patients with Parkinson's disease 										
134722		alcohol withdrawal	CHEMDEPENDENCY	CHEM	Hallucinations|Alcohol Withdrawal Delirium|Alcoholism|	5	5p15.3	SLC6A3	1445908	1498543		Limosin, F.  et al. 2004	15193761				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Neuroscience letters. 2004 May;362(2):91-4	The A9 allele of the dopamine transporter gene increases the risk of visual hallucinations during alcohol withdrawal in alcohol-dependent women.		126455	13817	2	2004	Our results suggest that the A9 allele of the DAT gene is involved in vulnerability to alcohol withdrawal complications in women, but that these complications differ from those associated with this polymorphism in alcohol-dependent men.	Cohort 64 Caucasian alcohol-dependent women with a history of alcohol withdrawal complications France 										
134723		schizophrenia	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Khodayari, N.  et al. 2004	15274029			promoter	Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Iranian		CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2004 Aug;129(1):2-Oct	Association of the dopamine transporter gene (DAT1) core promoter polymorphism -67T variant with schizophrenia.		126455	13818	2	2004	For the first time, these findings provide tentative evidence for the contribution of the DAT1 gene core promoter polymorphism to the etiopathophysiology of schizophrenia at least in the Iranian male population that we studied. Replication studies of independent samples and family-based association studies are necessary to further evaluate the significance of our findings.	Control:100 controls matched on the basis of sex, age, and:ethnicity;Case:100 schizophrenic patients										
134718		psychosis	PSYCH	PSY	Psychoses, Substance-Induced|Amphetamine-Related Disorders|Genetic Predisposition to Disease|	5	5p15.3	SLC6A3	1445908	1498543		Ujike, H.  et al. 2003	12931138				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			The pharmacogenomics journal. 2003 ;3(4):242-7	Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis		126455	13811	2	2003	The present study demonstrated that the presence of nine- or fewer repeat alleles of hDAT1 is a strong risk factor for a worse prognosis of METH psychosis.	Case:124 METH dependence/psychosis patients;Control:160:controls										
134719	Y	eating behavior	OTHER	OTH	Bulimia	5	5p15.3	SLC6A3	1445908	1498543		Shinohara, M.  et al. 2004	15069467			3' UTR	Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Journal of psychiatry & neuroscience. 2004 Mar;29(2):134-7	Eating disorders with binge-eating behaviour are associated with the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene		126455	13814	2	2004	 It seems plausible that the association between the DAT1 VNTR and binge-eating behaviour indicates that dysregulation of dopamine reuptake may act as a common pathophysiologic mechanism in eating disorders with binge-eating behaviour and in disorders related to substance use.	Control:115 healthy female controls;Case:90 female Japanese patients with eating disorders										
134720		schizophrenia; methamphetamine abuse	PSYCH	PSY	Psychoses, Substance-Induced|Amphetamine-Related Disorders|Acute Disease|Chronic Disease	5	5p15.3	SLC6A3	1445908	1498543		Liu, H. C.  et al. 2004	15091313				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		China|Taiwan	CDC GDPinfo	6531	Hs.406			Psychiatric genetics. 2004 Mar;14(1):33-7	DAT polymorphism and diverse clinical manifestations in methamphetamine abusers.		126455	13815	2	2004	No significant associations were demonstrated between this DAT polymorphism in genotype and allele frequency and the clinical outcome of MAP abusers. The biological relevance of the variable number tandem repeat polymorphism in the 3'-untranslated region of DAT in MAP abusers was not demonstrated in this study.	Case:146/79 methamphetamine abusers (n=146) and schizophrenics:(n=79);Control:72 healthy controls										
134715	Y	suicide	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Bayle, F. J.  et al. 2003	12707931				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2003 May;119(1):13-7	5HTTLPR polymorphism in schizophrenic patients:further support for association with violent suicide attempts.		126455	13806	2	2003	Although replication studies are warranted, these results in schizophrenia further support the hypothesis that 5HTTLPR polymorphism is a risk factor for violent suicidal behavior.	Control:159 gender and ethnically matched controls;Case:185 unrelated schizophrenic patients from a French Caucasian population										
134716		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Loo, S. K.  et al. 2003	12874502				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Journal of the American Academy of Child and Adolescent Psychiatry. 2003 Aug;42(8):986-93	Functional effects of the DAT1 polymorphism on EEG measures in ADHD.		126455	13809	2	2003	 The data suggest that the DAT1 polymorphism mediates medication-related changes in cortical activity among children with ADHD.	Cohort children with attention deficit hyperactivity disorder 	methylphenidate									
134717		attention deficit hyperactivity disorder	OTHER	OTH		5	5p15.3	SLC6A3	1445908	1498543		Kirley, A.  et al. 2003	12898575	480 bp			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Irish		CDC GDPinfo	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2003 Aug;121(1):50-4	Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.		126455	13810	2	2003	Our findings suggest a role for the 10-repeat DAT1 risk allele in medication response and may help to predict positive clinical outcome in ADHD.	Cohort 119 Irish children with ADHD 	methylphenidate									
134712		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease|Disease Susceptibility	5	5p15.3	SLC6A3	1445908	1498543		Lin, C. N.  et al. 2002	12422069	(1215A/G).			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			European neurology. 2002 ;48(4):207-9	Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G).		126455	13802	2	2002	Our findings confirm those of the previous negative report and, taken together, suggest that the DAT polymorphism (1215A/G) does not play a major role in the susceptibility to PD. Other DAT genetic variants, and the association of these variants with PD symptomatology or treatment response, may merit further investigation.	Case:102 Parkinson's disease patients;Control:174:controls										
134713	Y	delirium tremens, alcohol-induced; alcohol withdrawal	CHEMDEPENDENCY	CHEM	Seizures|Alcohol Withdrawal Delirium|Substance Withdrawal Syndrome|	5	5p15.3	SLC6A3	1445908	1498543		Gorwood, P.  et al. 2003	12513948				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Biological psychiatry. 2003 Jan;53(1):85-92	The A9 allele of the dopamine transporter gene is associated with delirium tremens and alcohol-withdrawal seizure		126455	13804	2	2003	 This study provides convergent data in favor of a significant role of the DAT gene in the risk for some severe withdrawal symptoms. If further replicated in larger samples, the DAT genetic polymorphism could be one of the factors to be analyzed to further assess the risk of some severe alcohol-withdrawal symptoms.	Cohort 120 alcohol-dpendent patients 										
134714	N	methamphetamine abuse	CHEMDEPENDENCY	CHEM	Substance-Related Disorders	5	5p15.3	SLC6A3	1445908	1498543		Hong, C. J.  et al. 2003	12658362				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Chinese		CDC GDPinfo	6531	Hs.406			J Neural Transm. 2003 Apr;110(4):345-51	Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males.		126455	13805	2	2003	The findings of this study suggest that these polymorphisms do not play major roles in METH dependence in the Chinese-male population.	Case Chinese male methamphetamine dependent cases;Control:controls										
134709		opiate abuse	CHEMDEPENDENCY	CHEM	Opioid-Related Disorders	5	5p15.3	SLC6A3	1445908	1498543		Galeeva, A. R.  et al. 2002	12173460				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Russian		CDC GDPinfo	6531	Hs.406			Molekuliarnaia biologiia. 2002 Jul-Aug;36(4):593-8	[VNTR polymorphisms of the serotonin transporter and dopamine transporter genes in male opiate addicts]		126455	13799	2	2002	Thus, our results implicate the serotonin and dopamine transporters in early opiate abuse in male Russians and Tatars, and allow the following	Control:110 healthy men (56 Russians and 54 Tatars) of the same age who had no psychiatric or narcological record and denied the abuse of psychoactive drugs;Case:177 men (94 Russians and 83 Tatars) treated for opiate:addition										
134710		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Nishimura, M.  et al. 2002	12210886				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Japan	CDC GDPinfo	6531	Hs.406			Movement disorders. 2002 Jul;17(4):831-2	Association between dopamine transporter gene polymorphism and susceptibility to Parkinson's disease in Japan.		126455	13800	2	2002	The 1215A/G genotype of the DAT gene was significantly different between PD patients and controls, suggesting a possible involvement of DAT in genetic susceptibility to PD.	Control:220:controls;Case:236 Japanese patients with Parkinson's disease										
134711	Y	smoking behavior	CHEMDEPENDENCY	CHEM	Tobacco Use Disorder	5	5p15.3	SLC6A3	1445908	1498543		Vandenbergh, D. J.  et al. 2002	12215242				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Nicotine & tobacco research. 2002 Aug;4(3):333-40	Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding thatnever-smokers may be different.		126455	13801	2	2002	When we distinguish between never-smokers (no cigarettes ever) and non-smokers (1-99 in lifetime), we find a reliable trend essentially in the opposite direction from Lerman et al. (1999), with the 10-copy allele being more frequent in never-smokers. Biobehavioral research on cigarette smoking should distinguish between never- and non-smokers. We have also developed an improved set of polymerase chain reaction conditions to increase the frequency of successful amplification of DAT'sw VNTR, which is a long, G+C-rich repeat.	Cohort A subset from 3383 adult volunteers contacted via a random-digit dialing telephone interview 										
134706	Y	Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease	5	5p15.3	SLC6A3	1445908	1498543		Zhang, L.  et al. 2001	11774209				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Zhonghua yi xue yi chuan xue za zhi. 2001 Dec;18(6):431-4	[Association between dopamine transporter gene polymorphism and Parkinson's disease]		126455	13795	2	2001	 The findings not only support an association between DAT gene and PD but also suggest the relationship of the 3'VNTR polymorphism of DAT gene with the age at the onset of PD.	Case:128 Parkinson's disease patients;Control:85 normal controls										
134707		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Wang, J.  et al. 2000	11798784				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Zhonghua yi xue za zhi. 2000 May;80(5):346-8	[Association between genetic polymorphism of dopamine transporter gene and susceptibility to Parkinson's disease]		126455	13796	2	2000	 DAT 3' VNTR 11-copy allele is a genetic factor susceptible to PD in the population tested.	Case:171 Parkinson's disease patients;Control:180 unrelated healthy controls										
134708	Y	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Retz, W.  et al. 2002	11834311			promoter	Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Neuroscience letters. 2002 Feb;319(3):133-6	Association of attention deficit hyperactivity disorder-related psychopathology and personality traits with the serotonin transporter promoter region polymorphism.		126455	13798	2	2002	Thus, our study supports the recently reported finding of an association of the 5-HTT polymorphism with ADHD. However, since a dimensional assessment of ADHD-related symptomatology was used in our study instead of a diagnostic approach, we are now on the way in performing further studies regarding diagnostic discrimination and comorbidity.	Cohort not specified in abstract 										
134703	Y	externalizing behavior problems; hyperactivity	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Jorm, A. F.  et al. 2001	11378848				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			American journal of medical genetics. 2001 May;105(4):346-50	Association of a polymorphism of the dopamine transporter gene with externalizing behavior problems and associated temperament traits: alongitudinal study from infancy to the mid-teens.		126455	13792	2	2001	No significant associations were found at any age. There are a number of methodological differences from earlier studies that might explain the lack of associations with hyperactivity. It is also possible that the earlier findings are not replicable	Cohort 660 children who had been assessed for temperament from 4-8 months to 15-16 years, and for behavior problems from 3-4 to 15-16 years 										
134704		alcohol dependence; alcoholic psychosis	CHEMDEPENDENCY	CHEM	Psychoses, Alcoholic|Acute Disease	5	5p15.3	SLC6A3	1445908	1498543		Galeeva A.R.  et al. 2001	11505915				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Russia	CDC GDPinfo	6531	Hs.406			Zhurnal nevrologii i psikhiatrii imeni SS Korsakova. 2001 ;101(5):43-5	[The evaluation of VNTR-polymorphism in the gene of dopamine transporter in men of different nationalities with acute alcoholic psychosis]		126455	13793	2	2001	There was association between an allele variant with 9 units of DAT gene repetition (in homozygous state first of all), and early development of alcoholic dependence and acute alcoholic psychosis.											
134705	N	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Galeeva, A. R.  et al. 2001	11558224				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Genetika. 2001 Jul;37(7):1018-20	[Polymorphism of the dopamine transporter gene in populations of the Volga-Ural region]		126455	13794	2	2001	Statistically significant differences in the dopamine transporter gene allele and genotype frequency distribution were revealed both between the populations belonging to one ethnic group and between the populations from different linguistic families.	Cohort populations of the Volga-Ural region 										
134700	Y	posttraumatic stress disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Segman RH et al. 2002	12232785				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			KGB	6531	Hs.406			Molecular psychiatry. 2002 ;7(8):903-7	Association between the dopamine transporter gene and posttraumatic stress disorder.		126455	7671	1	2002	These findings suggest that genetically determined changes in dopaminergic reactivity may contribute to the occurrence of PTSD among trauma survivors.	Case:102 chronic PTSD patients;Control:104 carefully-documented trauma survivors (TS) who did not develop PTSD										
134701	Y	externalizing behavior problems and associated temperament traits	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Jorm AF et al. 2001	11378848				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			KGB	6531	Hs.406			American journal of medical genetics. 2001 May;105(4):346-50	Association of a polymorphism of the dopamine transporter gene with externalizing behavior problems and associated temperament traits: a longitudinal study from infancy to the mid-teens.		126455	7673	1	2001	No significant associations were found at any age. There are a number of methodological differences from earlier studies that might explain the lack of associations with hyperactivity. It is also possible that the earlier findings are not replicable	Cohort 660 children who had been assessed for temperament from 4-8 months to 15-16 years, and for behavior problems from 3-4 to 15-16 years										
134702	N	Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease	5	5p15.3	SLC6A3	1445908	1498543		Kimura, M.  et al. 2001	11220753	(1215A/G)			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Annals of neurology. 2001 Feb;49(2):276-7	No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease.		126455	13791	2	2001	The results of this study confirm our previous findings on the 40-bp VNTR, namely, that the repeat number distribution of this polymorphism does not differ between PD patients and healthy control subjects. The consistency of our results may be supported by the fact that the two polymorphisms examined in this study were almonst in complete linkage disequilibrium. Taken together, these results strongly suggest that the 1215A/G polymorphism and the nearby loci of the DAT gene do not alter susceptibility to idiopathic PD.	Case:204 Japanese patients with idiopathic PD:Japan;Control:300 age- and gender-matched normal control subjects										
134697	N	Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease	5	5p15.3	SLC6A3	1445908	1498543	n	Kimura M et al. 2001	11220753				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			KGB	6531	Hs.406			Annals of neurology. 2001 Feb;49(2):276-7	No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease.		126455	7660	1	2001	The results of this study confirm our previous findings on the 40-bp VNTR, namely, that the repeat number distribution of this polymorphism does not differ between PD patients and healthy control subjects. The consistency of our results may be supported by the fact that the two polymorphisms examined in this study were almonst in complete linkage disequilibrium. Taken together, these results strongly suggest that the 1215A/G polymorphism and the nearby loci of the DAT gene do not alter susceptibility to idiopathic PD.	Case:204 Japanese patients with idiopathic PD:Japan;Control:300 age- and gender-matched normal control subjects										
134698	Y	Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Nishimura M et al. 2002	12210886				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Japan	KGB	6531	Hs.406			Movement disorders. 2002 Jul;17(4):831-2	Association between dopamine transporter gene polymorphism and susceptibility to Parkinson's disease in Japan.		126455	7661	1	2002	The 1215A/G genotype of the DAT gene was significantly different between PD patients and controls, suggesting a possible involvement of DAT in genetic susceptibility to PD.	Control:220:controls;Case:236 Japanese patients with Parkinson's disease										
134699		Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease|Disease Susceptibility	5	5p15.3	SLC6A3	1445908	1498543		Lin CN et al. 2002	12422069				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			KGB	6531	Hs.406			European neurology. 2002 ;48(4):207-9	Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G).		126455	7664	1	2002	Our findings confirm those of the previous negative report and, taken together, suggest that the DAT polymorphism (1215A/G) does not play a major role in the susceptibility to PD. Other DAT genetic variants, and the association of these variants with PD symptomatology or treatment response, may merit further investigation.	Case:102 Parkinson's disease patients;Control:174:controls										
134693	N	Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease|Hallucinations	5	5p15.3	SLC6A3	1445908	1498543	n	Wang J 2004	14732464	3?-UTR 40 bp VNTR			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Chinese		KGB	6531	Hs.406	visual hallucinations		Neuroscience letters. 2004 Jan;355(3):193-6	Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease.		126455	5451	1	2004												
134694		alcoholism	CHEMDEPENDENCY	CHEM	Seizures|Delirium|Alcoholism|Substance Withdrawal Syndrome	5	5p15.3	SLC6A3	1445908	1498543		Franke P et al. 1999	10088054				solute carrier family 6 (neurotransmitter transporter, dopamine), member 3				KGB	6531	Hs.406			Biological psychiatry. 1999 Mar;45(5):652-4	DAT1 gene polymorphism in alcoholism: a family-based association study.		126455	5452	1	1999	 Based on our data, the impact of the 9-repeat allele of the dopamine transporter gene in alcoholism and the severity of alcohol withdrawal symptoms is putatively not substantial.											
134695	Y	methylphenidate response	OTHER	OTH		5	5p15.3	SLC6A3	1445908	1498543		Kirley A 2003	12898575				solute carrier family 6 (neurotransmitter transporter, dopamine), member 3				KGB	6531	Hs.406			American journal of medical genetics Part B, Neuropsychiatric genetics. 2003 Aug;121(1):50-4	Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.		126455	5453	1	2003			methylphenidate									
134696	Y	Parkinson's disease	NEUROLOGICAL	NEUR	Parkinson Disease	5	5p15.3	SLC6A3	1445908	1498543		Zhang L et al. 2001	11774209				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			KGB	6531	Hs.406			Zhonghua yi xue yi chuan xue za zhi. 2001 Dec;18(6):431-4	Association between dopamine transporter gene polymorphism and Parkinson's disease		126455	7657	1	2001	 The findings not only support an association between DAT gene and PD but also suggest the relationship of the 3'VNTR polymorphism of DAT gene with the age at the onset of PD.	Case:128 Parkinson's disease patients;Control:85 normal controls										
134690	Y	Child hyperactivity-impulsivity and oppositional behaviors	OTHER	OTH	Prenatal Exposure Delayed Effects	5	5p15.3	SLC6A3	1445908	1498543		Kahn RS 2003	12915833				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			KGB	6531	Hs.406	smoking		The Journal of pediatrics. 2003 Jul;143(1):104-10	Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive~~~ and oppositional behaviors.		126455	5448	1	2003	 Child hyperactivity-impulsivity and oppositional behaviors were associated with a DAT polymorphism but only when the child also had exposure to maternal prenatal smoking. This study emphasizes the importance of incorporating environmental cofactors in genetic studies of attention deficit hyperactivity disorder.	Cohort 161 children was followed prospectively from age 6 months to 60 months	smoking (tobacco), maternal									
134691		smoking	OTHER	OTH	Tobacco Use Disorder|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Ling D 2004	14685824				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		China	KGB	6531	Hs.406			Journal of human genetics. 2004 ;49(1):35-9	Association between polymorphism of the dopamine transporter gene and early smoking onset: an interaction risk on nicotine dependence.		126455	5449	1	2004												
134692		Eating disorder	OTHER	OTH	Bulimia	5	5p15.3	SLC6A3	1445908	1498543		Shinohara M 2004	15069467	3'-UTR VNTR			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Japanese		KGB	6531	Hs.406			Journal of psychiatry & neuroscience. 2004 Mar;29(2):134-7	Eating disorders with binge-eating behaviour are associated with the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene.		126455	5450	1	2004	 It seems plausible that the association between the DAT1 VNTR and binge-eating behaviour indicates that dysregulation of dopamine reuptake may act as a common pathophysiologic mechanism in eating disorders with binge-eating behaviour and in disorders related to substance use.	Control:115 healthy female controls;Case:90 female Japanese patients with eating disorders										
134686		alcoholism	CHEMDEPENDENCY	CHEM	Alcoholism|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Ueno S et al. 1999	10578237				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Japan	KGB	6531	Hs.406			Molecular psychiatry. 1999 Nov;4(6):552-7	Identification of a novel polymorphism of the human dopamine transporter (DAT1) gene and the significant association with alcoholism.		126455	5444	1	1999												
134687	N	schizophrenia	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543	n	Hauser J et al. 2002	12149916				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Poland	KGB	6531	Hs.406			Psychiatria polska. 2002 May-Jun;36(3):403-12	Lack of association between VNTR polymorphism of DAT gene and schizophrenia trans Brak asocjacji pomiedzy polimorfizmem VNTR genu DAT a schizofrenia.		126455	5445	1	2002												
134688	N	dyslexia	NEUROLOGICAL	NEUR	Dyslexia	5	5p15.3	SLC6A3	1445908	1498543	n	Marino C 2003	14505070				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Italy	KGB	6531	Hs.406			European child & adolescent psychiatry. 2003 Aug;12(4):198-202	No evidence for association and linkage disequilibrium between dyslexia and markers of four dopamine-related genes.		126455	5446	1	2003												
134689	N	dyslexia	NEUROLOGICAL	NEUR	Dyslexia	5	5p15.3	SLC6A3	1445908	1498543	n	Marino C 2003	14505070				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		Italy	KGB	6531	Hs.406			European child & adolescent psychiatry. 2003 Aug;12(4):198-202	No evidence for association and linkage disequilibrium between dyslexia and markers of four dopamine-related genes.		126455	5447	1	2003												
134683	Y	alcohol withdrawl seizure and delirium tremens	CHEMDEPENDENCY	CHEM	Seizures|Alcohol Withdrawal Delirium|Substance Withdrawal Syndrome|	5	5p15.3	SLC6A3	1445908	1498543	0.0008	Gorwood P 2003	12513948	A(9) allele			Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	alcohol-dependant patients		KEW	6531	Hs.406			Biological psychiatry. 2003 Jan;53(1):85-92	The A9 allele of the dopamine transporter gene is associated with delirium tremens and alcohol-withdrawal seizure		126455	5441	1	2003	 This study provides convergent data in favor of a significant role of the DAT gene in the risk for some severe withdrawal symptoms. If further replicated in larger samples, the DAT genetic polymorphism could be one of the factors to be analyzed to further assess the risk of some severe alcohol-withdrawal symptoms.	Cohort 120 alcohol-dpendent patients										
134684	N	manic-depressive illness	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543	n	Gomez-Casero E et al. 1996	9149327				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Spanish		KGB	6531	Hs.406			Psychiatric genetics. 1996 ;6(4):209-12	No association between particular DRD3 and DAT gene polymorphisms and manic-depressive illness in a Spanish sample.		126455	5442	1	1996												
134685		major psychiatric disorders	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Georgieva L et al. 2002	11942948				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Bulgarian	Bulgaria	KGB	6531	Hs.406			Acta psychiatrica Scandinavica. 2002 May;105(5):396-9	Dopamine transporter gene (DAT1) VNTR polymorphism in major psychiatric disorders: family-based association study in the Bulgarian population.		126455	5443	1	2002	 Our results are in agreement with previous reports of a lack of association between this polymorphism and major psychiatric disorders.											
121799		attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	11	11p15.5	DRD4	627304	630703		DiMaio, S.  et al. 2003	12587848				Dopamine receptor D4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000797.2			CDC GDPinfo	1815	Hs.99922			Journal of psychiatry & neuroscience. 2003 Jan;28(1):27-38	Dopamine genes and attention-deficit hyperactivity disorder: a review.		126452	16395	2	2003	 The implication of SLC6A3 and DRD4 genes in ADHD appears to be one of the most replicated in psychiatric genetics and strongly suggests the involvement of the brain dopamine systems in the pathogenesis of ADHD. However, more work is required to further these findings by genotype-to-phenotype correlations and identify the functional allelic variants/mutations that are responsible for these associations. The role of other dopamine genes, which may have smaller effects than SLC6A3 and DRD4, needs also to be determined.											
134731	Y	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Simsek, M.  et al. 2005	15993876				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Clinical biochemistry. 2005 Aug;38(8):739-42	Association of the risk allele of dopamine transporter gene (DAT1*10) in Omani male children with attention-deficit hyperactivity disorder.		126455	13827	2	2005	 We determined the DAT1-VNTR alleles in 202 Omani subjects. There were two common alleles (DAT1*9 and *10) and five rare ones. The DAT1*10 allele distribution was essentially the same both in the control (60.9%) and the patient group (64.6%). There was, however, a relatively higher occurrence of the DAT1*10 allele in ADHD males (69.4%) than females (55%), but this gender difference was not present in the control group (males 60%, females 62%).											
134746	Y	alcoholism; delirium tremens, alcohol-induced	CHEMDEPENDENCY	CHEM	Alcohol Withdrawal Delirium|Alcoholism|Genetic Predisposition to Disease|	5	5p15.3	SLC6A3	1445908	1498543		Kohnke, M. D.  et al. 2005	15996968				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Alcohol and alcoholism (Oxford, Oxfordshire). 2005 Sep-Oct;40(5):339-42	Association of the dopamine transporter gene with alcoholism.		126455	19533	2	2005	 Our results reveal that the allele A9 is strongly associated with alcoholism but not with withdrawal symptoms or daily alcohol intake.											
134753		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543			16389200				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Archives of general psychiatry. 2006 Jan;63(1):74-81	A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy		126455	19540	2	2006	 The identification of a common haplotype in 2 independent populations is an important step toward identifying functionally significant regions of DAT1. Interaction between DAT1 genotypes and maternal use of alcohol during pregnancy suggests that DAT1 moderates the environmental risk and has implications for the prevention of ADHD. Further studies are required to delineate the precise causal risk factor involved in this interaction.		alcohol, maternal smoking (tobacco), maternal									
134784		alcohol abuse	CHEMDEPENDENCY	CHEM	Alcoholism|Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Dick, D. M.  et al. 2003	12766633				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDPinfo	6531	Hs.406			Alcoholism, clinical and experimental research. 2003 May;27(5):868-79	Candidate genes for alcohol dependence: a review ofgenetic evidence from human studies.		126455	28400	2	2003	Review article											
145722	N	smoking behavior	PHARMACOGENOMIC	PHARM		22	22q11.21-q11.23	COMT	18309308	18336530		Ton, T. G.  et al. 2007	17466074				Catechol-O-methyltransferase	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000754.2			CDC GDP info	1312	Hs.370408			Behav Brain Funct    2007    3(1)    22	Genetic polymorphisms in dopamine-related genes and smoking cessation in women		116790		CDC	2007	 However, effect modification on smoking cessation was observed between DRD2 Taq1A and SLC6A3 VNTR polymorphisms, DRD3 Ser/Gly and d,1-fenfluramine, and DRD4 VNTR and d,1-fenfluramine.		1-fenfluramine									
146777		heroin abuse	CHEMDEPENDENCY	CHEM	Heroin Dependence	11	11q23	DRD2	112785526	112851091			16526040				Dopamine receptor D2	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000795.2			CDC GDP info	1813	Hs.73893			Am J Med Genet B Neuropsychiatr Genet    2006	The effect of dopamine D2, D5 receptor and transporter (SLC6A3) polymorphisms on the cue-elicited heroin craving in Chinese		126450		CDC	2006												
146805	N	smoking behavior	PHARMACOGENOMIC	PHARM		11	11q23	DRD2	112785526	112851091		Ton, T. G.  et al. 2007	17466074				Dopamine receptor D2	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000795.2			CDC GDP info	1813	Hs.73893			Behav Brain Funct    2007    3(1)    22	Genetic polymorphisms in dopamine-related genes and smoking cessation in women		126450		CDC	2007	 However, effect modification on smoking cessation was observed between DRD2 Taq1A and SLC6A3 VNTR polymorphisms, DRD3 Ser/Gly and d,1-fenfluramine, and DRD4 VNTR and d,1-fenfluramine.		1-fenfluramine									
146832	N	smoking behavior	PHARMACOGENOMIC	PHARM		3	3q13.3	DRD3	115330246	115380589		Ton, T. G.  et al. 2007	17466074				Dopamine receptor D3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000796.3			CDC GDP info	1814	Hs.121478			Behav Brain Funct    2007    3(1)    22	Genetic polymorphisms in dopamine-related genes and smoking cessation in women		126451		CDC	2007	 However, effect modification on smoking cessation was observed between DRD2 Taq1A and SLC6A3 VNTR polymorphisms, DRD3 Ser/Gly and d,1-fenfluramine, and DRD4 VNTR and d,1-fenfluramine.		1-fenfluramine									
146893	N	smoking behavior	PHARMACOGENOMIC	PHARM		11	11p15.5	DRD4	627304	630703		Ton, T. G.  et al. 2007	17466074				Dopamine receptor D4	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000797.2			CDC GDP info	1815	Hs.99922			Behav Brain Funct    2007    3(1)    22	Genetic polymorphisms in dopamine-related genes and smoking cessation in women		126452		CDC	2007	 However, effect modification on smoking cessation was observed between DRD2 Taq1A and SLC6A3 VNTR polymorphisms, DRD3 Ser/Gly and d,1-fenfluramine, and DRD4 VNTR and d,1-fenfluramine.		1-fenfluramine									
146911		heroin abuse	CHEMDEPENDENCY	CHEM	Heroin Dependence	4	4p16.1	DRD5	9392700	9394731			16526040				Dopamine receptor D5	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_000798.3			CDC GDP info	1816	Hs.380681			Am J Med Genet B Neuropsychiatr Genet    2006	The effect of dopamine D2, D5 receptor and transporter (SLC6A3) polymorphisms on the cue-elicited heroin craving in Chinese		126453		CDC	2006												
153611		attention deficit disorder conduct disorder oppositional defiant disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Comings, D. E.  et al. 2000	11140838				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Clin Genet    2000    58    375-85	A multivariate analysis of 59 candidate genes in personality traits		126455		CDC	2000	While there was some tendency for this to be true, a more important trend was the involvement of different ratios of functionally related groups of genes, and of different genotypes of the same genes, for different traits. 											
153612		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543			16402340				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2006	No association between VNTR polymorphisms of dopamine transporter gene and attention deficit hyperactivity disorder in Chinese children		126455		CDC	2006	can be drawn about the association in any single ethnicity given the small number of studies.											
153613		tardive dyskinesia	PHARMACOGENOMIC	PHARM		5	5p15.3	SLC6A3	1445908	1498543			16424823				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Indian		CDC GDP info	6531	Hs.406			Pharmacogenet Genomics    2006    16(2)    111-117	Genetic susceptibility to tardive dyskinesia among schizophrenia subjects		126455		CDC	2006	Our study presents a detailed analysis of the possible role of dopaminergic genes in the genesis of TD.											
153615		cocaine abuse	CHEMDEPENDENCY	CHEM	Cocaine-Related Disorders	5	5p15.3	SLC6A3	1445908	1498543			16537431				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Proc Natl Acad Sci U S A    2006	A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample		126455		CDC	2006												
153617	Y	smoking behavior	CHEMDEPENDENCY	CHEM		5	5p15.3	SLC6A3	1445908	1498543		Timberlake, D. S.  et al. 2006	16569110				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Health Psychol    2006    25(2)    190-7	An association between the DAT1 polymorphism and smoking behavior in young adults from the national longitudinal study of adolescent health		126455		CDC	2006												
153618		attention deficit hyperactivity disorder	PSYCH	PSY	Diseases in Twins	5	5p15.3	SLC6A3	1445908	1498543		Mill, J.  et al. 2006	16585476				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	New Zealand		CDC GDP info	6531	Hs.406			Arch Gen Psychiatry    2006    63(4)    462-9	Prediction of heterogeneity in intelligence and adult prognosis by genetic polymorphisms in the dopamine system among children with attention-deficit/hyperactivity disorder		126455		CDC	2006	The findings indicate that genetic information of this nature may prove useful for etiology-based psychiatric nosologies.											
153619		personality traits	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Kim, S. J.  et al. 2006	16604301			promoter	Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Korean		CDC GDP info	6531	Hs.406			J Neural Transm    2006	An interaction between the serotonin transporter promoter region and dopamine transporter polymorphisms contributes to harm avoidance and reward dependence traits in normal healthy subjects		126455		CDC	2006												
153620		depressive disorder, major personality disorders	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Joyce, P. R.  et al. 2006	16623961				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Psychol Med    2006        1-7	A dopamine transporter polymorphism is a risk factor for borderline personality disorder in depressed patients		126455		CDC	2006	This replicated association in depressed patients between the 9-repeat allele of DAT1 and BPD may provide clues to understanding the neurobiology of BPD. The finding that the association is larger in the older depressed patients, suggests that the 9-repeat allele may be associated with a poorer prognosis BPD, rather than a young adult limited variant of BPD.											
153621	N	body mass obesity	METABOLIC	MET	Obesity; Body Weight	5	5p15.3	SLC6A3	1445908	1498543		Need, A. C.  et al. 2006	16674552				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Ann Hum Genet    2006    70(Pt 3)    293-303	Obesity is Associated with Genetic Variants That Alter Dopamine Availability		126455		CDC	2006												
153623		cognitive function	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Rybakowski, J. K.  et al. 2006	16712949				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Psychiatry Res    2006	Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET)		126455		CDC	2006												
153624		attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Barkley, R. A.  et al. 2006	16741944				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2006	An examination of the behavioral and neuropsychological correlates of three ADHD candidate gene polymorphisms (DRD4 7,+ DBH TaqI A2, and DAT1 40 bp VNTR) in hyperactive and normal children followed to adulthood		126455		CDC	2006												
153625		attention deficit hyperactivity disorder	PHARMACOGENOMIC	PHARM	Tourette Syndrome	5	5p15.3	SLC6A3	1445908	1498543		Gilbert, D. L.  et al. 2006	16760197				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Brain    2006	Dopamine transporter genotype influences the physiological response to medication in ADHD		126455		CDC	2006	MPH and ATX have similar effects on SICI in children with ADHD.		atomoxetine methylphenidate									
153626		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Ohadi, M.  et al. 2006	16782077			promoter	Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Iranian		CDC GDP info	6531	Hs.406			Brain Res    2006	Attention-deficit/hyperactivity disorder (ADHD) association with the DAT1 core promoter -67 T allele		126455		CDC	2006												
153628	Y	dopamine release	CHEMDEPENDENCY	CHEM	Tobacco Use Disorder	5	5p15.3	SLC6A3	1445908	1498543		Brody, A. L.  et al. 2006	16818870				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Arch Gen Psychiatry    2006    63(7)    808-816	Gene Variants of Brain Dopamine Pathways and Smoking-Induced Dopamine Release in the Ventral Caudate/Nucleus Accumbens		126455		CDC	2006	Smokers with genes associated with low resting dopamine tone have greater smoking-induced (phasic) dopamine release than those with alternate genotypes. These findings suggest that dopamine system genotype variabilities explain a significant proportion of the interindividual variability in smoking-induced dopamine release and indicate that smoking-induced dopamine release has a genetic predisposition.		smoking (tobacco)									
153629	Y	attention deficit hyperactivity disorder	PSYCH	PSY	Genetic Predisposition to Disease	5	5p15.3	SLC6A3	1445908	1498543		Brookes, K. et al  et al. 2006	16894395				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Mol Psychiatry    2006    11(10)    934-53	The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder		126455		CDC	2006												
153630		attention deficit hyperactivity disorder drug hypersensitivity	PHARMACOGENOMIC	PHARM		5	5p15.3	SLC6A3	1445908	1498543		Mick, E.  et al. 2006	16917950				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2006	Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD		126455		CDC	2006			methylphenidate									
153632		attention deficit hyperactivity disorder methyphenidate side-effects	PHARMACOGENOMIC	PHARM	Tics	5	5p15.3	SLC6A3	1445908	1498543		McGough, J.  et al. 2006	17023870				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			J Am Acad Child Adolesc Psychiatry    2006	Pharmacogenetics of Methylphenidate Response in Preschoolers With ADHD		126455		CDC	2006	Emerging evidence suggests the potential for understanding the individual variability of response to and side effects of ADHD medications from the study of genetics, although additional research is required before these findings are proven to have clinical utility.											
153633		manic depression	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Stober, G.  et al. 2006	17042887				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2			CDC GDP info	6531	Hs.406			Bipolar Disord    2006    8(5 Pt 1)    490-5	Association study of 5'-UTR polymorphisms of the human dopamine transporter gene with manic depression		126455		CDC	2006	In 											
153634		attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Qian, Q.  et al. 2006	17044099				Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2		China	CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2006	Evaluation of potential gene-gene interactions for attention deficit hyperactivity disorder in the Han Chinese population		126455		CDC	2006												
153635	Y	attention deficit hyperactivity disorder	PSYCH	PSY		5	5p15.3	SLC6A3	1445908	1498543		Genro, J. P.  et al. 2006	17044101	SLC6A3  (-839 C > T)		promoter	Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NM_001044.2	Brazilian		CDC GDP info	6531	Hs.406			Am J Med Genet B Neuropsychiatr Genet    2006	A promoter polymorphism (-839 C > T) at the dopamine transporter gene is associated with attention deficit/hyperactivity disorder in Brazilian children		126455		CDC	2006												
